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i 
ABSTRACT 
Currently, a large portion of the world's population uses medication on a regular 
basis and uses health services frequently, mainly due to the increase of 
longevity and the growing number of chronic diseases (CD).  
Consequently, a correct medication management is needed in order to improve 
the responsible use of medicines and health outcomes. Portugal shows a high 
prevalence of CD such as hypertension, obesity, dyslipidaemia and diabetes. 
Moreover, the Algarve region presents some shortcomings in accessibility to 
healthcare. 
Therefore, this research project arises with the main aim of establishing a 
methodology to analyse the outcomes of the process of medication use (MU) 
through medication review (MR) , in a clinical practice setting in Southern 
Portugal (AEDMADA clinic), applied in the ReMeD study. Patient´s data was 
collected individually and then systematically analysed considering the 
humanistic, economic and clinical outcomes. 
A questionnaire (SAHL-S&E) was previously adapted for the Portuguese 
language aimimg to identify subjects with low health literacy (HL), which was 
then used during the MR.  
The ReMeD study was conducted in 118 patients, mainly 65 years, 
hypertense, diabetic, dyslipidemic and presenting a very high cardiovascular 
risk.  
Humanistic outcomes showed 25.4% of patients having low medication 
knowledge, 43.2% with low HL and about 25% being non-adherent to 
medication.  
Economic outcomes revealed that most patients were polymedicated (73.8%) 
and monitored by 2-3 Physicians, and about 15% suffering hospitalization in the 
last year.  
Negative clinical outcomes (NCO) were identified in 99.2% of patients, and 
74.6% presented risks of developing NCO.  
ii 
As a whole, the ReMeD methodology seems appropriate to identify situations 
from the process of MU, useful to outline new strategies aimed to improve 
patient's MU and the empowerment for disease management.  Applying this 
novel approach enables the conduction of MR in a clinical setting, allowing to 
pinpoint modifiable situations, contributing to improve health outcomes. 
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1 
1 INTRODUCTION 
The increasing number of lived years per subject involved a rise in the amount 
of the chronic diseases suffered, many starting at a young age, and presenting 
a long duration. (1) These clinical situations usually require the use of long-term 
therapeutic schemes, leading to the emergence of new pharmacological 
therapies and other approaches to improve patient´s health and quality of life. 
New and more therapeutic alternatives have emerged in recent decades, as a 
result of the research carried out by the pharmaceutical industry and research 
groups in several clinical areas.  
However, the increment in the variety and duration of the use of medicines 
cannot happen inconsequently, leading to an increased risk of adverse drug 
reactions, especially in those patients who are under polymedication (2), and 
comprising a growth in the healthcare costs.  
Therefore, as a consequence of the needs triggered by the increase of patient´s 
lifespan, health services also present a high rate of utilization, with an increasing 
difficulty in responding to the population´s needs. Unfortunately, the 
accessibility to the Portuguese healthcare is not yet at the level of other 
European countries, presenting inequality for the various population groups and 
in the various regions of the country. (3) 
Health professionals are often called upon to contribute effectively to the 
improvement in the rational use of health services and to the provision of 
effective services aiming to enhance the subject´s health outcomes.  
Therefore, the Pharmacist has a central role to be developed in the provision of 
services related to the use of medicines, contributing with his extensive 
knowledge and expertise in the area of pharmacotherapy management, 
targeting the improvement of patient´s health outcomes. (4) 
Pharmaceutical services, despite their general diversity and variety of 
approaches, are directed towards the provision of patient-centered services. (5) 
These services have added great value when provided within a multidisciplinary 
team of professionals, including Pharmacists in liaison with other professionals, 
2 
such as medication review and pharmacotherapy follow-up, particularly when 
developed in primary healthcare units. (6) 
There are several countries where the medication review service is already 
implemented as an integrated service within the health system, contributing to 
the improvement of patient´s health outcomes, with benefits for the reduction of 
costs associated with patient´s health and quality of life. (7) 
The medication review service is not formally integrated in the healthcare 
services provided in Portugal, although it is a potential opportunity to improve 
patient´s health outcomes, and for professionals such as Pharmacists, allowing 
the extension of services available to the population within healthcare units and 
contributing to improved health outcomes. It is therefore important to develop 
further research in order to help better understand how this medication review 
service could be implemented in Portugal. 
Considering the current scenario described above, the main aim of this 
research is to establish a methodology to analyse outcomes in the process of 
medication use through medication review, in a clinical setting.  
Therefore, the hypothesis of this study is that a specific methodology applied in 
the medication review will be feasible and useful for the identification of specific 
situations, contributing to an improvement of patient's health outcomes. 
To test this hypothesis, there were specific goals: 1) the adaptation to the 
Portuguese language of the “Short Assessment of Health Literacy - Spanish 
and English  (SAHL-S&E)”; and 2) the clinical patient evaluation, 
characterization of pharmacotherapeutic profile, analysis of medication review 
outcomes, identification of predictive factors for clinical outcomes associated to 
medication review, and analysis of eligibility criteria for medication review 
programs available in Australia, Canada and England, developed as the 
ReMeD study.  
A literature review is enclosed in the Introduction chapter, including a revision 
about the state of healthcare in Portugal (health outcomes, health system and 
medicines use), the concept of pharmaceutical care, and which services are 
3 
provided in this scope, as the medication review service. Beside, the tools 
identified by other authors to perform this same activity in other countries, such 
as medication adherence evaluation, medication knowledge evaluation, disease 
knowledge evaluation and identification of inappropriate medication, were also 
approached within this literature review. 
Health literacy (HL), as it might influence the capacity of the patients to manage 
their own medication and have an impact in health outcomes (8), was also 
included in the literature review. The tools used to assess HL were identified 
and the SAHL-S&E was then selected to be adapted to the Portuguese 
language, since it was previously recognized to be appropriate to identify 
subjects with low degree of health literacy. The resulting tool from this 
adaptation was used in the medication review activity held in the ReMeD study. 
The Results chapter is presented in two separate sub-chapters; the first one is 
related to the adaptation of the SAHL-S&E questionnaire to the Portuguese 
language; and the second to the results obtained in the ReMeD study. 
 
1.1 Healthcare in Portugal 
1.1.1 Health Outcomes 
In the last two (2) decades an increase in longevity has been observed in the 
Portuguese population, both at birth and at 65 years. (9) 
This increase in longevity is followed by a greater number of the pathologies 
suffered by the Portuguese subjects. 
Currently, in Portugal, the main causes of morbidity, disability and premature 
death are circulatory system diseases (30%), malignant tumors (24%), 
respiratory diseases (12%), and endocrine, nutritional and metabolic diseases 
(5%). (9) 
Regarding circulatory system diseases, the most common is ischemic heart 
disease, whose most relevant clinical manifestation is acute myocardial 
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infarction, and cerebrovascular disease, including ischemic stroke. However a 
positive outcome was observed in recent years in the mortality by acute 
myocardial infarction, which decreased 18.23% between 2009-2013 (10) The 
analysis from the burden of disease in Portugal identified the cerebrovascular 
and ischemic heart diseases, as well as diabetes, as the main causes of 
DALYS (disability-adjusted life years), with a most pronounced burden in the 
last decade (death and disabilities combined). (11) The risk factors identified 
associated to these causes, in descending order were: dietary, high systolic 
blood pressure, tobacco, high body mass index, high fasting plasma glucose, 
alcohol and drug use, high total cholesterol, occupational risks, low glomerular 
filtration rate and low physical activity. (9) 
Consequently, the inclusion of high-risk individuals, regarding intervention in the 
management of risk factors for cardiovascular diseases, is a major priority 
(Table 1). (12)  
 
Table 1: Priority patients regarding cardiovascular diseases (CVDs).  
Priority 
patients 
for CVDs 
Established CVD 
Diabetes mellitus 
Renal disease (moderate to severe) 
High level of individual risk factors 
High SCORE risk 
Legend: CVD – Cardiovascular Disease; SCORE - Systematic 
Coronary Risk Evaluation. 
[Adapted from (12)]  
 
Several risk factors have been identified as the main contributors to increase 
this risk for CVDs, some that can be treated and changed, others that cannot be 
modified. (Table 2).   
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Table 2: Major risk factors for cardiovascular diseases (CVDs).  
Major 
risk 
factors 
Non-modifiable 
Age  
Familiar prevalence of early-onset CVD (before 55 
years in men and 65 years in women) 
Modifiable 
Systolic blood pressure  
Diabetes 
BMI > 25 kg/m2 
Smoking habits 
Diet 
Legend: CVD – Cardiovascular Disease; BMI - Body mass index. 
[Adapted from (12)] 
 
Arterial hypertension (HT) is highly prevalent in most Western countries 
populations, and was already identified not only as one of the major risk factors 
for cardiovascular diseases (CVDs), but also as a very serious public health 
problem worldwide, being responsible for about half of the deaths from heart 
disease and stroke. (13) 
Blood pressure (BP) is a physiologic parameter that will vary with subjects´ age, 
presenting higher values with the increase of the subject´s age, mostly in elderly 
subjects (Figure 1). (14) 
 
Legend: DBP – diastolic blood pressure; SBP – systolic blood pressure; Y - years. (14) 
Figure 1: Changes in blood pressure values according to subjects´ age.  
6 
In Portugal, the results of a population study obtained in 2003/04 indicated that 
the prevalence of hypertension (HT) was 42.1%, from which only 39.0% were 
treated patients and 11.2% had controlled BP values. (15)  
Another Portuguese study (VALSIM) held in primary care setting (2006/07), 
showed a prevalence of HT adjusted for gender, age and region size of 42.6% 
(16). Regarding the group of diabetic hypertensive patients, 78.4% were being 
treated with antihypertensive drugs, but only 9.3% had controlled blood 
pressure (17). 
More recently, the PHYSA study, a Portuguese population-based cross-
sectional survey (2011/2012), which enrolled a stratified sample (for age and 
sex) of subjects from 18-90 years old, was developed to find out the prevalence, 
awareness, treatment and control of hypertension and the 24-h sodium 
excretion (24h-UNa). (18) This study included the assessment of blood 
pressure at two moments (visit 1 and 2), and at the first visit, the prevalence of 
hypertension was of 42.2%. Among hypertensive patients, about three quarters 
(74.9%) were being treated and 42.5% had their BP values under control 
(BP<140/90 mmHg). The value for 24h- UNa (urine sodium concentration) was 
greater in patients with diagnosis of hypertension , when compared to 
normotensive individuals (185.4±64.8 vs. 177.8±64.5 mmol/day; p<0.02), 
concluding that the daily intake of salt (10.7 grams) was almost double the 
WHO recommendation (19), which should be less than 5 grams. (18) 
It is noteworthy that the Algarve region presented the lowest rate of control of 
hypertension in the national territory (18.4% for men and 21.8% for women), 
according to the results of a Portuguese report regarding cerebrovascular 
diseases (2015). (9) 
Dyslipidemia is another major risk factor associated with cardiovascular 
disease, and the effectiveness of the treatment is closely related to a significant 
reduction of cardiovascular risk. (12)  
The results from a Portuguese study including a sample of patients treated with 
statins, indicated that the majority of patient´s values for LDL-C (62.9%) and 
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total cholesterol (68%) were not in the range of the recommended values by the 
European Society of Cardiology. (20)  
Diabetes mellitus (DM) is also a major risk factor for CVD and the most  
common cause of kidney failure in the Western world. (12) 
The prevalence of diabetes in the Portuguese population was 12.9% (20 - 79 
years) in 2012, which corresponded to an estimation of 1 million individuals with 
diabetes. A strong direct correlation between the increase in the prevalence of 
diabetes and the aging of individuals was found. (21) 
The first prevalence study performed in Portugal by Gardete-Correia et al. 
(2010), found 43.6% undiagnosed diabetic patients (population between 20 and 
79 years old) and about 90% of diabetic patients being overweight or obese. 
(22) 
Although in the last five years a significant decrease has arisen in the number of 
potential life years lost (YLL) for Diabetes mellitus (DM) in Portugal (-15%), in 
2012 this disease still accounted for approximately seven YLL per death from 
diabetes in the population under 70 years of age. In addition, the number of 
patients discharged from the hospital associated with DM diagnosis has 
significantly increased throughout the same period (increased 78.5% between 
2003 and 2012). (21) 
Nevertheless, between 2005 and 2013, there has been a decrease of 1.6% in 
the number of new cases of DM in Portugal.  According to the 2014 report, DM 
has an overall prevalence of 13.1%, in which 7.4% of the patients were 
diagnosed and 5.7% weren´t. (23)  
In the same report, about 20% of diabetic patients followed in the Portuguese 
National Health Service had a value for HbA1c >8%, 66.2% had a LDL-C value 
<100 mg/dL (although this prevalence was only 8.1% in 2012), 37.7% had a 
blood pressure value <130/80 mmHg, and 67.7% had a value for blood 
pressure <140/90 mmHg. (23) 
In diabetic patients, a number of microvascular and macrovascular 
complications may arise, and the risk of complications increases with increased 
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hyperglycaemia (Figure 2). (24) While microvascular complications may be 
associated with previous hyperglycaemia, a less pronounced association has 
been verified for macrovascular complications. Nevertheless, relative to 
macrovascular complications such as myocardial infarction, it has been 
established that the risk decreases 14% for each 1% of reduction on the mean 
value of HbA1c. (25)   
 
Figure 2: Diabetes complications pathways.  
Legend: AGE - advanced glycated end-products; FFA - free fatty acids; GLUT- 4 - glucose 
transporter 4; HDL-C - high-density lipoprotein cholesterol; LDL - low-density lipoprotein; NO - 
nitric oxide; PAI-1 - plasminogen activator inhibitor-1; PKC - protein kinase C; PPARy - 
peroxisome proliferator-activated receptor y; PI3K - phosphatidylinositide 3-kinase; RAGE - 
AGE receptor; ROS - reactive oxygen species; SR-B - scavenger receptor B; tPA - tissue 
plasminogen activator. (24) 
 
Adults who have both diabetes and hypertension have increased risk for kidney 
disease (evaluated through albumin excretion and/or impaired glomerular 
filtration rate - GFR) and atherogenic risk factors including dyslipidaemia, 
hyperuricaemia, elevated fibrinogen and left ventricular hypertrophy (24). 
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Moreover, different studies have demonstrated that an increase in body weight 
can lead to an increase of harmful effects on cardiovascular health, being 
obesity also  marked as a major risk factor for CVDs. (12,26) 
Smoking habits have been widely identified as a key factor for the increased 
risk for CVDs. (12,26) Interestingly, this fact has been reflected in the policies of 
several countries including Portugal, where measures that discourage tobacco 
use have been implemented in the last decade. (27,28) 
The use of tobacco products has been related to CVDs such as fatal myocardial 
infarction and stroke. (29)  
Also in another population-based case-control study in young people with 
incident acute myocardial infarction cases, a dose–effect response was present, 
and the odds favouring myocardial infarction reached an eight-fold increase for 
those that smoked more than 25 cigarettes per day compared to those who 
never smoked.  (30) 
The Portuguese National Health Survey (2014) identified a prevalence of 
smoking habits in about 20% of the Portuguese population (15 years or 
above), where from those 16.8% smoked daily. An increased consumption in 
male subjects (27.8%) was observed, compared to female (13.2%). (31) 
Physical activity can improve modifiable metabolic risk factors, such as high-
density lipoprotein cholesterol (HDL-C), total cholesterol, obesity, hypertension, 
and glucose metabolism and control, promoting a decrease in the risk of CVDs. 
(12,32) (32)  
A Portuguese report about physical activity published in 2011 described a 
positive correlation in the amount of minutes per day of sedentary activity with 
individual´s age, verifying an average of 602±115 minutes per day for male and 
580±112 for female older subjects. Only 9% of Portuguese subjects indicated to 
practice physical exercise regularly (at least 5 days a week) and 36% reported 
not to practice any kind of physical exercise. (33) 
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A protective effect for CVD mortality in healthy individuals can be reached 
through physical activity, which can be observed in subjects with isolated or in 
clusters risk factors, and those who have  1 metabolic risk factor may benefit 
from significant decreases in CVD mortality risk by practicing a light or 
moderate/vigorous activity ( 3 times/week). (34) 
Improving global cardiovascular risk requires in most cases a multifactorial 
approach. For that reason, the National Program for Cardiovascular Diseases 
and the National Health Plan 2020 included as goals the global reduction of 
cardiovascular mortality, the reduction of early mortality and finally, the 
reduction of the global burden of disease and morbidity. (9,10) 
 
1.1.2 Health System 
The health of the Portuguese citizens is covered mainly by a public system 
(National Health System – NHS). There are some private healthcare providers 
in the health market, and some of those private institutions may have 
agreements with the NHS for the provision of health services. 
The Portuguese NHS arose in 1979, whereby the Portuguese State guarantees 
the right to health protection for all Portuguese citizens, regardless of their 
economic situation. (35) The Portuguese State assumes the responsibility of 
defining and coordinating the Portuguese health policy. 
The legislation that consolidates the bases of the Portuguese NHS was 
published in 1990, which included the rights and duties of the users of public 
health services. (36) 
Two levels of care arose in the NHS: The primary health care includes health 
promotion, disease prevention and outpatient care, while the 
secondary/differentiated health care is related to hospital care, hospitalization, 
and specialized outpatient care. (35,36) 
Over the last years, with the increase in longevity and in the number of chronic 
diseases, there has been a greater demand for health services in general. 
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Hence, several reforms have been placed with the aim of improving the 
accessibility of citizens to health services, since the existing services seem to 
be insufficient to meet the needs of the entire Portuguese population. (37)  
Consequently, a number of private groups have emerged in the Portuguese 
healthcare market over the last decade in order to provide such health-related 
needs. (38)  
In addition, some public-private partnerships by the Portuguese government 
were established, with the aim to fill the existing gaps in the response to the 
needs of the Portuguese patients. 
Despite their original definition, primary health care centers are more centred in 
the treatment of diseases than in the primary level of health promotion. Human, 
material and physical resources are not sufficient for the services demanded by 
the Portuguese population. This situation worsened with the recent economic 
crisis, which has forced Portugal to strong fiscal restraint measures since 2010. 
Consequently, a decrease in health expenses has been registered since 2010, 
on a % above the average of the OCDE countries. (39) 
To make matters worse, a decrease in the number of doctors per 100,000 
inhabitants in primary health care was also verified in recent decades. (40) 
The referral process of patients for specialized health care is slow and has 
some limitations, as well as its waiting list, which has been increasing in recent 
years. (41)  
Recently, users from Portuguese primary health care units who participated in a 
satisfaction survey regarding these units and the services provided, scored as 
the weakest point the information provided for the procedures performed in 
hospital setting. (42)  
Portuguese citizens often utilize private healthcare, particularly searching for 
specialized care. The use of these private healthcare may be fully borne by 
patients or reimbursed by patient´s private health insurance.  
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Accessibility to health care is variable according to the geographical area within 
the country. Areas with the lowest population density, where the inhabitants are 
older, are the places where accessibility is more limited. (41) 
In the Portuguese territory we can find variations along the different regions in 
the absolute number of General Practitioners, and the ratio of General 
Practitioners per 100,000 inhabitants. In addition, the specialized care 
distribution is not uniform throughout the national territory. (41)  
The region of Algarve together with Alentejo, both in the south of Portugal, 
presented the lowest concentration of medical specialists (41), as well as a 
lower average of medical consultations, when compared to the national 
average. (43)  
Considering the health care provided to diabetic patients within the Portuguese 
National Health System (NHS) in primary care units, the Algarve region 
presented the lowest coverage rate of provided consultations (59.1%, 72.8% for 
Portugal). (44) It is important to note that a growth in the incidence rate of 
diabetes is expected to happen in the coming years (2016-2024) in Portugal. 
(45) 
 
1.1.3 Medicines Use 
In Portugal, it is the Ministry of Health that establishes the level of 
reimbursement for each medicine placed in the outpatient market. After this 
decision, the co-payment is decided according to 4 levels (A-90%, B-69%, C-
37% and D-15%), according to several criteria such as the therapeutic 
indications of the medicine, its use, the entities that prescribe it, and with the 
levels of consumption for patients suffering from certain pathologies. (46) 
The so-called special co-payment of medicines is provided for two types of 
situations, depending on the beneficiaries themselves or on the pathologies or 
special groups of users. For medicines integrated in the group A an increase of 
5% in co-payment is added and in medicines from Group B, C and D an 
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increase of 15% is added for pensioners with low incomes (i.e, < 14 times the 
minimum monthly guaranteed payment). (46) 
The co-payment attributed to the Portuguese citizens has been increasing 
during the last years, which may have been influencing their decision of 
purchasing or not the drugs prescribed, and consequently affecting their 
adherence to treatment and therefore, the expected health outcomes. (41) 
Since 2010, in the context of reducing health expenses, the Portuguese 
Government has also implemented actions to decrease expenses with 
prescribed drugs, particularly costs at outpatient level. In the period between 
January and April 2016 the amount spent on medicines by the National Health 
Service was about EUR 400 million (about 52 million packages), 0.5% higher 
than the same period the previous year (2015). (47) The pharmacotherapeutic 
groups that represented a greater expense were “other antidiabetics” and 
“agents acting on the renin-angiotensin system”, corresponding to the following 
drugs: metformin-vildagliptin, metformin-sitagliptina, rivaroxaban, fluticasone-
salmeterol, glargine insulin, rosuvastatina, quetiapine, dabigatran, olmesartan 
medoxomil- hydrochlorothiazide and sitagliptin (Table 3). (47) 
Table 3: Portuguese National Health System charges with drugs (Jan-April 2016).  
Pharmacotherapeutic Group Expenses by NHS (€) 
Expenses 
(%) 
Other oral antidiabetics 59.775.937 15.1 
Agents acting on the renin-angiotensin system  33.719.830 8.5 
Antithrombotic agents 28.422.782 7.2 
Antipsycothics 22.792.090 5.8 
Insulins 21.748.380 5.5 
Antidyslipidemic agents 20.540.691 5.2 
Antiepileptics and Anticonvulsants 15.168.894 3.8 
Selective beta-2 adrenoreceptor agonists 13.454.942 3.4 
Antidepressants 10.767.132 2.7 
Others (Group 3.4.6) 10.621.660 2.7 
Others Groups 159.133.824 40.2 
Total 396.146.162 100.0 
Legend: Group 3.4.6 - Cardiovascular System, Others; NHS – National Health System. 
[Adapted from (47)] 
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Considering the number of packages dispensed, the 10 (ten) 
pharmacotherapeutic groups with higher dispensing number were those 
including mainly drugs acting in the cardiovascular system, central nervous 
system and in the alimentary tract and metabolism (Table 4). (47) 
 
Table 4: Portuguese National Health System market analysis of number of 
medicines packages (Jan-April 2016).   
Pharmacotherapeutic Group Number of packages % 
Agents acting on the renin-angiotensin system  4.727.202 9.0 
Antidyslipidemic agents 3.738.277 7.1 
Anxiolytics sedatives and hypnotic 3.594.048 6.9 
Other oral antidiabetics 3.025.944 5.8 
Antidepressants 2.596.343 5.0 
Gastric acid modifiers 2.429.463 4.6 
Antithrombotic agents 2.306.187 4.4 
Analgesics and antipyretics 1.646.894 3.1 
Diuretics 1.439.842 2.7 
Antiepileptics and Anticonvulsants 1.328.071 2.5 
Other Groups 25.542.171 48.8 
Total 52.374.442 100.0 
[Adapted from (47)] 
 
Throughout the year 2014, about 27.82 million of antihypertensive medicines, 
10.62 million of antidyslipidemic medicines and 6.77 million of anticoagulants 
and antithrombotic (number of packages) were consumed in Portugal. About 
half of expenses on drugs of the cardiovascular group was within 
antihypertensive drugs (53.05%), and a quarter within antidyslipidemic dugs 
(26.69%). (9) 
After the legislation change on the ownership of Pharmacy in 2007 (48), some 
medicines were also allowed to be dispensed in other stores, although 
exclusively the ones not subject to medical prescription (the so-called over the 
counter medicines - OTCs). In 2015, the most frequently dispensed drugs in 
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these stores were: paracetamol (14%), ibuprofen (5%), diclofenac (5%), 
chlorpheniramine/paracetamol (4%) and saccharomyces boulardii (4%). (49) 
In January 2016, the Portuguese National Health System (NHS) showed a 
deficit of €259 million, being pharmaceutical products (medicines), products 
dispensed in Pharmacies, resources of diagnosis and complementary 
therapies, and public-private partnerships and capital expenditures, the items 
that were identified contributing to this great increase in expenses. (50) 
Among the European countries, Portugal appears with one of the highest 
consumption of medicines, although the health outcomes are not better than 
those observed in other countries which present lower consumption and 
consequently lower costs. (51)  
Besides direct expenses with medication, there are also indirect expenses. 
These can be attributed to the costs associated with adverse drug reactions 
(ADRs), including costs related to hospital admissions and other health care 
associated costs. (52) 
Data from several prospective studies conducted in the USA, showed that 
ADRs are responsible for 15% of hospital admissions. (53) In Europe, a median 
rate of 3.5% was found for hospitalizations caused by ADRs, and 10.1% for 
ADRs during hospitalization. (54)  
A Portuguese study, which analysed ADRs occurred in hospitals at Lisbon area, 
found an incidence of 11.1% for ADRs, being more than 50% avoidable. (55) 
Another Portuguese study held in subjects visiting the urgency at Faro´s 
Hospital found that a negative result of pharmacotherapy was the cause of the 
visit in 53% of the subjects. (56) 
Mortality can be a parameter associated to the use of medicines. In a tertiary 
Spanish hospital, about 10% of deaths were suspected of having been caused 
by drugs and in about 8% of deaths, drugs were suspected to have contributed. 
(57)  
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Also patient´s morbidity appears to be related with medicine´s use. In a study 
conducted in a Spanish tertiary care hospital, Pedrós et al. (2014) identified that 
only 4.2% of urgent hospitalizations were caused by ADRs, but that about 92 % 
of cases were predictable. (58) 
ADRs may arise as a cause of hospital admission but also during 
hospitalization, and in that period the incidence of ADRs appears to be 
increased. (59) 
Morbidity associated to drugs is also increased in patients with chronic 
conditions, such as the increase of hospitalizations induced by ADRs in patients 
with polypharmacy, particularly in elderly patients. (60,61) Considering this fact 
concerning the elderly population, Nair et al. (2016) already validated a score 
aimed to predict ADRs related hospitalization in subjects 65 years and older. 
(62) 
The preventable drug-related morbidity has been pointed as a main cause of 
hospital admissions, leading to resource consumption and increased health 
costs. (52,63) In Portugal it was estimated that 43,000 patients are hospitalized 
unnecessarily every year. (63) 
Prevention of drug-related morbidities is a complex process, and implies a 
multifactorial approach, either with intervention both at the organizational level 
and at the patient level. (64,65)  
The additional costs for a longer length of stay attributed to ADRs in a group of 
American community hospitals were of $3.000 dollars on average and also an 
increment of 3.1 days in the length of hospitalization was achieved. (66)  
In order to contribute to subject´s health care, it is necessary to include in the 
health system an activity that can contribute to medication management, and 
this could be the responsibility of the Pharmacist. Medication review can be a 
great contribution to the improvement of the responsible use of the medicines 
and may contribute to an optimization of the resources spent on health, 
particularly in the context of the pharmacological treatment. 
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1.2 Pharmaceutical Care  
In recent decades, the pharmaceutical profession has evolved to be more 
patient-oriented. (67,68) The concept of “Pharmaceutical Care” appeared in the 
United States of America, being first presented by Mikeal et al. in 1975, and 
defined as “the care that a given patient requires and receives which assures 
safe and rational drug usage”. (69) 
Latter, Brodie et al. introduced a new definition targeted to the patient, adding 
the identification of patient needs related to pharmacotherapy, and the provision 
of the necessary service before, during and after the treatment. (70) 
In 1990, Hepler & Strand published what was a milestone in the concept of 
Pharmaceutical Care, defining it as “the responsible provision of drug therapy 
for the purpose of achieving definite outcomes which improve a patient’s quality 
of life”. A new role was identified for the Pharmacist, including collaboration with 
the patient and other health professionals in the implementation and monitoring 
of the therapeutic plan, becoming aware of these professionals’ responsibility in 
morbidity and mortality related to drugs. The following outcomes were expected: 
identifying potential and actual drug related problems (DRPs); resolving actual 
DRPs; and preventing potential DRPs. (71) 
Also the American Society of Hospital Pharmacists (ASHP), published in 1993 
its position on the concept of Pharmaceutical Care, defining it very similarly to 
Hepler & Strand. (72)   
In that same year (1993), the International Pharmaceutical Federation (FIP) 
signed a document dedicated to Pharmaceutical Care enhancing the 
awareness for the importance of the Pharmacist role. The document showed 
the need for the Pharmacist’s integration in multi-professional health teams and 
to develop standard operation procedures for developing programs in this area, 
which included identification and monitoring of therapeutic outcomes, evaluation 
and assessment of drug related problems. The Pharmacist was assigned with 
an important role, not only in the individual patient but also within the 
community. (4) 
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In 1994, a group of European researchers devoted to the subject, founded the 
Pharmaceutical Care Network Europe (PCNE), a network dedicated to the 
development of Pharmaceutical Care in the daily practice, aiming to contribute 
to the development of improved pharmaceuticals based practice. (73) 
The book “Pharmaceutical Care Practice”, published by Cipolle, Strand and 
Morley in 1998, focused increasingly on the patient. (74) A second edition was 
published in 2004, further enhancing the Pharmacist's role in optimizing 
pharmacotherapy (resulting from medical prescription and others) in order to 
improve outcomes and patient quality of life by integrating a multidisciplinary 
team. (75) In the third edition (2012), the authors added to the previous 
definition “the goal of achieving positive outcomes for the patient's health”. (76)  
In 1999, a group of Spanish researchers introduced the concept of “Atención 
Farmacéutica”, the corresponding process to Pharmaceutical Care raised by 
Strand et al., having the goal of "achieving appropriate, effective and safe 
pharmacotherapy for all patients”, that included not only the content of the 
Pharmaceutic Care, but also the analysis of two modalities of Pharmaceutic 
Care: global and at-risk-group. (77,78) 
In 2001, the Spanish Department of Pharmacy and Health Products published a 
document with the concepts regarding Pharmaceutical Care, called 
Pharmaceutical Attention and defined as “active participation of the pharmacist 
in the assistance of the patient through the dispensation and monitoring of 
pharmacotherapeutic treatment in co-operation with doctors and other health 
service staff, in order to achieve results that improve the patients quality of life”. 
A set of clinical activities were included in this concept: the indication of drugs 
that do not require a prescription, disease prevention, health education, 
pharmacovigilance, personalized pharmacotherapeutic monitoring and all 
others that are related to the rational use of drugs. According to their definition, 
the pharmacotherapeutic monitoring should include “the detection, prevention 
and solution of Adverse Drug Reactions (ADR)”. (79) 
In 2013, the Pharmaceutical Care Network Europe (PCNE) together with other 
Pharmacists experts in Pharmaceutical Care from several European countries, 
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USA and Australia, established Pharmaceutical Care as “the pharmacist’s 
contribution to the care of individuals in order to optimize medicines use and 
improve health outcomes”. (80) 
 
1.2.1 Pharmaceutical Services 
Pharmaceutical Services have been defined as “those relating to drug therapy 
including pharmaceutical care services, medication management services, 
clinical services and cognitive pharmaceutical services”. (81)  
Some authors defend that clinical pharmacy include two main service´s areas: 
services to monitor and identify risk factors in the process of medicine´s use 
(dispensing of drugs, preventable morbidity indicators, medication review) and 
services to act reactively (pharmacotherapy follow-up and disease 
management). (5) 
Nevertheless, the terminology used at the level of the pharmaceutical services 
it’s not consensual, becoming therefore important to define the content and the 
definitions used in each research project and considered in the services 
provided. (82) 
The inclusion of the Pharmacist within the primary care team or in the 
community pharmacy has been recommended in the referral-consultation 
process, as an asset in the process of medicine´s use by the patients. (83) 
The assessment of Pharmacist´s Interventions (PI) on the results of published 
studies is not performed consistently and comprehensively in several fields, 
being the clinical domain the most reported and more systematically used. (84) 
Other scopes such as humanistic, economic, and process-related aspects are 
often omitted, incomplete, or ambiguous in most tools. (84) 
A systematic review conducted by Aguiar et al. (2016) identified a positive effect 
of the Pharmacist interventions in the accomplishment of type 2 diabetic 
patients to achieve glycemic control, namely on the HbA1c target value, 
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verifying a greater homogeneity between randomized controlled trials (RCTs) 
conducted in the United States with a baseline value for HbA1c of 9%. (85) 
Some studies showed a positive impact on adherence, clinical and humanistic 
outcomes, while health care utilization and costs were less assessed (n=15, 
23.4%). (86) Other studies didn´t achieved a statistical significant improvement 
from the Pharmaceutical Care, as shown in the results of the RESPECT trial, 
considering no significant changes reached in the appropriateness of 
prescribing or quality of life in older patients included in this trial. (87) 
In Portugal, the studies carried out within the Pharmaceutical Care scope are 
still few and these services are not carried out systematically. In addition, the 
partnership with health institutions and other health professionals are still scarce 
and punctual. The public health system does not yet include, to date, these 
services in a formal and contractual model. (6) 
Nevertheless, a couple of studies have been already carried out in this area, 
both in private and public health´s institutions, and performed within academic 
research projects. (6) 
An intervention study was conducted in type 2 diabetes patients in a 
Portuguese primary health care center, to evaluate the impact of a medication 
follow-up program on clinical and humanistic outcomes. (88) 
A prospective randomised controlled trial, developed in a Portuguese secondary 
care hypertension/dyslipidemia outpatient clinic in the university teaching 
hospital of Cova da Beira Hospital Centre, showed a positive impact of the 
pharmaceutical care program, finding a significant improvement in blood 
pressure control (for systolic blood pressure: -6.8 mmHg, p=0.006; for diastolic 
blood pressure: -2.9 mmHg, p=0.020) and medication adherence (74.5% vs. 
57.6%, p=0.012) in patients treated with antihypertensive agents. (89) 
Published in 2010, a study was performed with the main goal of exploring the 
acceptability to users of pharmaceutical care provided in Portuguese community 
pharmacies. The results evidenced a trusting and collaborative relationship 
where the Pharmacist was seen as a health care provider, despite the fact that 
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patients were not able to identify clear expectations about the service, neither in 
terms of the Pharmacist’s role or their expected outcomes. (90) 
The American College of Clinical Pharmacy defined “Clinical Pharmacy” as “that 
area of pharmacy concerned with the science and practice of rational 
medication use”, and is inserted within the philosophy of Pharmaceutical Care. 
The clinical Pharmacist is recognized as an expert in the therapeutic use of 
medications and to provide therapeutic evaluations and recommendations. (91) 
In 2010 a research group presented a broad hierarchical model for Cognitive 
Pharmaceutical Services including the following sections: medicines 
information; compliance, adherence and/or concordance; disease screening; 
disease prevention; clinical intervention or identification and resolving drug 
related problems; medication use reviews; medication management/medication 
therapy management (which includes home medication reviews, residential 
care home medication reviews and medication reviews with follow up); disease 
state management for chronic conditions; participation in therapeutic decisions 
with medical practitioners (in clinical setting and/or in the pharmacy); and 
prescribing (supplement or independent). (92) 
A systematic search for systematic reviews, following the recommendations of 
the Cochrane Collaboration, identified eight categories of clinical services: 
patient counselling, risk factors prevention and control, adherence/compliance, 
medication review, pharmacotherapy follow-up, medication reconciliation, 
information to Physicians or the health care team and prescription of new 
treatments. (93) 
Despite the different nomenclatures and definitions of clinical pharmaceutical 
services, the main goal lies in improving the medicine´s use process and 
clinical, humanistic, and economic outcomes. 
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1.3 Medication review 
A single and worldwide definition for medication review (MR) does not exist. For 
different countries, depending on their health care policies and professional 
operating, MR could involve different inclusion criteria, procedures and also 
outcomes.  
However, several countries such as Australia, Canada, New Zealand, United 
Kingdom and United States of America have developed and implemented 
medication review systematically under the Pharmaceutical Care programs. 
(94) 
 
1.3.1 Pharmaceutical Care Network Europe (PCNE)  
In Europe, the PCNE group has discussed and presented for the first time in 
Leuven (2012) a definition and levels of pharmacist-led medication review. 
During the following PCNE meetings this matter was being addressed and 
some changes were made, as a result of the evidence provided by research 
groups from several countries [Berlin (2013), Malta (2014) and Mechelen 
(2015)].  In 2012, PCNE published a definition for MR that includes “an 
evaluation of a patient‘s medicines with the aim of optimizing the outcomes of 
medicine therapy”, that involve “identifying the risks, detecting medication-
related problems and suggesting solutions”. (95) 
The latest PCNE definition of medication review (2016) describes MR as “a 
structured evaluation of a patient‘s medicines with the aim of optimising 
medicines use and improving health outcomes”, including “detecting drug 
related problems and recommending interventions“. Prescribed medicines 
(including devices) and products over-the-counter (OTC´s) or obtained  in other 
locations are all included in “patient´s medicines”, and “optimising” refers to 
effectiveness, quality of life, efficiency and safety, in order to improve clinical, 
economic and humanistic outcomes relative to the previous parameters. 
Identification of drug-related problems (DRPs) is expected (actual or potential), 
as well the recommended interventions (although follow-up is not included). (96) 
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Pharmaceutical Care Network Europe considers actually four (4) types of MR, 
as described in Table 5. 
 
Table 5: Types of Medication review (MR) according PCNE.
MR Type Sources of information Possible Outputs 
Type 1 
Simple  Medication history 
Drug interactions 
Some side-effects 
Unusual dosages and adherence issues 
Type 2a 
Intermediate  
Medication history 
Patient interview 
Drug interactions 
Some side-effects 
Unusual dosages 
Adherence issues 
Drug-food interactions 
Effectiveness issues 
Side effects 
Problems with OTC 
Type 2b 
Intermediate 
Medication history 
Patient interview 
Clinical data 
Drug interactions 
Some side-effects 
Unusual dosages 
Adherence issues 
Drug-food interactions 
Effectiveness issues 
Indication without a drug  
Drugs without indication 
Type 3 
Advanced 
Medication history 
Patient interview 
Clinical data 
Drug interactions 
Some side-effects 
Unusual dosages 
Adherence issues 
Drug-food interactions 
Effectiveness issues 
Side effects 
Problems with OTC 
Indication without a drug  
Drugs without indication 
Dosage issues 
Legend: MR - Medication Review; OTC - Over-the-counter medicines; PCNE – 
Pharmaceutical Care network Europe. 
[Adapted from (80,96)] 
 
According to a cross-sectional European wide online survey (2014), about 64% 
of the 25 European countries indicated having at least one type of medication 
review procedure in their country, but a low rate of type III clinical medication 
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reviews was achieved, being established in only 6 countries (Croatia, Denmark, 
Finland, Netherlands, Spain and Sweden). (97) 
 
1.3.2 United States of America  
The Medicare Modernization Act (MMA), in the United States America (2003), 
was created to help the Medicare beneficiaries to afford the increasing cost of 
prescription drugs, and the use of “Medication Therapy Management (MTM)” 
programs were developed to contribute to an appropriate and cost-effective 
drug use among beneficiaries, targeted to patients with multiple chronic 
diseases taking multiple medications. (98) 
In 2004, a group of American Associations assembled and reached the 
definition of Medication Therapy Management (MTM) services as being “a 
distinct service or group of services that optimize therapeutic outcomes for 
individual patients”, which was not focused on individual medicines. (99)  
Later, in 2008, a new version included a set of services that should be provided 
according to the individual needs of patients (Table 6). (99) 
Table 6: Medication Therapy Management (MTM) services. 
MTM Services 
 Performing or obtaining necessary assessments of the patient’s health status 
 Formulating a medication treatment plan  
 Selecting, initiating, modifying, or administering medication therapy  
 Monitoring and evaluating the patient’s response to therapy, including safety and 
effectiveness  
 Performing a comprehensive medication review to identify, resolve, and prevent 
medication-related problems, including adverse drug events 
 Documenting the care delivered and communicating essential information to the 
patient’s other primary care providers  
 Providing verbal education and training designed to enhance patient 
understanding and appropriate use of his/her medications  
 Providing information, support services, and resources designed to enhance 
patient adherence with his/her therapeutic regimens  
 Coordinating and integrating MTM services within the broader health care 
management services being provided to the patient  
Legend: MTM – Medication Therapy Management. 
[Adapted from (99)] 
 
25 
Some MTM services were included in health services of the public sector 
(Medicaid and Medicare Part D plans) that adopted a comprehensive 
medication therapy review service (MTR), as well in the private sector (insured 
groups, managed care populations, self-insured employers, and self- paying 
individual patients).  These MTM services should be provided by Pharmacists, 
in collaboration with the patient, the Physician and other health professionals.  
Five core elements were included in the MTM services in the pharmacy 
practice: Medication therapy review (MTR), Personal medication record (PMR), 
Medication-related action plan (MAP), Intervention and/or referral, and 
Documentation and follow-up. (99) 
The MTM has been pointed as a positive contribution to medication 
appropriateness or drug therapy regimens, although these benefits were not 
always converted into improvements in health or costs, leaving the 
recommendation for the future determination of which points of MTM that really 
contribute to health outcomes. (100) In this review, 44 studies were analysed, 
including 21 trials and 4 non-randomized controlled studies, where 28 had a 
medium, low, or mixed risk of bias. MTM services were considered effective for 
adults with one or more chronic diseases who were taking prescription 
medications regarding intermediate outcomes (such as biometric and laboratory 
measures, drug therapy problems identified, drug therapy problems resolved, 
medication adherence, goals of therapy met, and patient engagement in 
medication management), patient-centered outcomes (such as disease-specific 
morbidity, disease-specific or all-cause mortality, adverse drug events, health-
related quality of life, activities of daily living, patient satisfaction with health 
care, work or school absenteeism, and patient and caregiver participation in 
medical care and decision making), and resource utilization (such as 
prescription drug costs, other health care costs, and health care utilization). 
(100) 
Effectively, MTM comprises a set of distinct services. One is Medication 
Therapy Review (MTR) that comprises conducting a “Comprehensive 
Medication Review (CMR)”, by a Pharmacist. This review should include a 
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structured analysis based on the patient as a whole. Previous to the CMR, 
patient´s consent must be obtained, then a “Personal Medication Record” and a 
“Medication List” should be achieved. Then, a copy should be delivered to the 
patient to be shared with the Physician or caregiver and to maintain a current 
record of medication, respectively. During interview, Medication Related 
Problems (MRP´s) should be identified (including adherence), and a 
“Medication-related Action Plan (MAP)” should be developed in order to solve 
problems or to prevent its occurrence. After MTR a referral to other healthcare 
professionals may be required. The frequency of this service is a CMR per year, 
and the eligibility criteria are described in Table 7.  The need for a MTM can be 
identified either by a Pharmacist, Physician or other healthcare professionals. 
(99,101) 
 
Table 7: Eligibility criteria for Medication Therapy Management (MTM).  
El
ig
ib
ili
ty
 
Cr
ite
ria
 
 Patient has experienced a transition of care, and his or her regimen has 
changed  
 Patient is receiving care from more than one prescriber 
 Patient is taking five or more chronic medications (including prescription and 
non-prescription medications, herbal products, and other dietary supplements) 
 Patient has at least one chronic disease or chronic health condition (e.g., heart 
failure, diabetes, hypertension, hyperlipidaemia, asthma, osteoporosis, 
depression, osteoarthritis, chronic obstructive pulmonary disease) 
 Patient has laboratory values outside the normal range that could be caused by 
or may be improved with medication therapy  
 Patient has demonstrated non-adherence (including underuse and overuse) to 
a medication regimen  
 Patient has limited health literacy or cultural differences and therefore requires 
special communication strategies to optimize care  
 Patient wants or needs to reduce out-of-pocket medication costs  
 Patient has experienced a loss of or significant change in health plan benefit or 
insurance coverage  
 Patient has recently experienced an adverse event (medication- or non–
medication-related) while receiving care  
 Patient is taking high-risk medication(s), including narrow therapeutic index 
drugs (e.g., warfarin, phenytoin, methotrexate)  
 Patient self-identifies and presents with perceived need for MTM services  
 Additional targeted MTRs for new or ongoing medication-related problems, 
or further significant changes in patient´s health status or conditions 
[Adapted from (99,101)] 
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In 2013, the most common MTM activities/services reported by providers 
included: creation of a personal medication record/list (63%), providing an 
intervention/recommendation to prescriber (59%) and conducting a CMR (58%). 
(102) 
1.3.3 Australia 
The Pharmaceutical Society of Australia recognizes two types of MR: basic and 
comprehensive, wherein the first is the process that occurs during the 
dispensing of drugs at the pharmacy counter, and the second is a structured 
and collaborative service provided by Pharmacists and General Medical 
Practitioners (GPs). (103) 
Since July 2015, four types of services are included in the Community 
Pharmacy Programmes in the scope of “Medication Management Programmes” 
which aims to “support quality use of medicines services that are designed to 
reduce adverse medicine events and associated hospital admissions or medical 
presentations”: Clinical Interventions, Home Medicines Reviews (HMR), 
Residential Management Medication Reviews (RMMR), MedsCheck and 
MedsCheck Diabetes. The service referred as “Clinical Interventions” has a 
focus on intervention to resolve and document drug-related issues that are 
identified within community pharmacy. The others services have a main goal of 
enhancing quality use of medicines and reduce the number of adverse 
medicines events, and are to be held in the following locations respectively: 
patient´s home, aged care facilities and community pharmacies. (104)  
In programmes that cover a medication review, a clinical medication review is 
performed, established as “a structured and collaborative service aimed at 
identifying and resolving medication-related problems (MRPs)”. (105)  
In the MedsCheck service, a comprehensive medication review is not 
completely performed as in HMR and RMMR, and only the available data at the 
time of consultation is considered.  
The services described are performed by a registered Pharmacist or accredited 
Pharmacist (Table 8). (105–107)  
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Table 8: Description of Medication Review services available in Australia.  
Service Eligibility Criteria Frequency Referral 
Home 
Medicines 
Review 
(HMR) 
 
 
 Patient is living in a community setting; 
 Currently taking five or more regular medicines 
 Taking more than 12 doses of medicine per day 
 Experiencing significant changes to their medicine 
regiment (in the last three months) 
 Recently discharged from hospital 
 Taking medicine with a narrow therapeutic index or that 
requires therapeutic monitoring 
 Experiencing symptoms suggestive of an adverse 
medicine reaction 
 Having difficulty managing their own medicines because of 
low level literacy and language skills or impaired sight 
 Attending a number of different doctors, both General 
Practitioners and specialists 
Att: Not available to in-patients of public or private hospitals, 
day hospital facilities, transition care facilities or to residents 
of a Government Funded Facility 
One each 24 months, except for a list 
of situations: 
 Discharge from hospital after an 
unplanned admission in the previous four 
weeks; 
 Significant change to medication regimen 
in the past three months; 
 Change in medical condition or abilities 
(including falls, cognition, physical 
function); 
 Prescription of a medicine with a narrow 
therapeutic index or requiring therapeutic 
monitoring; 
 Presentation of symptoms suggestive of 
an adverse drug reaction; 
 Sub-therapeutic response to therapy 
Pharmacist; consumer 
or their carer; GP or 
other healthcare 
provider 
Residential 
Medication 
Management 
Review 
(RMMR)  
Patient is a permanent resident of: 
 An Australian Government funded ACF, as defined by the 
Aged Care Act (1997); or a MPS facility 
 Patient is a resident in an Australian Government funded 
transition care facility for more than 14 consecutive days 
One each 24 months, except for the  
list of situations identified for HMR and: 
 Suspected non-compliance or problems 
with managing medication related 
devices 
Att: must be done within 90 days of the 
date of the referral to be remunerated 
Pharmacist; consumer 
or their carer; GP or 
other healthcare 
provider 
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Table 8 (Continued) 
Service Eligibility Criteria Frequency Referral 
MedsCheck 
 Living at home in a community setting 
 Has not received a MedsCheck, Diabetes MedsCheck, Home 
HMR or RMMR in the previous 12 months 
 Taking five or more prescription medicines 
 Had a recent significant medical event (a recent event or new 
diagnosis that has the potential to impact on the consumer’s 
medication adherence or knowledge of their medicine regime and 
may increase the risk of medication misadventure) 
One each 12 months 
Pharmacist; consumer 
or their carer; GP or 
other healthcare 
provider 
MedsCheck 
Diabetes 
 Living at home in a community setting  
 Has not received a MedsCheck, Diabetes MedsCheck, HMR or 
RMMR in the previous 12 months 
 Type 2 diabetes diagnosed within the past 12 months and unable 
to gain timely access to existing diabetes education /health 
services in their community 
 Type 2 diabetes is less than ideally controlled and unable to gain 
timely access to existing diabetes education /health services in 
their community. 
One each 12 months 
Pharmacist; consumer 
or their carer; GP or 
other healthcare 
provider 
Legend: ACF: Australian Conservation Foundation; DVA: Department of Veterans´ Affairs; GP – General Medical Practitioners; MPS: Medication 
Packaging Systems Australia Pty Ltd. 
Adapted from [(105–107)] 
 
All the services outputs should include a medicines list of patient´s current medication and an action plan including goals and 
actions agreed by the patient and any agreed follow-up with the patient’s GP and/or other healthcare provider(s) (Table 9).  
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Table 9: Outcomes from the Medication Review services in Australia. 
Service Process Outcomes 
H
o
m
e
 
M
e
d
i
c
i
n
e
s
 
R
e
v
i
e
w
 
(
H
M
R
)
 
 Patient interview 
 Clinical assessment 
 Written report to the referring 
GP and patient´s community 
Pharmacy choice   
Findings:  
 Medicine use without indication  
 Untreated indication  
 Drug selection  
 Sub-therapeutic dosage  
 Over dosage  
 Continued use of medicine for a condition that has resolved or step down therapy for a 
condition that is well controlled 
 Adverse drug reactions  
 Drug interactions (patient has a medical issue that is the result of a drug-drug, drug – 
disease, drug-food or drug-laboratory test interaction); 
 Failure to receive medicine  
 Dose/drug related issues (confusing dosage schedules, incomplete or missing directions, 
duplication of medicines, disposal of unwanted or expired drugs, storage issues, problems 
with brand substitution or duplication, dose forms, dosing interval, route of administration or 
timing of dosing) 
 Patient medication management issues (continuing ceased medicine, incorrect medicine 
use, signs of adherence issues, swallowing difficulties, dexterity issues, confusion or 
misunderstanding of medicine purpose or use)  
 Determination of correct use and suitability of, or the need for, compliance aids, therapeutic 
devices and appliances 
 Identification of the need for written/verbal information and education for the consumer 
regarding safe and effective use of medicines, therapeutic devices, compliance aids and self-
care activities, which may include CMI leaflets 
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Table 9 (Continued) 
Service Process Outcomes 
M
e
d
s
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 Patient interview 
 Clinical assessment with available 
data 
 Written report to the referring GP 
and patient´s community Pharmacy 
choice 
 
 Patient´s concerns and beliefs about their medicines 
 Medication adherence assessment 
 Patient´s education needs including providing written information to support improved 
understanding and use of medicines  
 Drug-related problems that have been identified from the information available at the time 
of providing the service, using DOCUMENT  
 Provide patients education and guidance on correct use of medication/monitoring devices  
 Discuss with patients the management of chronic condition(s) including lifestyle factors 
related to medicine use and self-management 
Legend: CMI – Consumer medicine information; GP – General Medical Practitioners. 
[Adapted from (105,107–109)]  
 
1.3.4 Canada 
Medication review services are available in the state of Ontario (Canada) since 2007, as a programme in the scope of 
Pharmaceutical Care. The MedsCheck programme was established with the aim of helping patients “to better understand their 
medication therapy and to ensure their medications are taken as prescribed and that patients are getting the most benefit from 
their medications” by conducting a medication review. (110,111) 
Eligibility criteria for medication review programmes are not uniform all over the world, even within a country such as Canada 
that has implemented this service in the Ontario province, other programs are underway in other provinces with inconsistent 
and highly variable criteria. The eligibility criteria for MedsCheck programmes in Ontario are described in Table 10, and this 
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includes conducting an interview held by a Pharmacist registered in part A (Pharmacists who provide direct patient care) of the 
OCP (Ontario College of Pharmacists) or a registered pharmacy intern/registered pharmacy student under the direction of the 
Pharmacist. MedsCheck programs are accessible to Ontario´s resident with a valid Ontario Health Card, and that agree to 
participate voluntarily. (112)  
Table 10: Description of MedsCheck programmes available in Ontario (Canada). 
Program Eligibility Criteria Frequency Referral 
MedsCheck  
 
 
 Taking a minimum of 3 prescription medications for a chronic condition 
 Eligible for a MedsCheck Follow-Up (annual): 
o Discharged from the hospital within the previous 2 weeks 
o A Pharmacist’s documented decision due: significant changes made to an 
existing medication profile or the addition of new medication 
o Documented evidence of patient non-compliance 
o Patient changed their residence and transferred their prescriptions to other 
pharmacy 
o A planned hospital admission 
One review per year 
Pharmacist, 
Physician 
or Nurse 
MedsCheck for 
Ontarians living 
with Diabetes  
 Individuals diagnosed with type 1 or type 2 diabetes and taking 1 or more 
medications for treating diabetes 
One review per year, a 
follow-up review can 
be performed 
Pharmacist, 
Physician 
or Nurse 
MedsCheck at 
Home  
 Individuals taking a minimum of 3 prescription medications for a chronic condition 
and unable to present to the community pharmacy One review per year 
Pharmacist, 
Physician 
or Nurse 
MedsCheck for 
Long Term Home 
Residents(LTC) 
 Individuals resident in a licensed long-term care home 
 Annual: Chronic multiple conditions, multiple medications, or requiring medications 
with a narrow therapeutic index or requiring therapeutic drug monitoring 
A quarterly medication 
review and an annual 
interdisciplinary 
medication review 
Pharmacist, 
Physician 
or Nurse 
[Adapted from (111,113–115)] 
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The Pharmacist conducting a MedsCheck will elaborate the MedsCheck Personal Medication Record, that should be shared 
with the patient, his primary care provider (Physician, Nurse), and other people as agreed with the patient, with the outcomes 
(Table 11). For diabetic patients under MedsCheck for Diabetes program, a Diabetes Education Patient Take-Home Summary 
must be also delivered to the primary care provider. (116) 
Table 11: Outcomes from MedsCheck programs.  
MedsCheck  MedsCheck for Long Term Home Residents (LTC) 
Drug therapy problems (DTPs): 
 Therapeutic duplication; drug may not be necessary 
 Requires drug; needs additional drug therapy 
 Suboptimal response to a drug; Dosage too low; Adverse drug reaction 
 Dangerously high dose; potential overuse; abuse; Non-
compliance/adherence 
 Other DTPs requiring further assessment or consult patient´s prescriber 
 Follow-up measures including potential dates for subsequent Pharmacist 
communication and/or visits 
 Referral services that might include Heart and Stroke, Alzheimer Society, 
Homecare, Diabetes Education Centres, or other 
Annual: 
In-depth medication review as for other programs. 
Quarterly 
Information including: 
 Medication selection, dosage, hours and route of administration, 
duration of therapy, treatments, allergies, drug-drug and drug-
food interactions 
 Identification of DTPs that may require a more in-depth therapy 
analysis (annual review) and follow-up 
 Address prescribing protocols in the best interest of patient care 
[Adapted from (116) ] 
34 
 
1.3.5 New Zealand 
In New Zealand, several services are available in community pharmacies under 
the scope of “Medicines Management Services” (Table 12). (117) 
The long-term conditions (LTC) service is focused on optimising the supply and 
use of prescribed medicines and to manage patient´s adherence, while 
medicines use review (MUR) is a systematic assessment, orientated to the 
patient´s understanding of medicines and adherence. Medicines therapy 
assessment (MTA) is defined as “a systematic, patient-centred clinical 
assessment of all medicines currently taken by a patient, identifying, resolving 
and preventing medication-related problems as well as optimising the 
effectiveness of medication treatment”, whilst comprehensive medicines 
management (CMM) is a service provided by an autonomous Pharmacist 
integrated in a healthcare team in order to provide support and advice about 
patient´s medication management with complex clinical needs. (117) 
 
Table 12: Medicines Management services available in New Zealand.  
 Medicines Adherence Medicines Optimisation 
 Level 1 Level 2 Level 1 Level 2 
Se
rv
ic
e Long-Term 
Conditions 
(LTC) 
Medicines Use 
Review (MUR) 
Medicines 
Therapy 
Assessment  
(MTA) 
Comprehensive 
Medicines 
Management  
(CMM) 
G
o
al
 Optimise supply 
and use of 
medications 
Optimise 
medication 
understanding 
and adherence 
Optimise 
medication 
efficacy 
Optimise 
management of 
prescribed 
medications 
[Adapted from (117)] 
 
Considering the two available services including a systematic assessment of all 
medicines used by the patients, there are specific eligibility criteria for these 
services (Table 13). 
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Table 13: New Zealand: Medicines use review (MUR) and Medicines therapy assessment (MTA) eligibility criteria and outcomes.  
Eligibility Criteria Outcomes 
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(
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U
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 Patients living independently in the community who have 
one or more chronic disease states and meet one or more 
of the following conditions: 
 Taking three or more medicines and/or 12+ doses per 
day  
 Multiple prescribers  
 Have had a recent admission to hospital (especially if 
there was a medicine change)  
 Taking or about to commence taking medicine(s) with a 
high risk of adverse effects, narrow therapeutic index 
and/or requires therapeutic monitoring, or is suspected 
of being inappropriately used 
 Have a particular medicine related problem e.g. 
adverse reaction, nonadherence 
 Are non-adherent or unable to manage their medicines  
 Have literacy or language difficulties, dexterity 
problems, impaired sight, or cognitive deficiencies that 
impact on their ability to manage medicines 
 Medicines Information  
 Synchronisation of al medicines prescribed to patient  
 Reminders in order to improve adherence 
 Adherence support 
 Medication Management Plan to improve medicine´s 
adherence 
 Dispensing services, with dispensing frequency tailored to 
patient´s need 
 Detailed assessment of level of understanding of prescribed 
treatment and supplementing knowledge gaps as required 
 Assessment of level of adherence to prescribed medications 
and reasons or behaviours behind non-adherence 
 Action plan with the patient to address adherence issues 
 Formal referral and report to other health professionals 
 Removal of out of date medicines and medicines that are no 
longer required (with permission) 
 Provision of health behaviour changing strategies aimed at 
improving lifestyle factors 
 
 
 
36 
 
Table 13 (Continued) 
Eligibility Criteria Outcomes 
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(
M
T
A
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 Patients who have one or more chronic disease state, two 
or more co-morbidities, and meet one or more of the 
following conditions:  
 Taking 4 or more medicines and/or 12+ doses per day 
 Increased risk of medicine-related problems  
 Experiencing or are at risk of experiencing sub-optimal 
response to pharmacotherapy 
 Experienced significant changes in their medicine 
regimen during the last 3 months 
 Taking or about to commence taking one or more 
medicines with a high risk of adverse effects 
 Have signs/symptoms of a medicine adverse effect  
 Taking medicine(s) with a narrow therapeutic index 
and/or requires therapeutic monitoring, where sub-
therapeutic or toxic effects are suspected 
All the outcomes from MUR, added to the following: 
 Assessment of the level of adherence in the context of the 
potential effect on clinical outcomes 
 Assessment of clinical status based on all available 
information, including clinical notes 
 Review appropriateness of therapy and compare against 
alternative therapy options as appropriate  
 Review cost-effectiveness of therapy  
 Identify and evaluate actual and potential medicine therapy 
problems  
 Negotiate treatment goals and timelines for attainment of 
goals with both patient and medical practitioner 
 Reporting of suspected significant adverse medicine effects 
 Formulate and document a pharmaceutical care plan 
 Contribute to multidisciplinary team on the formulation and 
documentation of a comprehensive care plan, and to assist 
the team in modifying the care plan based on regular 
assessment of the patient’s status 
 Provision of health behaviour changing strategies aimed at 
improving lifestyle 
 Recommend therapeutic medicine monitoring using target 
concentration intervention as appropriate 
 Provide accurate and timely medicines information to health 
professionals and patients 
[Adapted from (117)] 
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1.3.6 United Kingdom 
Medication Review was incorporated in the General Medical Services 
contractual requirements in 2004 (118), in  community pharmacy contracts in 
England and Wales since 2005 as “Medicines Use Reviews” and in Scotland 
since 2010 as “Chronic Medication Service” (119). The service of medication 
review appears to be pointed as an important tool to improve medicines use, 
contributing to manage polypharmacy, particularly in elderly patients and also to 
increase medication adherence. (119) 
A UK partnership, in 2002, defined Medication review (MR) as “a structured, 
critical examination of a patient’s medicines with the objective of reaching an 
agreement with the patient about treatment, optimising the impact of medicines, 
minimising the number of medication related problems and reducing waste”. 
Four levels of MR were identified in this document: level 0 (Ad hoc: an 
unstructured opportunistic review), level 1 (prescription review: a technical 
review of a list of patient´s medicines), level 2 (treatment review: a review of 
medicines with patient´s full notes) and level 3 (clinical medication review: face-
to-face review of medicines and condition with the patient). (120) 
Since some services in this area such as Medicines Use Review (MUR), a 
service provided in the community pharmacy, didn´t accomplish the levels 
defined in the previous document, a new document was published in 2008. 
(121) Three types of MR were then identified, replacing the previous defined in 
2002, which were the following: Type 1 (prescription review), Type 2 
(concordance and compliance) and Type 3 (clinical medication review). Only on 
Type 3, the patient´s presence was mandatory and there was access to 
patient´s clinical notes. In this service of medication review all participants 
should be included in the process (patient, Physician, Pharmacist and other 
health professionals), and should be conducted including all prescribed 
medicines, OTC´s and complementary medicines. (121)  
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The service of “Medicines Use Review” was introduced formally in 2005, and 
since then some changes arouse, introducing one of the most relevant in 2011, 
being the addition of target groups. (122)    
In 2013, the Pharmaceutical Services Negotiating Committee (PSNC), a 
representative of NHS Pharmacy contractors, and NHS employers have 
published a guidance on “Medication Use Review”, clarifying several points, and 
actually service works as described in the Table 14. (123–125) 
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Table 14: Medicines Use Review (MUR) service characterization.   
Prg Eligibility criteria Frequency Referral 
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 Patients taking at least one “High risk medicine”: NSAIDs, anticoagulants (including low molecular 
weight heparin), antiplatelets or diuretics; 
 Patients taking two or more medicines for respiratory disease (adrenoreceptor agonists, 
antimuscarinic bronchodilators, theophylline, compound bronchodilator preparations, 
corticosteroids, cromoglicate and related therapy, leukotriene receptor antagonists and 
phosphodiesterase type-44 inhibitors). 
 Patients recently been discharged from hospital who had changes made to their medicines while 
they were in hospital. Ideally patients discharged from hospital will receive an MUR within four 
weeks of discharge but in certain circumstances the MUR can take place within eight weeks of 
discharge. Prescribed two or more medicines to be eligible for a post-discharge MUR 
 Patients at risk of or diagnosed with cardiovascular disease and regularly being prescribed at 
least four medicines: one or more medicines for CV/CV risk conditions (Coronary heart disease, 
Diabetes, Atrial fibrillation, Peripheral arterial disease, Renal/chronic kidney disease, 
Hypertension, Thyroid disorders, Heart failure, Stroke/TIA, Lipid disorders), with a prescription of 
at least one medicine from Chapters 2 (cardiovascular), 6.1 (diabetes) or 6.2 (thyroid) of the BNF. 
To be included the MUR target group patients must also be regularly prescribed four or more 
medicines in total. 
 MUR only provided to patients who have been using the pharmacy for the dispensing of their 
prescriptions for the previous three months.   
No more than 
one 
consultation 
in 12 month 
period, 
unless: 
 Pharmacist 
opinion 
 Recently 
discharged 
from 
hospital. 
 
 
Other 
health-
care 
profession
als, 
patients 
 
Legend: BNF - British national formulary; CV – Cardiovascular; NSAIDs - Nonsteroidal anti-inflammatory drugs; Prg – Program; TIA - Transient 
ischemic attack. 
[Adapted from (123–125)] 
 37 
 
According to PSNC data, during the year of 2015 (January – December) about 
82.51% of Pharmacies were conducting MUR, in which about 11.639 
Pharmacies were submitting reimbursement claims for each of the months 
during this period. (126)  
Last update of Pharmacy contractual framework occurred in January 2015 and 
included new advanced services as “New Medicine Service (NMS)” focused in 
the use of new medicines for the patient, including a close personalized 
monitoring of the patient and dispensing information about medicines (at 
dispensing time, four nights after and until 21-28 days after the beginning of 
treatment) (127); “Stoma appliance customisation service” dedicated to patients 
using stoma appliance, to promote a proper use and improve the duration of 
use; “Appliance Use Review Service” as a service of medication review 
performed at patient´s home. (128)  The MUR service has been defined as a 
structured and documented process, also to allow evaluation of the 
effectiveness of the service (Table 15). (129,130)  
 
Table 15: Medicines Use Review (MUR) inputs and outputs.  
Inputs Outputs 
M
ed
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(M
UR
) 
Review: 
 Effectiveness of treatment;  
 Appropriateness of treatment based on 
latest evidence;  
 Adverse drug effects;  
 Test results, interpreting them and acting 
on them where required;  
 Whether the recommendations of 
previous reviews have been acted upon;  
 Recommend new treatments, e.g. 
aspirin or statins in CHD patients;  
 If the Pharmacist is a prescriber they 
would be able to make changes to the 
patient’s treatment as agreed with the 
doctor.  
Medicines-related problems:  
 Patient not using a medicine as 
prescribed (non-adherence)  
 Problem with pharmaceutical 
form of a medicine or use of a 
device 
 Patient reports need for more 
information about a medicine or 
condition 
 Patient reports side effects or 
other concern about a medicine 
 Other (free text information can 
be entered in the clinical record) 
Legend: CHD – Coronary heart disease.  
[Adapted from (129,130)] 
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MUR´s outcomes must include a plan of actions which comprises: 
information/advice provided, yellow card report submitted to Medicines and 
Healthcare Products Regulatory Agency (MHRA), patient’s issues raised with 
the medicine needed to be considered by the GP practice or another primary 
health care provider. 
 
1.3.7 Other models 
A randomized controlled trial was conducted in Netherlands, with students of 
the Dutch School of Medicine, to validate this tool to be used to improve 
prescriptions in elderly patients. This study design included the use of a five 
steps tool (Table 16), constructed (to Dutch language) from an existing explicit 
method to optimize prescriptions of multiple medications (START and STOPP 
criteria), already validated by the respective authors. The results for the new 
tool were positive, with the number of correct decisions increasing and the 
number of harmful decisions decreasing, more in the intervention group than in 
the control group. (131) 
 
Table 16: STRIP (Systematic Tool to Reduce Inappropriate Prescribing) steps.  
1. Structured history of medication use 
2. Structured pharmaceutical analysis 
3. Decision-making for medication choice by Physician and 
Pharmacist 
4. Definite choice by shared decision-making with the individual 
5. Follow-up and monitoring 
[Adapted from (131)] 
 
AbuRuz et al. (2006) created a classification system for treatment-related 
problems (TRPs) with 6 (six) main categories: indication, effectiveness, safety, 
knowledge, adherence and miscellaneous, nine subcategories and a total of 29 
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treatment related problems, which included a section on the analysis of the 
TRPs, indicating being useful for the training of Pharmacists for detecting 
TRPS. Adherence assessment addresses the issue of patient´s adherence to 
self-care activities or non-pharmacological therapy. (132) 
Bondesson et al. (2009) built a questionnaire to identify medication errors and 
assess patient´s compliance to and beliefs about medicines called “Structured 
Medication Questionnaire” (Table 17). (133).  
 
Table 17: Structured medication questionnaire developed by Bondesson et al.  
Questions/Issues Answers/Observations 
Question 1: Do you have any person 
helping you with drug handling at 
home? 
If the answer was “yes”, the following 
questions were asked. 
Question 2: Who are helping you? 
Question 3: With what? Att: These are sequential questions 
Question 4: How do you know how and 
when to take your drugs? 
By memory, by labels at the container, 
by the prescriptions, by the drug list or 
in another way 
Question 5: What routines are used in 
order to remember to take your drugs? 
None, together with meals, multi-dose 
container or in another way 
Medication list  
Comparison made between the 
medications ordered at the hospital and 
the medications taken at home, 
according to the patient 
Frequency of drug´s use Always or as needed (how many times) 
Drug´s changes 
Mentioned in the medical records, 
changes of medication to a generic 
drug, incorrect dosage interval but total 
daily dosage not changed or withdrawal 
of drugs with long dosage interval 
Discrepancies 
Classified in 4 groups: medication 
erroneously added, medication 
erroneously not ordered, ordered dose 
to high and ordered dose to low 
[Adapted from (133)] 
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Hellström et al. (2011) used this questionnaire to prepare a model [Lund 
Integrated Medicines Management (LIMM)] including systematic medication 
reconciliations upon hospital admission and a medication review while in 
hospital. The impact of this model was validated in a prospective, controlled 
study with 210 patients (65 years or older), who were admitted to one of three 
internal medicine wards at a University Hospital in Sweden, and with the 
collaboration of a multi-professional team. Results showed a significant 
decrease in the number of inappropriate drugs in the intervention group than in 
the control group and a lower number of unscheduled revisits to hospital among 
elderly patients, related to drug use. (134) 
Modig et al. (2016), in Sweden, used the LIMM model, conducted by a 
multidisciplinary team, to evaluate the quality of clinical pharmacy service in 
primary care using medication reviews, orientated to the clinical relevance of 
recommendations provided by clinical Pharmacists. At the end, a positive 
impact of clinical Pharmacist´s role was achieved, with benefits for elderly 
patients included in this study. (135)  
Mast et al. (2015) have developed and tested a tool (“Amsterdam Tool”) to be 
used in clinical medication reviews by community Pharmacists, containing an 
interview script with 5 (five) sections and 34 questions, using as source the 
PCNE classification of DRPs (v6.2) and a list of DRPs compiled by De Smet et 
al. (2007) and resulting from older patients with chronic diseases. The created 
tool was focused on the DRPs and patient´s perspective about DRPs. (136) 
In the Netherlands, Kempen et al. (2014) made a large-scale deployment of an 
online CMR (Clinical Medication review) tool allowing a systematic registration 
of DRPs and implemented interventions achieved from CMRs in daily practice. 
(137) 
Also in the Netherlands, Geurts et al. (2016) carried out a randomized 
controlled trial in the primary care setting, with elderly polypharmacy patients 
with a cardiovascular disorder, using an application (W-PCP) to establish 
communication between Pharmacists and General Practitioners (GP´s), 
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allowing both to access patient´s data. Patients included in the intervention 
group were forwarded to the Pharmacist to a clinical medication review, then a 
pharmaceutical care plan (PCP) was established by the cooperation among 
Pharmacist and GP with the patient´s acceptance. The expected outcomes 
were potential DRPs and pharmaceutical care issues (PCIs), proposed care 
interventions to achieve treatment goals, and implementation of interventions. 
All patients were followed by a period of 1 (one) year (control group received 
usual care, without intervention). (138) 
The “WestGem-study”, conducted in Northwest Germany (2012-2015) in 
outpatients with an established goal of evaluating the efficacy of a 
comprehensive medication review. Enrolled patients were 65 years or older, 
with 3 or more chronic diseases (out of 2 different organ systems), at least one 
cardiovascular disease, using systemically 5 or more available drugs, and 
having a history of 1 or more visits to the General Physician during each of the 
past 3 quarters of the year. The Medication Appropriateness Index (MAI) was 
defined to assess the quality of therapy including a weighted score (1, 2 or 3) 
when drug related problem were detected (139) and then the scores of all items 
were sum mated. Patients were randomized into three clusters, each one with 
an intervention at a different time, beginning all at the same time as the control 
group. The first medication review was conducted at the first intervention time 
by blinded Pharmacists, using data from medical records and the results of a 
standardized, comprehensive patient interview. Outcomes from medication 
review were provided to the Physician and another medication review was 
performed after 6 months. (140)  
The conSIGUE program, developed in 178 Spanish community pharmacies, a 
cluster randomized controlled trial, prosecuted with 6 (six) months of follow-up 
(Medication Review with follow-up – MRF) in a population of older adults ( 65 
years) with polypharmacy (5 medicines per day, considering prescribing 
medicines and OTC´s). Three distinct areas of outcomes were analysed: clinical 
outcomes [Negative outcome related to medicines (NOM), Risk of negative 
outcome related to medicines (rNOM) and Drug related problem (DRP)], 
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economic outcomes (number of medicines, emergency departments visits and 
hospitalization) and humanistic outcomes (health-related quality of life, 
medication adherence, patient’s medication knowledge, perception of the 
severity of the health problem, perception of the medication Usefulness). The 
methodology adopted was the Dáder method defined by the Pharmaceutical 
Care Research Group at the University of Granada (2005). (141,142) 
Swiss community pharmacies offer a service since 2013 called “Polymedication 
Check” that includes an intermediate medication review (according PCNE 
definition), focused on adherence problems, patients’ knowledge, and handling 
problems, including registration of all the situations, referral to a doctor if 
necessary and recommendations to the patient. This service is paid by the 
patient´s health insurance. (143) 
 
1.3.8 Portugal 
The implementation of “Pharmaceutical Care” in the daily current practice is not 
yet a reality in Portugal. Some research has been conducted, although there is 
still not a broad implementation of pharmaceutical care or the services included 
such as medication review.  
Recent results indicated an added value of integrating Pharmacists and 
pharmacies in the Primary Health Care network in Portugal, including drug 
information services, monitoring of health status, screening for various 
diseases, medication review and pharmacotherapy follow-up with other 
providers of health care structure (6)  
Alves da Costa et al. (2016) proposed to identify DRPs in elderly subjects 
institutionalized in four (4) nursing homes (in Alentejo, Lisbon and Vale do Tejo 
regions), considering data from medical records and using concepts of the II 
Consensus of Granada (DRPs classification: necessity, effectiveness and 
safety). (144) 
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Another cross-sectional study was developed in 6 (six) Portuguese nursing 
homes, aiming to evaluate the need for pharmaceutical care implementation in 
institutionalized, polymedicated elderly, accessing patient data available at the 
institution, applying the tool START/STOPP to identify potentially inappropriate 
and appropriate, and PCNE classification for DRP´s (v 6.2).  (145) 
A Portuguese (mainland) cross-sectional study held in nursing homes, using 
medication regimen complexity index (MRCI) to assess medication regimen 
complexity in institutionalized elderly individuals, refers this tool as an asset to 
be used in routine medication review as part of the Pharmacists´ intervention. 
(146)  
Salgado et al. (2013) carried out a qualitative study to explore the opinions of 
Australian and Portuguese nephrologists towards a potential future provision of 
clinical pharmacy services in outpatient dialysis centers, in which Portuguese 
nephrologists identify concerns with professional boundaries (Physician-
Pharmacist) and lack of awareness and knowledge of Pharmacist skills, while 
Australian nephrologists have identified medication review, medication re- 
conciliation, medication history update, patient and staff education, patient 
compliance improvement and development and implementation of anaemia 
protocols as potential services to be provided by Pharmacists. (147) 
A transversal descriptive study in type 2 diabetic patients, users of a 
Portuguese community pharmacy located in Coimbra, was developed by 
Simões et al. (2012) to identify risk situations for negative clinical outcomes in 
the process of drug use through medication review, having achieved an 
average of 10.2±4.8 findings per patient. (148)  
Brazinha & Fernandez-Llimos (2014) investigated barriers to implementation of 
advance clinical pharmacy services at the Portuguese hospitals, being 
Pharmacist´s mentality and predetermined attitudes identified as the main 
obstacles to implementation of these services.  (149) 
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In a cross-sectional European wide online survey (2014), Portugal indicated 
only to be carried out in Portugal Type II adherence and compliance review in 
hospital setting (national level) since 2001. (97) 
 
1.3.9 Contributions from medication review  
The results of a retrospective analysis of medication reviews with two time 
periods (pre-integration of the practice Pharmacist and post-integration of the 
practice Pharmacist) showed that the integration of a Pharmacist into the 
general practice team was associated with an increase in the timeliness and 
completion rate of medication reviews and a decrease in the time to complete a 
MR from a median of 56 days to 20 days. (150) 
Also a systematic review and meta-analysis examined the impact of fee-for-
service pharmacist-led medication review on patient outcomes and quantified 
this according to the type of review undertaken (adherence support and clinical 
medication review). Their conclusion was that fee-for-service pharmacist-led 
medication reviews had positive benefits on patient outcomes, in which 
interventions including a clinical review had a significant impact on patient 
outcomes. (7) 
The impact of medication review in mortality and hospitalization for nursing 
home residents did not reveal positive results, according to the results of 
systematic review and meta-analysis. (151)  
Hohl et al (2015) could not reach conclusive results for the effects of medication 
review on patient-oriented outcomes, due to study limitations such as the 
variation in interventions, missing data, methodological flaws of individual 
studies, and it suggested that more quality randomized trials should be 
conducted in future. (152)  
Another systematic review aimed to assess the contribution of the Pharmacist 
to the programs Home Medicines Review (HMR) and Residential Medication 
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Management Review (RMMR), in which evidence was found to support the role 
of Pharmacists in delivering these services. Nevertheless, further research has 
been recommended on the actual clinical outcomes, since for example 54 (5.6 
%) recommendations were not in line with respective guidelines. (153) 
Patients using automated drug-dispensing systems could benefit from a 
medication service, as verified by Kwint et al. (2011) in a pragmatic randomized 
controlled study conducted in primary care, with patients recruited in Dutch 
community pharmacies. Patients were eligible for the study when they were 65 
years-old or above, taking five (5) or more different drugs, of which at least one 
had to be dispensed via an automated system, and were randomized to the 
intervention group (received a medication review at the start of the study) or 
waiting-list group (received a medication review after 6 months). A significant 
decrease of 29% in the number of DRPs after 6 months in the intervention 
group versus 5% in the waiting-list group was observed, wherein at baseline 
there were no differences between the two groups. (154) 
A positive impact on the implementation of recommendations from medication 
review arises from the collaboration between General Practitioners (GP) and 
Pharmacists, as it has been showed in a systematic review performed by Kwint 
et al. (2014). (155) 
A controlled trial implemented in Germany, was conducted in psychiatric 
inpatients, to assess the effect of pharmacist-led medication reviews on the 
medication safety and the resolution of Drug Related Problems (DRP), 
throughout a medication reconciliation at the admission time. (156) This activity 
was performed weekly during hospital stay, at discharge and three months after 
discharge, and the results sent to the Physician. The intervention was 
discussed between all these professionals (intervention group). The role of the 
Pharmacist has been reinforced as a positive contribution integrated in a 
multidisciplinary team in order to improve prescribing appropriateness. 
However, outcomes from the interventions performed in this study do not show 
a clear improvement on clinical outcomes. (156) 
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Furthermore, Clyne et al. (2016) identified studies with several interventions on 
potentially inappropriate prescribing (PIP) in community-dwelling older adults. It 
wasn´t clear if a positive improvement in clinical outcomes resulted from the 
medication review, and also an assessment of PIP prevention impact was 
necessary. (157)   
Results from “WestGem-study” (Germany, 2012-2015), a cluster-randomized 
controlled study, identified the number of drugs used by patients as a significant 
criteria regarding patient´s selection for medication review. Elderly patients with 
multimorbidity, polymedication and a cardiovascular disease seem to benefit 
from a longitudinal care including repeated reviews conducted by a 
multidisciplinary team of professionals more than a single medication review. 
(140) 
A prospective observational study was carried out in 15 nursing homes in 
Andalusia (Spain) during 12 months, which included resident patients 65 years 
and older (332 patients), and where a medication review with follow-up was 
conducted. Compared to the concurrent control group, in the intervention group 
was observed a resolution of 1.2 (average) negative clinical outcomes per 
patient and a significant reduction in the average number of prescribed 
medication. (158) 
Jokanovic et al. (2016) identified improvements in medicines use and health 
outcomes as a result from clinical medication review (CMRs), in community-
settings in Australia. Although the analysed outcomes were not consistent 
across all included studies, an improvement was achieved in this systematic 
review for the following outcomes: reductions in numbers of medications 
prescribed, hospitalizations, potentially inappropriate prescribing and costs. 
(159) 
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1.4 Drug Related Problems 
The activity of MR includes the identification of Drug Related Problems (DRPs) 
(96), but there is no consensus for designation and classification of DRPs. Even 
in the designation itself, besides drug-related problems (DRP), several other 
terms are used in the literature, such as drug therapy problems (DTP), 
medicine-related problems (MRP), medication-related problems (MTP), 
pharmacotherapy failures, drug treatment failures, pharmacotherapy problems 
and treatment-related problems. (160) 
A systematic research study presented by Basger et al. (2014) identified 20 
(twenty) different types of DRPs classification systems, finding that about 75% 
of the studies used a modified existing classification (Table 18). (161)  
 
Table 18: Dug-related problems classifications.  
APS-Doc Cipolle et al. (1998 and 2004) 
Consensus of Granada (1st, 2nd, 3rd)  PROGRAM 
GSASA classification Krska et al. 
Norwegian  PCNE (versions 4, 5, 6 or 7) 
SFPC (Societe Française de 
Pharmacie Clinique) Strand et al. (1990) 
Westerlund et al. (1999) Basger et al. (2015) 
[Adapted from (161–163)] 
 
Westerlund et al. (1999) developed a classification system to document drug-
related problems (DRPs) (type and number) identified in Sweden community 
pharmacies, considering DRP as “a circumstance of drug therapy that may 
interfere with a desired therapeutic objective”. (164) This system allows the 
classification of DRPs by type and kind of intervention carried out by pharmacy 
professionals (Table 19). (165) 
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Table 19: DRPs classification system by Westerlund et al.  
Types of DRPs Types of Interventions 
1. Uncertainty aim of drug 
2. Underuse of medication 
3. Overuse of medication  
4. Other dosage problem 
5. Drug duplication  
6. Drug-drug interaction 
7. Therapy failure 
8. Side effect 
9. Difficulty swallowing tablet 
10. Difficulty opening container  
11. Other practical problem  
12. Language deficiency 
13. Prescribing error 
14. Other drug-related problem 
No intervention 
Patient medication counselling 
Practical instruction to patient 
Patient referred to prescriber 
Prescriber informed only 
Prescriber asked for information 
Intervention approved by prescriber 
Intervention disapproved by prescriber 
Switch of drug  
Referral to colleague 
Other intervention 
[Adapted from (165)] 
 
This tool only documented problems identified in patient´s medicines (OTC´s 
included) but not potential problems, and has a focus on DRPs documentation 
and intervention description. The author refers some limitations for the study, 
such as potential issues with self-reported data, being the participants to decide 
the DRP classification; underestimation of DRPs during peak hours; and low 
rate of drug-drug interactions, probably due to lack of knowledge about all the 
medication used by the patients.  
A decade later, Hohmann et al. (2009) developed a system to document and 
classify DRPs hierarchically in inpatient settings (APS-Doc). (166)  
More recently, in 2012, a new system for classifying DRPs in the hospital 
setting was created with 10 main categories and 48 subcategories, resulting 
from a modification of PCNE classification of DRPs (v5.1) and PI-Doc (167), 
which proved to be suitable for use in the various parts of the medication 
process such as medication reconciliation and drug therapy within both non-
surgical and surgical wards. (168)  
A group of Australian community Pharmacists, who conducted research for a 
few years in the clinical intervention in community pharmacy, developed and 
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validated a system to classify drug-related problems in the practice of 
community pharmacy, called DOCUMENT, which arose as an output of the 
research project “PROMISe Trial”. (169,170) This DRP classification system 
included eight (8) categories of DRPs, having each one 1-5 subcategories 
(Table 20), a list of actions used to investigate DRPs, recommendations to 
resolve DRPs (5 categories and 1-7 subcategories each), clinical significance to 
patient of the interventions purposed (5 levels) and the possibility of a partial 
acceptance of the proposed interventions by the Pharmacist also existed. (109)  
   
Table 20: DOCUMENT - Classification of drug-related problems.   
Drug selection 
DRPs related to the choice of drug prescribed or taken (such as 
drug duplication, drug interaction, wrong drug and no apparent 
indication) 
Over or underdose 
prescribed 
DRPs related to the prescribed dose or schedule of the drug 
(such as dose too high, dose too low and incorrect schedule) 
Compliance 
DRPs related to the patient’s medication- related behaviour (such 
as taking too little, taking too much, intentional drug misuse and 
difficulty using a dosage form) 
Untreated 
indications 
DRPs related to actual or potential conditions that require 
management (such as a diagnosed condition not adequately 
treated or preventative therapy required) 
Monitoring 
DRPs related to inadequate monitoring of the efficacy or adverse 
effects of a drug (including laboratory and non-laboratory 
monitoring) 
Education or 
information 
 
DRPs related to knowledge of the disease or its management 
(such as requests for drug information, confusion about therapy 
or disease states and demonstration of dose administration 
devices) 
Non-clinical DRPs related to administrative aspects of the prescription 
Toxicity or adverse 
reaction 
DRPs related to the presence of signs or symptoms which are 
suspected to be related to an adverse effect of the drug (such as 
toxicity caused by dose, drug interaction or unknown causes) 
[Adapted from (109)] 
 
DOCUMENT has some specific characteristics to be applied in community 
pharmacy, and users need training to allow a better identification of DRPs. 
(169) This tool was used to document DRPs within the trial and the created 
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software was available in the pharmacy computer system. The outcomes from 
previous trial did not include analysis of DRPs resulting from the use of OTC´s. 
(170)  
In Spain, the first Consensus of Granada was published in 1999, resulting from 
a work group of Pharmacists who gathered in Granada in 1998, introducing a 
new concept in the scope of Pharmaceutical Care: “The detection, prevention 
and resolution of drug-related problems”, which resulted in a new tool for 
professionals to use in the clinical practice for evaluating the results of patient´s 
pharmacotherapy, and were adopted by several health professionals. From the 
first Granada Consensus, the definition of Drug Therapy Problems (DTPs) was 
“a health problem, related to pharmacotherapy that interferes or may interfere 
with the expected patient health outcomes”. (171) The second Consensus of 
Granada (2002) introduced significant changes in order to clarify some 
difficulties that had arisen in the DPRs interpretation and some doubts of use, 
and the concept of drug related problems (DRP) was then defined as “health 
problems, understood as negative clinical outcomes, resulting from 
pharmacotherapy, that for different causes, either do not accomplish therapy 
objectives or produce undesirable effects”. Three classes of DRPs were defined 
and described: necessity, effectiveness and safety (Table 21). (172) 
Table 21: DRPs Classification (Second Consensus of Granada).  
Necessity: 
DRP 1: The patient suffers from a health problem as a consequence of not receiving 
the medication that he needs. DTP 2: The patient suffers from a health problem as a 
consequence of receiving a medicine that he does not need. 
Effectiveness: 
DRP 3: The patient suffers from a health problem as a consequence of a non- 
quantitative ineffectiveness of the medication. 
DRP 4: The patient suffers from a health problem as a consequence of a 
quantitative ineffectiveness of the medication 
Safety:  
DRP 5: The patient suffers from a health problem as a consequence of a non-
quantitative safety problem of a medicine.  
DRP 6: The patient suffers from a health problem as a consequence of a 
quantitative safety problem of a medicine. 
[Adapted from (172)] 
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In 2004, an intercultural translation from Spanish to Portuguese language was 
performed by Santos et al. allowing the use of this DRP classification system 
and the respective methodology by the Portuguese Pharmacists. (173) 
After the Second Consensus of Granada, some authors raised the question 
whether DRPs would be elements of the medication use process or would be 
the outcomes of this process, suggesting the abandonment of DRPs 
designation and the use of “Negative Clinical Outcomes”. (174) 
As a result of the Third Consensus of Granada (2007), DRPs were recognised 
as elements of process, designed as “situations, which throughout the process 
of the use of medicines, cause or may cause the appearance of a negative 
outcome associated with medication (NOM)”. NOM was defined as “a situation 
in which the patient is at risk of suffering from a health problem associated with 
the use of medicines, generally due to the existence of one or more DRPs, 
which we can consider as risk factors of this NOM”. (160) NOMs were classified 
in three different types (Table 22). (160) 
 
Table 22: Classification of Negative Outcomes associated with Medication 
(NOM), Third Consensus of Granada (2007).  
Necessity 
Untreated health problem: The patient suffers from a health 
problem as a consequence of not receiving the medicine that he 
needs.  
Effect of unnecessary medicine: The patient suffers from a health 
problem as a consequence of receiving the medicine that he does 
not need. 
Effectiveness 
Non-quantitative ineffectiveness: The patient suffers from a 
health problem associated with of a non-quantitative ineffectiveness 
of the medication.  
Quantitative ineffectiveness: The patient suffers from a health 
problem associated with of a quantitative ineffectiveness of the 
medication. 
Safety 
Non-quantitative safety problem: The patient suffers from a 
health problem associated with a non-quantitative safety problem of 
the medication.  
Quantitative safety problem: The patient suffers from a health 
problem associated with a quantitative safety problem of the 
medication. 
[Adapted from (160)] 
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Furthermore, in the Third Consensus of Granada a list of DRPs was identified, 
although not being exclusive but being adaptable according to the needs in 
clinical practice (Table 23). (160)  
 
Table 23: List of drug-related problems (Third Consensus of Granada). 
 Wrongly administered drug 
 Personal characteristics 
 Unsuitable storage 
 Contraindication 
 Inappropriate dose, dosage schedule and/or duration 
 Duplicity 
 Dispensing errors 
 Prescription errors 
 Non-compliance 
 Interactions 
 Other health problems that affect the treatment 
 Probability of adverse effects 
 Health problem insufficiently treated 
 Others 
[Adapted from (160)] 
 
The methodology used in the Granada´s group is directed to the identification of 
negative outcomes associated with medication (NOM), with the analysis 
focused on the drug and thus directing only to the pharmacological treatment. In 
clinical practice, the management of some health problems favours the use of 
non-pharmacological measures, i.e., this methodology does not allow to identify 
a NOM in these cases.  
Furthermore, Granada´s classification of DRPs focuses more on the 
classification of negative outcome associated with medication (NOM) rather in 
health outcomes, which in some cases may lead to doubts in the classification 
without any added value for the improvement of health outcomes.  
PCNE has also been reaching some classification´s system of “Drug-related 
problems” over the last decade, wherein version 1.0 included 6 domains for 
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“Problems” (23 sub-categories), 6 categories of “DRPs” (34 sub-categories) and 
5 levels for “Intervention” (12 sub-categories). (175) 
Over the years, ten (10) further versions of classification of DRPs have been 
published, being the most recent released in July 2016 (v7.0). (176) 
The previous version (v6.2) has been widely used for several authors since 
2010, and DRPs were classified according to the nature, prevalence and 
incidence, considering four (4) primary domains for Problems, eight (8) primary 
domains for Causes, five (5) primary domains for Interventions and four (4) 
primary domains for Outcome of Intervention. (177) 
The main changes between PCNE classifications of DRPs v6.2 and v7.0 were 
the following: the problem section was reduced to 3 domains (“treatment costs” 
has been moved); a sequence prescribing-dispensing-use was adopted for 
causes; an intervention level was introduced (“Acceptance” section); and the 
name of last section was changed to “Status of the DRP” instead of “Outcome 
of intervention (Table 24). (176–178) 
 
Table 24: PCNE DRPs classification (v6.2 and v7.0)  
v6.2 v7.0 
Domain  Domain  
Problems Problems 
P1 
P2 
P3 
P4 
Treatment effectiveness  
Adverse reactions  
Treatment costs  
Others 
P1 
P2  
P3 
Treatment effectiveness  
Adverse reactions  
Other 
Causes Causes 
C1 
C2 
C3 
C4 
C5 
C6 
C7 
C8 
Drug selection  
Drug form  
Dose selection  
Treatment duration  
Drug use/administration process  
Logistics  
Patient  
Other 
C1 
C2 
C3 
C4 
C5 
C6 
C7 
C8 
Drug selection  
Drug form  
Dose selection  
Treatment duration  
Dispensing  
Drug use/ process  
Patient related 
Other 
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Table 24 (Continued) 
v6.2 v7.0 
Domain  Domain  
Planned Interventions Interventions 
I0 
I1 
I2 
I3 
I4 
No intervention  
At prescriber level 
At patient (or carer) level 
At drug level 
Other 
I0 
I1 
I2 
I3 
I4 
No intervention  
At prescriber level 
At patient level 
At drug level 
Other 
  
Intervention Acceptance 
A1 
A2 
 
A3 
Intervention accepted  
Intervention not 
accepted  
Other 
Outcome of Intervention Status of DRP 
O0 
O1 
O2 
O3 
Outcome intervention unknown  
Problem totally solved  
Problem partially solved 
Problem not solved 
O0 
O1 
O2 
O3 
Problem status unknown 
Problem solved  
Problem partially solved 
Problem not solved 
The main changes between the two versions are marked in bold. 
[Adapted from (176–178)] 
 
The PCNE classification for DRPs, uses an approach per drug/medicine, 
however to conduct a patient-centred approach focused on clinical 
conditions/health problems some situations may not be included in this 
approach. For example, if the patient has an untreated clinical condition, this 
issue would not be included in this approach. Considering the hierarchical 
character of the classification of DRP from PCNE, in situations where there is 
no identified DRP there is no possibility to identify circumstances of risk for the 
occurrence of DRPs (eg, medicine taken in the wrong time), unless the 
Pharmacist has a very systematic approach on identifying all potential DRPs. 
The allocation of specific causes to DRPs identified in the classification of DRPs 
from PCNE becomes difficult to determine, in practice, due to the plurality of 
causes that can lead to a DRP, since some could have a non-pharmacological 
origin. As an example, if a diabetic patient treated with various oral antidiabetic 
drugs, has an uncontrolled glycemic profile, which are the drugs that are going 
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to be assigned as ineffective? Can the origin of this uncontrolled glycemic 
profile be other than a pharmacological cause?. Moreover, in this classification 
system there are some issues related to the drug such as the patient's 
knowledge of medication or relative to the procedure´s monitoring of the 
disease to be undertaken by patient, that are not covered. 
In 2015, the GSASA system was prepared by Maes et al., being validated using 
inpatients against the PCNE classification system (v6.2), and containing 5 
categories of problems and 41 subcategories: detected problem (5 
subcategories), type of problem (2 subcategories), cause of intervention (18 
subcategories), intervention (11 subcategories), and outcome of intervention. 
(162) Two subcategories were added to problems: “Untreated conditions” and 
“Patient dissatisfaction” relative to the PCNE classification (v6.2). Also all 
problems were classified as “Manifest” or “Potential”, and in the intervention 
domain a subdomain “Report to pharmacovigilance centre” was added. (162) 
Horvat & Kos (2016) have translated, validated and upgraded the PCNE 
classification of DRPs (v6.2) to be used in Slovenian community pharmacies. 
The main changes to the original version were the following: potential problem 
was added as a subdomain of problem´s domain; the cause´s domain was 
changed to “risk factors”, and subdomain was organized in prescribing, 
dispensing and use of drugs; and the intervention´s level were organized 
according to communication and agreement with the prescriber. (179) 
Basger et al. (2015) constructed a system for classification of DRPs by 
aggregating seven (7) systems already used, hence resulting in an extensive 
classification system that includes nine (9) categories of causes of DRPs, 33 
subcategories and 58 sub-subcategories. (163)  
The methodology for classification of DRPs is not consensual and the need for 
a consistent and reliable system for classifying DRPs is still a reality. (161,180) 
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One of the points that was reported, which seems to contribute to the 
identification of DRPs, was clinical knowledge of Pharmacists and training 
appears to have an important role to improve these skills. (181,182) 
1.5 Tools for Medication Review 
1.5.1 Inappropriateness of medication 
The incidence of drug adverse reactions increases with the use of multiple 
drugs, such as in polymedicated patients. This condition is common particularly 
in elderly patients, who with advancing age become carriers of multiple 
pathologies and need to use multiple drugs simultaneously as a therapeutic 
approach. (183,184) 
To undergo on DRPs systematic identification tools should be used in order to 
identify situations which can lead to the onset of drugs adverse reactions, such 
as tools to evaluate the adequacy of therapy and to identify risk situations for 
specific patient groups. 
Appropriateness of pharmacological treatment has been associated with 
increasing number of drugs used and number of diagnoses. (185) 
Several designations can be used in this scope, such as “potentially 
inappropriate drug therapy (PIDT)”, “potentially inappropriate medication (PIM)”, 
and “potentially inappropriate prescribing (PIP)”.  As many as 50 terms to refer 
to this matter have been identified in a systematic review. (186)  
Gallagher et al. (2008) defined “potentially inappropriate medications (PIMs)” as 
“medications that have no clear evidence-based indication, carry a high risk of 
adverse side effects or are not cost-effective”. (187) 
The concept of potentially inappropriate may have a different significance from 
inadequate, since the last situation is applicable to situations depending on the 
patient’s clinical condition, and/or relative to a potential drug-drug interaction 
and pharmacological disease. Then, the first concept referred can be applied to 
implicit methods and the other two can be applied to explicit methods. (186) 
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Implicit methods are judgment based, patient specific, and consider the entire 
medication regimen, requiring a high level of skill from the assessor [e.g. 
Medication Appropriateness Index (MAI) and Hamdy questionnaire]. Explicit 
methods are based on a list(s) with explicit drug-oriented and/or disease- 
oriented criteria (e.g. Beers’ lists, STOPP/START, PRISCUS, and NORGEP). 
(188)  
A systematic review with the main goal of identify tools for measuring the 
appropriateness of drug therapy useful in patients with multiple chronic 
condition, have found two (2) implicit methods [Medication Appropriateness 
Index (MAI) and Hamdy questionnaire] and six (6) explicit methods (Beers 
criteria, IPET, STOPP/START, ACOVE, CRIME and NORGEP), although none 
have specificity for patients with multiple chronic conditions. Within the implicit 
methods only MAI having been validated in clinic environment and with elderly 
patients, for explicit methods Beers criteria and STOPP/START fulfilled these 
premises. (189) 
Kaufmann et al. published a review including 46 assessment tools for 
inappropriate prescribing, implicit and explicit methods being most (36) focused 
on elderly patients. Considering the total of tools analysed, no one covered all 
aspects of inappropriate prescribing, been under-prescribing the less 
approached. (190) 
Santos et al. identified in a systematic review, 27 tools to detect PIDT, about a 
quart (27.7%) of analysed studies using two criteria, being Beers criteria used 
by 82.3% of the studies in its various versions. (186) 
Beers criteria was developed by the American Geriatrics Society in 1991 and 
was the first published criteria for potentially inappropriate medications (PIMs) 
identification, having first been created to detect PIMs in nursing homes. (191) 
In 1997, an updated and expanded version of the Beers criteria was launched, 
with 35 criteria defining PIM use in elderly and respective PIMs for 15 common 
medical conditions, also to be used in outpatient settings (192). A third version 
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of the Beers criteria has been published in 2003, including 48 drugs or drug´s 
classes to avoid in elderly and 20 diseases/conditions and drugs to be avoided 
in patients with these conditions. (193) 
In 2012, the American Geriatrics Society (AGS), updated the Beers criteria, 
including the guidelines of the Institute of Medicine standards for clinical 
practice, the updated list of drugs/clinical conditions, and a new table of 
“medications to be used with caution”, among other changes. (194) 
More recently, in 2015, the AGS, launched a new version, which added a list of 
selected drugs that should be avoided or need to have their dose adjusted 
based on the individual’s kidney function and also drug–drug interactions 
documented to be associated with harms in the elderly. The purpose of this new 
version was to be applied to all older adults, except for those in palliative and 
hospice care. (195) 
In 2008, Soares et al. provided an operationalization of the Beers criteria to the 
Portuguese language, being adapted to the active substances approved in 
Portugal. This document includes two tables, one containing the list of PIMs for 
older adults and the other listing the PIMs according to specific clinical 
conditions. (196) 
The Beers criteria are still very directed to the American reality, and no newer 
version was operationalized into Portuguese. Moreover, the last operationalized 
version was not found to be widely used in the country in the clinical setting, but 
only on a few academic projects such as the one performed by Eiras et al. 
(2016) in a Primary Care Health Centre in Oporto. (197) 
STOPP/START criteria have been validated using a Delphi consensus method 
by Gallagher et al. (2008), an Irish group of researchers, consisting a list of 65 
drugs and specific conditions which prescription was potentially inappropriate in 
subjects being 65 years or above. (187)  
Latter, in 2014, a second version of STOPP/START criteria was launched, in 
order to integrate sets of PIMs and Potential Prescribing Omission (PPO) that 
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could have serious negative impact on elderly patient´s health in a clinical 
setting. (198) 
STOPP is a tool for detection of potentially inappropriate prescriptions in elderly, 
consisting in a list of drugs whose prescription is potentially inappropriate in 
subjects with age  65 years. START criteria is a tool to address the Physician 
about indicated and appropriate treatments, for subjects with age  65 years 
with specific diseases, whereas no contraindications exists for their use. (198) 
There is still no Portuguese version available of the STOPP/START criteria. 
A Medication Appropriateness Index (MAI) was developed by Hanlon et al. 
(1992), consisting of 10 criteria for each medication prescribed (indication, 
effectiveness, dosage, correct directions, practical directions, drug–drug 
interaction, drug–disease interaction, duplication, duration, expense) and then 
each medication is rated as appropriate, marginally appropriate, or 
inappropriate. The design of this instrument also aimed to be used as an 
indicator of quality care outcome in America. (199) In 1994, a weighting scheme 
was created to produce a single summated MAI score per medicine. (139) 
Afterward in 2006, Spinewine et al. pointed out a list of suggestions that could 
contribute to evidence the validity and reliability of the instrument, including e.g. 
an update of the list of drug–disease interactions, considering allergy as a drug–
disease interaction, among others. (200) 
In Spain, Gavilán Moral et al. (2013) provided an adaptation and validation of 
the MAI instrument to Spanish language, with a good internal consistency value 
(Cronbach alpha 0.99) and high reliability. (201)  
Until now the adaptation and validation of this instrument into the Portuguese 
reality hasn´t been performed. 
EU(7)-PIM list was developed by a panel of European experts, from the 
German PRISCUS list of potentially inappropriate medications (PIM) and other 
PIM lists from the USA (Beers criteria), Canada and France. EU(7)-PIM is a list 
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of 275 chemical substances, in which some PIM concepts are dose-related or 
defined by length of use or drug regimen. There were no Portuguese experts in 
the preparation of this list. (202) Some authors consider the EU(7)-PIM list more 
suitable to be used with administrative databases or surveys, in 
pharmacoepidemiological applications, without any subjects’ clinical 
information. (188) 
A consensus on which tools should be used to identify inappropriate 
medication/drugs is not yet available, mainly because each country has a 
specific range of available drugs, so probably each country should create/adapt 
their own specific(s) tool(s). (186) 
Some authors believe that PIMs criteria may be used to assess the quality of 
the prescription (203), even in databases and using automated electronic 
applications, however these are not yet ready to be used directly. These tools 
are not used in the same way or are applied to the patient level in all countries, 
and are applied to the patient level. The European Science Foundation (ESF) 
recommended that some work should still be performed so that they could be 
used globally, and in particular at the European level. (188) 
The results obtained in relation to potentially inappropriate medications (PIMs) 
depend on the tool used, and there is still no consensus on the best tool to use. 
Characteristics of the health systems are different across countries and 
continents, and these differences can be a limitation for the creation of a global 
tool. (204) 
A recent Portuguese descriptive cross-sectional study was developed in four 
nursing homes and used several PIMs detection tools (Portuguese adaptation 
of Beers criteria, Beers criteria 2012, and START criteria) and START criteria 
(to identify potential prescribing omissions). A significant lower proportion of 
PIMs were detected, using the Portuguese adaptation of Beers criteria, while 
with the START/STOPP criteria a significant higher proportion of PIMs were 
identified, allowing also to detect situations such as low levels of cardiovascular 
risk prevention in the Portuguese elderly population. (205) 
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1.5.2 Medication Adherence  
According to the WHO, adherence is defined as the "the extent to which a 
person's behaviour - taking medication, following a diet, and/or executing 
lifestyle changes, corresponds with agreed recommendations from a health 
care provider”. (206) 
Several items have been addressed related to medication adherence, such as: 
adherence rates, causes of non-adherence, barriers, enablers to medication 
users, interventions to promote adherence, impact of non-adherence on health 
outcomes. (207) 
Different terms and terminology may be used to refer to medication adherence. 
Within this framework, the ABC consortium held a meeting in September 2009 
(Bangor University, Wales, UK), coordinating the “European consensus meeting 
on the taxonomy and terminology of patient compliance”. The process of 
medication adherence was described as shown in Figure 3, and comprises 
three components: initiation, implementation, and discontinuation. (208) 
 
Legend: Adherence to medication (light blue); Process of management of adherence (dark blue) 
Figure 3: Illustration of the process of adherence to medication and the process 
of management of adherence.  
[Adapted from (208)] 
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Non-adherence was identified as the following situations:  
 Late or non-initiation of the prescribed treatment; 
 Sub-optimal implementation of the dosing regimen; 
 Early discontinuation of the treatment. (208) 
Also a new designation was achieved “Pharmionics”, which was defined as “an 
adherence-related science concerned with the quantitative assessment of the 
three measurable components of adherence to medications (initiation, 
implementation, and discontinuation), and their respective contributions toward 
the effects of medicines”. While initiation and discontinuation are discontinuous 
actions, implementation is a continuous action that requires information 
regarding prescribed drug dosing regimen and the patient’s drug dosing history. 
(208) 
Medication adherence has been a persistent problem having a higher impact in 
chronic diseases. (209)  For chronic diseases, medication adherence has an 
estimated average of only 50% for developed countries, being even lower in 
developing countries. (206)  
Long term medication adherence has been evaluated in prospective studies, 
and the compliance rate showed decrease over the period of medication use. 
(210,211) 
In the prevention of cardiovascular diseases, patients using statins for primary 
prevention showed to be a predictive factor for nonadherence, whereas these 
patients had  higher probability (64%) to be more non-adherent than those who 
started statins on secondary prevention. (210) 
Non-adherence leads to relevant complications in two different but related 
levels: clinical and economic outcomes. Medication non-adherence may prompt 
to adverse drug events (ADEs), either those could be generally responsible for 
poorer health outcomes and a barrier to patients further adherence. (212) 
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Through research conducted in this area in recent decades, adherence was 
described to comprise a variety of health-related behaviour’s that extend 
beyond taking prescribed medications. (206) 
Causes for non-adherence can be multiples, most of them individual with 
different clinical outcomes reached depending on the conditions and 
characteristics of patients, thus, the identification of barriers to adherence is 
highly relevant and the patient has a central role in this process. (213) 
Research results over time has reached a list of determinants for patient´s 
adherence, which were grouped into the following dimensions as shown in 
Table 25. (206,214) 
 
Table 25: Dimensions for determinants of patient adherence.  
Determinants (Dimensions) 
Treatment duration Long term vs short term treatment 
Components Implementation of the dosing regimen Persistence  
Dimension  
Socio-economic factors 
Health care team 
System-related factors 
Condition-related factors 
Therapy-related factors 
Patient-related factors 
Direction of effect 
Classification according to their effect on 
adherence: 
 positive, negative, neutral, or not defined effect  
[Adapted from (206,214)] 
 
A systematic review including 51 other systematic reviews was carried out by 
Kardas et al. in 2013 (214),  with the purpose of reviewing determinants of 
patient adherence resulting from research (Table 26), most of them related to 
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the adherence component of implementation [defined as the “extent to which a 
patient’s actual dosing corresponds to the prescribed dosing regimen” (208)]. 
 
Table 26: Factors having effect on adherence.  
Healthcare team 
and system-related 
factors 
 Barriers to healthcare 
 Drug supply 
 Prescription by a specialist 
 Information about drug administration 
 Healthcare provider-patient communication and 
relationship 
 Follow-up  
Socio-economic 
factors 
 Family support 
 Family/Caregiver factors 
 Social support 
 Social stigma of disease 
 Costs of drugs and/or treatments 
 Prescription coverage 
 Socioeconomic status 
 Employment status 
Patient-related 
factors 
 Age 
 Gender 
 Marital status 
 Education 
 Ethnicity 
 Housing 
 Cognitive function 
 Forgetfulness and reminders 
 Knowledge 
 Health beliefs 
 Psychological profile 
 Comorbidities and patient history 
 Alcohol or substance abuse 
 Patient related barriers to compliance (such as 
transportation difficulties) 
[Adapted from (214)] 
 
A list of causes can be addressed to medication non-adherence, and can be 
labelled as intentional or unintentional, when patient chooses to deviate from 
the treatment regimen, motivated by a rational decision-making process or the 
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patient (passive attitude) may be careless or forgetful about adhering to the 
treatment regimen, respectively. (215) 
Unintentional non-adherence can be predicted by patients’ medication beliefs, 
chronic diseases and socio-demographics, and can be a predictive signal for 
intentional non-adherence. (216) 
Nevertheless, medication adherence rates are not always similar for patients 
with different illnesses. (217)  
In addition, the cause for patient non-adherence cannot be attributed 
exclusively to the patient. (218) 
Most of the methodologies used to estimate patient non-adherence 
systematically exclude patients who do not fill the medication order and also 
those who only fill the medication order once and do not refill it. Currently, there 
is lack of research linking medication orders to dispensing. (219) 
According to Raebel et al. (2011), in a retrospective cohort study held at Kaiser 
Permanente Colorado (KPCO), including 15417 patients who were newly 
prescribed hypertensive, antidiabetic, or anti-hyperlipidaemia medication, the 
adherence rate was overestimated by 9-18% not including primary non-
adherents and early non-persistent. (220) 
According to a systematic review regarding the medication nonfulfillment rates 
and reasons, the three primary reasons identified were concerns about 
medications, lack of perceived need for medications, and medication 
affordability issues. (221) 
Failure of medication regimen will have an effect on several levels: patient’s 
quality of life, clinical results obtained, and costs to the health care system and 
society in general. 
Poor medication adherence can be associated to less positive health outcomes 
such as disease-specific hospitalizations for hypertension patients (+10.9% at 2 
years) and complications (+14% at 2 years), as verified by Han et al. (2014) in a 
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retrospective cohort study using the Korean National Health Insurance Claims 
Database, wherein all patients with hypertension, hyperlipidaemia and diabetes 
were identified and those who had prescribed medications for these diseases 
were enrolled. (86) 
A study held by Rabin et al. (2014) on diabetic patients suggested that several 
interventions can lead to a decrease on the risk of early readmission, such as 
patient diabetes education, improving communication of discharge instructions, 
and increasing patient’s involvement in medication reconciliation and post-
discharge planning. (222) 
Medication adherence has been widely studied for cardiovascular diseases 
since adherence can be indirectly measured by some markers regarding the 
control of risk factors such as blood pressure and lipid levels. (218) 
In the dimension of patient related factors, literacy,  patient knowledge, 
attitudes, and beliefs about the disease can have a negative effect on 
adherence (223). Furthermore belief in the necessity of medication is 
associated to compliance as reported by Ross et al. (2004). (224) 
In a Cochrane review provided by Haynes et al. (2008) interventions performed 
to improve medication adherence in a long term care were complex, with the 
objective of achieving several adherence determinants. Despite the amount of 
research performed in order to demonstrate methodologies to improve drug use 
and health, the results haven´t been very large, and further improvements are 
needed to assist chronic diseases patients. (225)   
Assessment of medication non-adherence can be provided using different 
sources, such as relevant databases, electronic health records, and pharmacy 
fill records. (219,226) 
Measuring adherence can be achieved using various methodologies that can be 
classified as direct or indirect methods. Although direct methods (drug or 
metabolite level in urine or blood) are more accurate, they become much more 
expensive, being the indirect methods often used such as patient 
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questionnaires, patient self-reports, pill counts, rates of prescription refills, 
assessment of patient’s clinical response, electronic medication monitors, 
measurement of physiologic markers, as well as patient diaries. (227) 
A systematic review (Suliman et al., 2012) analysed the adherence barriers that 
were included in instruments used in 1712 citations from 5 electronic databases 
and described the psychometric properties of the identified surveys. The results 
showed that the most used instrument was the Morisky Medication Adherence 
Questionnaire (MAQ), in most instruments patient-related barriers were most 
commonly addressed, while condition, therapy, and socioeconomic barriers 
were underrepresented. (228)  
MAQ has several positive points, being the quickest to administer, and it is the 
tool that has been validated in the broadest range of diseases. Self-Efficacy for 
appropriate Medication Use Scale (SEAMS), Brief Medication Questionnaire 
(BMQ), the “Hill-Bone Compliance Scale” and Medication Adherence Rating 
Scale (MARS) allows to self-efficacy assessment and therefore may be useful 
in medication management clinics, in spite of the difficulty of a global utilization 
since the latter scale is being directed to psychiatric populations and the prior 
one to hypertensive patients. (229) 
The validity of self-report adherence scales must be a relevant point to be 
considered, and in practice, different methodologies are being used. This was 
analysed by Nguyen et al. (2014) considering an overview of 43 adherence 
scales. These results revealed less remark in the way as the information 
obtained from scales, by identifying patient-specific barriers and beliefs 
associated with adherence, may be a positive contribute for rational use of 
medication. (230) 
There is no ideal methodology to assess medication adherence, so the 
literature refers to using multiple tools simultaneously as the most accurate way 
to manage this assessment, using two or more medication adherence tools in 
parallel. (226) 
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1.5.3 Medication Knowledge Assessment 
Patient´s medication knowledge can be a factor contributing to patient´s 
medication adherence and to health outcomes as highlighted in the results of a 
systematic review and meta-analysis relative to patient-centred outcomes 
reported in studies testing interventions to increase medication adherence, 
being important their inclusion in medication review outcomes. (231) 
Garcia-Delgado et al. (2009) reached a definition for patient´s medication 
knowledge (PMK) as “the information acquired by the patient on medication, 
necessary for proper use of it that includes the therapeutic objective (indication 
and effectiveness), the process of use (dosage, regimen, route of administration 
and duration of treatment), security (adverse effects, precautions, 
contraindications and interactions) and conservation”. (232) 
A cross-sectional study carried out in Spanish community pharmacies identified 
72% of the patients with inadequate knowledge considering medication used. 
The lowest scores of knowledge were verified in the scope of “medication 
safety”, respectively 12.6% for “contraindications” and 15.3% for the item “side 
effects”. (233) 
A prospective study developed in patients with inflammatory bowel disease 
(IBD) by Tae et al. (2016) showed a greater risk of relapse of IBD for non-
adherent patients, and found an association of low medication knowledge with 
non-adherence and consequent risk of relapse. (234) 
In order to asses patient´s medication knowledge some tools are available, 
mostly in English (235), such as the use of interviews or specific questionnaires 
as methodology without assessment of validity and reliability (236–239). 
Garcia-Delgado et al. (2009) validated a questionnaire to assess patient´s 
medication knowledge level, including four (4) dimensions and respective 
determinants, having obtained a value of 0.68 for Cronbach´s alfa (Table 27). 
(232)  
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Table 27: Medication knowledge assessment: different dimensions of drug use 
and its determinants.  
Dimension Determinants 
Therapeutic goal Indication Effectiveness indicators 
Medicines Use Process 
Posology 
Dosing regimen 
Methodology of administration 
Duration 
Security 
Adverse effects 
Precautions 
Interactions  
Contraindications 
Conservation Conservation 
[Adapted from (232)] 
 
Romero-Sanchez et al. (2016) applied this validated questionnaire [(Garcia-
Delgado et al. (2009)] in Spanish pharmacy users who went to the pharmacies 
getting one or more medications dispensed. The predictive factors for 
inadequate patient medication knowledge achieved were the unskilled workers, 
caregiver, and the use of more than one drug and patient´s that did not know 
the name of the medication. (233) 
Rubio et al. promoted a cultural adaptation to European Portuguese language 
of the questionnaire previous developed by Garcia-Delgado et al. (2009) called 
“Patient Knowledge about their Medications (CPM-PT-PT)”. However, the 
authors mentioned the need for further studies to demonstrate the equivalence 
of the psychometric properties (reliability and validity) of the Portuguese 
version, so it could be used in pharmaceutical care research projects in 
Portugal. (240) 
Wali & Grindrod (2016) designed a protocol with semi-structured interviews to 
explore the major challenges in population with low health literacy regarding 
medication information (age >50 years, speaking English as a second 
language). The major barriers identified were: short time with the Pharmacist, 
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understanding medication information, forgetting medication information, side 
effects and drug interactions. (241) 
1.5.4 Disease Knowledge Assessment 
A lack of knowledge about disease has been reported as an important factor 
contributing for patient´s medication adherence, and negative health outcomes. 
(242) 
The assessment of patient´s knowledge about disease is not a procedure 
performed across the board, nor there is a systematic methodology for its 
implementation, since each pathology has specific characteristics and the 
activity of disease prevention and monitoring is characteristic for each particular 
disease. 
However, it is a common assessment  procedure in chronic diseases in which 
the patient's behaviour, lifestyle or when managing implications in their daily life, 
represents a high burden in the degree of control of their disease such as in 
asthma (243,244), diabetes, cystic fibrosis (245,246), inflammatory bowel 
disease, among others. 
Some tools used to assess patient´s disease knowledge are presented as a 
mixed evaluation of disease knowledge with medication knowledge and 
attitudes toward disease and medication. (247) 
Kim et al. evaluated patient´s knowledge addressing open questions about 
chronic diseases regarding ways to prevent the onset of diseases and ways to 
detect diseases such as breast cancer, diabetes and hypertension. (248) 
Some tools to access patient´s knowledge about diabetes have been developed 
for several groups of researchers, mostly in English such as e.g. “Brief Diabetes 
Knowledge Test” (thirteen multiple-choice questions) (249), that has been used 
for several research studies. (250) A latest version of the previous 
questionnaire, “Revised Diabetes Knowledge Test (RevDKT)”, allows to 
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evaluate the patient’s general knowledge of diabetes and diabetes self-care (23 
multiple-choice questions). (251) 
A group of New Zealander researchers carried out a systematic review, which 
identified a group of questions used to assess knowledge regarding 
cardiovascular diseases such as stroke. (252) 
Giardina et al. (2012) developed a longitudinal observational program to assess 
the relationship between cardiovascular disease knowledge, race/ethnicity, 
education, and body mass index (BMI). The three questions that were placed to 
adult women were: “1. What is the leading cause of death among US women?; 
2. What are early warning symptoms of heart attack?; 3. What are the actions to 
take if experiencing a heart attack?”. (253) 
Arikan et al. (2009) validated a questionnaire to measure the knowledge level of 
adults about risk factors for cardiovascular diseases (CVD), which included 
several domains: features of cardiovascular diseases, risk factors, and the 
results of adopting a risk-free attitude. Nevertheless, this tool was only 
developed in Turkish language. (254)  
Tian et al. (2011) developed a cross-sectional study to assess patient´s 
knowledge about chronic diseases (diabetes and hypertension), using a group 
of 12 questions, addressing basic knowledge (e.g. target values for blood 
pressure and glucose), risk factors for chronic diseases and daily self-care 
techniques. The answers were summed into a total knowledge score, being 
results <5 considered a low score. (255) 
In a Portuguese prospective randomized trial to evaluate the Pharmacist’s 
interventions, conducted by Morgado & Castelo-Branco (2011), patient´s 
knowledge about hypertension was evaluated considering target values for 
blood pressure and consequences of uncontrolled hypertension (at least two 
complications). (89)  
Monitoring blood pressure is one of the recommendations provided and that can 
be advantageous in untreated hypertense subjects as well in treated patients 
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since it enables monitoring the effectiveness of pharmacological treatment and 
increase treatment adherence, and could be applicable to both ambulatory and 
home blood pressure. (12)  
A low level of patient´s disease knowledge is a significant risk factor for 
negative outcomes in disease control such as chronic obstructive pulmonary 
disease (COPD). (256) 
There is still no available tool to assess patient´s disease knowledge, to be 
used specifically in patients with diabetes, hypertension or dyslipidaemia 
patients, in a systematic way and that has been translated into Portuguese 
language.  
1.5.5 Health Literacy  
In 2004, a publication from the Institute of Medicine Committee on Health 
Literacy defined health literacy as “the degree to which individuals have the 
capacity to obtain, process, and understand basic health information and 
services needed to make appropriate health decisions”. (257)  
In the United States of America it has been estimated that 90 million adults 
have trouble understanding and acting on health care information. (257)  
Patients with low literacy had fewer skills to interpret prescription medication 
warning labels correctly (3.4 times less). (258) 
An exploratory study performed in Portugal (2009) suggested that most users of 
the Imaging Service of Lisbon Central Hospital did not have the literacy 
desirable but only minimally adequate, they felt the need to rely on other people 
to help read hospital flyers, and individuals who had only completed the first 
year of school were those who had more difficulties in reading patient 
information leaflet. (259)  
Although in the last decade illiteracy has reduced in Portugal, according to the 
2011 census, there are still about 500.000 residents aged 10 years or older who 
cannot read or write, i.e., unable to read and comprise written words or writing a 
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complete sentence. In the Algarve region, about 11% of the population is 
illiterate, and about 25% has only 1st full cycle. (260) 
Low health literacy has been associated to higher difficulty accessing health 
care, following instructions from a Physician, and taking medication properly, 
and understanding medical information. A need has been detected concerning 
a more careful selection of information that is transmitted to the patient and how 
it is transmitted, especially by the Physician and other health professionals, 
including Pharmacists. (261)  
A meta-analysis including 48 studies (2016) identified a positive and significant 
correlation between health literacy and patient adherence, in which non-
adherence was more than 1.33 times higher (standardized relative risk) among 
individuals who had lower health literacy. (262) 
Mantwill & Schulz (2015) identified, from a multiple regression analysis, “, that 
type 2 diabetic patients with lower health literacy levels tended to have higher 
medication costs. (263) 
A few number of tools are available to assess health literacy, with different 
methodologies used, most of them having been validated to be applicable in 
English spoken subjects. The following tools are the ones that are available to 
be used: REALM (Rapid Estimate of Adult Literacy in Medicine), WRAT (Wide 
Range Achievement Test), TOFHLA (Test of Functional Health Literacy in 
Adults), NVS (Newest Vital Sign)(264), SAHLSA-50 (Short Assessment of 
Health Literacy for Spanish Speaking Adults). (265)   
REALM tests the word recognition and pronunciation of 66-item, evaluating the 
vocabulary domain, but not a reading comprehension instrument, and it is 
expected to take about 3-4 minutes to apply this instrument (266) The REALM-
R is a shorter version of REALM, including only 7-item to be applied in several 
research conditions. (267) 
TOHFLA has been identified as a reliable indicator of patient ability to 
read health-related materials, including 50-item reading comprehension and 17-
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item numerical (filling blank spaces of a text using words from a list), taking 
about 22 minutes to be applied. (268) A shorter version (S-TOFHLA) was later 
developed in 1999, including 4 numeracy items and 2 prose passages (12 
minutes to be applied). (269) 
NVS (Newest Vital Sign) is an instrument to assess health literacy base on six 
(6) questions about a food nutrition label, with scores from 0 to 6, been 
validated to be used in the United Kingdom. (270) 
Salgado et al. evaluate the utility of this instrument as a proxy for medication 
adherence in community-dwelling older adults, enrolling users of 12 daycare 
centers in Amadora (Portugal). Nevertheless, the results showed a high 
prevalence of wrong answers, about 90% for all questions excluding number 5 
(49.0% of wrong questions). Also no correlation was found between these 
results and SILS, the other instruments used to detect limited reading ability. 
This instrument included one question: “How often do you need to have 
someone help you when you read instructions, pamphlets, or other written 
material from your physician or pharmacy?”, a five-point Likert-type scale [(from 
1, never, to 5, always), for score lower than 2 a difficulty with reading printed 
health-related material was identified. (271) 
SAHLSA-50 was developed from REALM, to be used in Spanish-speaking 
population, allowing an evaluation of subject’s comprehension of medical terms 
commonly used in clinical and public health settings. Includes 50 items, for 
which one it has a question, a key word (correct choice) and a distractor 
(plausible but incorrect choice), where the subject is asked to identify the 
correct word for the item, or the interviewer can identify the answer as “Don´t 
know”. (265)  
The results obtained during the SAHLSA-50 validation suggested that it was a 
useful instrument to identify Spanish speakers with low health literacy. (265) 
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Interestingly, SAHLSA-50 has been already adapted and validated to 
Portuguese language (Brazilian) by Souza et al. (2014), including 18 items 
selected from the 50 initial from SAHLSA-50. (272)  
SAHL-S&E is an instrument constructed based on the methods used for 
SAHLSA-50, but containing 18 items selected from REALM, having presented 
good reliability and results indicated that it may be useful to recognize 
individuals with low levels of health literacy ( >0.90), and to be used in both 
subjects speaking Spanish and English. (273)  
Despite several studies showing the association between low health literacy 
and non-adherence, it appears to exist differences between low, moderate and 
high health literacy individuals and their non-adherent behaviour.  Otini et al. 
(2014) suggested a possible U-shaped curve in the relationship between non-
adherence and health literacy. This approach suggested that people with low 
health literacy would need a different level of intervention (self-efficacy and 
knowledge improvement) comparing to people with moderate levels of health 
literacy (that may not require intervention), while people with high health literacy 
may in fact be intentionally non-adherent. (274) 
A new instrument has been recently validated to assess patients´ beliefs about 
their capability to successfully manage problematic situations related to 
communication with their doctor: The toll Patient’s Communication Perceived 
Self-efficacy Scale (PCSS), can be applied to patients with inadequate or 
marginal health literacy. (275) 
King et al. (2011) have reached a new definition, “pharmacotherapy literacy” as 
“an  individual’s capacity  to  obtain,  evaluate,  calculate,  and comprehend  
basic  information  about pharmacotherapy  and  pharmacy  related services  
necessary  to  make  appropriate medication-related  decisions, regardless  of  
the mode  of  content  delivery  (e.g.  written, oral, visual images and symbols)”. 
(276)    
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Health Literacy may lead to negative outcomes on patient´s health, and this can 
occur from several ways (Figure 4). (277) 
 
Figure 4: Health literacy and improvements in health outcomes.  
Adapted from (277) 
The assessment of subject´s health literacy is not mandatory for all subjects, 
but can be a way allowing the identification of specific needs of individuals or 
population groups, and to a future implementation of interventions that improve 
patient´s health outcomes. (277) 
A low health literacy has been associated with negative health outcomes such 
as more hospitalizations and increased use of emergency care, lower specific 
medical care such as mammography screening and influenza vaccine, poorer 
ability to have an appropriate use of medication; and worse overall health status 
and higher mortality incidence among elderly subjects. (8) Also a poorer use of 
healthcare services appears associated with a low level of health literacy. (278) 
A cross-sectional study developed in Switzerland, aimed to analyse the 
association between health literacy and three years of medication costs (2009–
2011) in a group of patients with type 2 diabetes. It was verified a significant 
association (p<0.05) between low health literacy and higher medication costs 
(year 2010 and 2011).  (263) 
A systematic review aiming to identify Interventions to improve medication 
knowledge and adherence in low health literate populations, identified 37 
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studies assessing knowledge (of 47) and others assessing adherence (26 of 47) 
with a significant effect on the intended outcomes in 27 and 19 of the studies, 
respectively. (279)  
Bandura (1977) defended a cognitive theory referring to an individual’s belief  in  
his  or  her  ability  to  categorize  and  perform  vital actions  to  reach for  
certain  outcomes, considering that expectations of personal efficacy will 
determine future coping behaviour. (280)  
Nevertheless, intervention strategies considering knowledge transfer may need 
to address self-efficacy among patients across all literacy levels to be 
successful in improving patient´s adherence. (281) 
 
1.6 Rational and Approach - ReMeD study  
The increase in the Portuguese population longevity led to a marked growth of 
patients presenting multiple morbidities, mainly chronic diseases. Among these 
chronic diseases there are several major risk factors associated with the main 
cause of death in Portugal, which are the circulatory diseases. (9) In addition, 
for diseases such as hypertension, dyslipidaemia, diabetes mellitus, among 
others, the Portuguese population presents a high prevalence and a low rate of 
disease control. (18,282,283) 
Therefore, there has been an increase in the use of health services, reflected in 
an increasing number of visits to health care units during recent years. (41) 
This situation, along with the economic crisis, evidenced some existing failures 
of the Portuguese health system in the capacity to respond effectively to the 
patient´s needs. This means that there is a growing need for better 
management of the Portuguese health resources. 
Among this scenario, the number of medicines used by patients also increased. 
(47) This may represent not only an increase in direct medicines costs in 
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Portugal, but also an increase in indirect drug costs, which includes the costs 
associated with adverse drug reactions. 
The Pharmacist, a health professional focused on patient centered care, could 
play an important role on patient´s health outcomes, being also an excellent 
opportunity to extend the services provided in the field of pharmaceutical care. 
The medication review service, already available in several countries and using 
different methodologies, have been shown to contribute to the improvement of 
patient´s health outcomes in different settings such as the pharmacy, primary 
care units, hospitals and residential care units. In Portugal, this service has not 
yet been systematically implemented, so there is no systematic methodology 
available to be applied by the Portuguese Pharmacists. 
Therefore, the aim of this thesis was to establish a methodology to analyse 
outcomes in the process of medication use through medication review, with the 
acronyms of ReMeD study. 
The ReMeD study was developed in a clinical setting in the Southern Portugal, 
the “Association for the Diabetes mellitus study and support to diabetic patients 
in the Algarve” (AEDMADA) clinic located in Faro. This institution was 
established in 2006, with the aim of assisting diabetic patients and their families, 
by providing differentiated healthcare and improve patient´s health outcomes. 
The methodology established to achieve the thesis objectives included three 
main features: patients’ clinical evaluation, patients’ medication review, and 
outcomes obtained from the medication review analysis.    
In order to identify which patients might be more likely to benefit from this 
service, the predictive factors associated with negative outcomes were also 
identified. 
A comparison of the eligibility criteria for medication review services, which 
have been systematically implemented in other countries (Australia, Canada 
and England), was performed in order to find out whether the MR methodology 
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used in the ReMeD study would allow similar benefits and outcomes as those 
obtained using other methodologies. 
One of the humanistic outcomes that was considered in the methodology 
applied in the ReMeD study was patient´s health literacy, given the recognized 
relevance in patient´s health outcomes. In order to enable the signalization of 
patients with low health literacy, the adaptation of the questionnaire “Short 
Assessment of Health Literacy - Spanish and English (SAHL-S&E) to 
Portuguese language was performed (SAHL-PT). This was another objective 
defined for this thesis and was carried out prior to the implementation of the 
ReMeD study itself. 
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2 AIM AND OBJECTIVES 
2.1 AIM 
The main purpose of this study is to establish a methodology to analyse 
outcomes in the process of medication use through medication review, in a 
clinical setting.  
2.2 OBJECTIVES 
1) Adaptation to Portuguese language of the “Short Assessment of Health 
Literacy - Spanish and English  (SAHL-S&E)” (273) 
2) ReMeD study:  
a. Clinical patient evaluation: 
i. Characterization of patient´s health problems; 
ii. Characterization of biomarkers and other risk factors for 
cardiovascular diseases (blood pressure, lipid profile (total 
cholesterol, triglycerides, LDL-C, HDL-C), glycemic profile 
(fasting glucose, postprandial glucose and HbA1c), body 
mass index (BMI), smoking habits, physical exercise habits 
and dietary habits;  
iii. Assessment of the cardiovascular risk;  
iv. Analysis of the degree control of risk factors for 
cardiovascular diseases; 
b. Characterization of pharmacotherapeutic profile; 
c. Analysis of medication review outcomes: 
i. Clinical outcomes: 
1. Identification of negative clinical outcomes;  
2. Identification and characterization of drug related 
problems;  
3. Identification of risk situations for negative clinical 
outcomes; 
ii. Economic outcomes: 
1. Number of medicines; 
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2. Number of hospitalizations; 
3. Number of Physicians following patient; 
4. Rate of reimbursement of medicines.  
iii. Humanistic outcomes: 
1. Medication adherence assessment; 
2. Patient medication knowledge; 
3. Patient knowledge about disease and monitoring 
procedures;  
4. Patient health literacy [previous adaptation of the “Short 
Assessment of Health Literacy - Spanish and English 
(SAHL-S&E)” to Portuguese language (Portugal) - 
SAHL-PT]; 
5. Help with medication; 
6. Self-perceived health status; 
iv. Potential interventions; 
d. Identification of predictive factors for clinical outcomes associated 
to medication review; 
e. Analysis of eligibility criteria for medication review programs 
available in Australia, Canada and England. 
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3 METHODOLOGY 
3.1 Adaptation to Portuguese language of the “Short 
Assessment of Health Literacy - Spanish and English (SAHL-
S&E)”  
Study Design  
Observational, descriptive, cross sectional population-based study. 
Study Population 
Users of the Algarve region pharmacies (8 pharmacies). 
Inclusion criteria 
 Patients aged 18 years and older; 
 Can read and write;  
 Fluent in Portuguese. 
Exclusion criteria 
 Patient with cognitive impairment; 
 Serious vision or hearing problems. 
Sample  
Subjects were recruited from Faro district pharmacies (8) users in the period of 
2 weeks (September 2014). 
 
Data collection 
All subjects who met inclusion criteria and accepted voluntarily to participate in 
this research study were enrolled in this project. 
Data collection was conducted through structured interviews, by completion of a 
questionnaire (Appendix A). 
Subject´s data were collected anonymously without identification of the subject 
who agreed to participate in the project.  
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Translation  
A translation of the Spanish version of the questionnaire (273) from Spanish to 
Portuguese was performed, using the following procedure: 
1) Translation from Spanish into Portuguese by two investigators who have 
expertise in the Spanish language at the University of Algarve; 
2) The Portuguese version of the instruments was evaluated by two 
Portuguese/Spanish bilingual persons; 
3) The questionnaire was translated back into Spanish by two Portuguese-
Spanish independent translators, two other university professors with expertise 
in research.  
4) Both versions were compared to the original language, confirmed checks 
with the translators, considered the differences, and a final version was 
generated.  
5) The previous version of the questionnaire was applied in a pilot sample of 20 
subjects who accomplished the inclusion criteria for this adaptation study, in 
order to identify some difficulties in the practical application of the questionnaire. 
In this pilot sample, there were no difficulties registered during the questionnaire 
application. Therefore, this version was used as the final version of the 
adaptation of this instrument for the Portuguese population, the SAHL-PT 
(Appendix B).  
 
Application 
The questionnaire included 18 medical terms to assess in Portuguese adults, 
the ability to read and understand common medical terms. The test application 
was conducted through the use of cards 10.5 x 14.8 cm (A6), each containing a 
medical term printed in bold at the top, and the two words associated, the 
keyword and the distractor, at the bottom.  
The following instructions were used by the interviewer (Table 28): 
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Table 28: Interview instructions. 
1.  
Before the test, the interviewer should tell the individual being examined: 
"I'll show you a card with 3 written words. First, I would like you to read a 
word that is on the top aloud. Then you'll read the two words below and 
please tell me which of the two words is related to the word from above. If 
you do not know the answer, please say "do not know". Do not guess.” 
2.  The first card is shown; 
3.  The interviewer should tell the individual being examined: 
"Now, please read the word that is on the top aloud" 
4.  
The interviewer should then read the keyword and the distractor (the two 
words at the bottom of the card), and say: 
"Which of the words is related to the word above? If you do not know the 
answer, please say, "I do not know."  
5.  The interviewer can repeat the instructions until the individual examined feel 
comfortable with the procedure; 
6.  The test continues with the remaining cards; 
7.  
The right answer for every test item was determined by the correct 
pronunciation and the association. Each correct answer corresponds to one 
(1) point. 
 
The interviewer had a score table for recording the responses of subjects being 
examined. This registration was done without the examined subject seeing it 
nor being distracted by the procedure. When the test was finished, the account 
of the total score was performed generating the final score of the Short 
Assessment of Health Literacy – Portuguese (SAHL-PT) (Appendix B). 
 
Study Variables 
The maximum score that can be achieved is 18, corresponding to 1 point for 
each of the items included in the questionnaire. 
Subjects who obtained a score equal or under 14 were considered as having 
“low health literacy”.  
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Statistical analysis 
Data were analysed with IBM-SPSS software version 24.0 (SPSS Inc., Chicago, 
IL, USA). 
All quantitative data were analysed using descriptive statistics presented as 
mean, median, standard deviation, minimum and maximum. The qualitative 
variables were described by counts (n) and percentages (%). 
Reliability was examined using Cronbach´s  test, which is one of the measures 
most commonly used to evaluate the internal consistency of a group of 
variables (items), and can be defined as the correlation expected to be derived 
from the scale used and other hypothetical scales of the same universe, with 
equal number of items that measure the same characteristic. (284)  This 
measure indicates the extent to which the reliability of the test scores was 
similar in the study sample.  
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3.2 ReMeD Study 
 
3.2.1 Study Design  
Observational, population based, descriptive and cross-sectional study (pilot). 
Study Population 
This study was developed at the clinic “Association for the Diabetes mellitus 
study and support to diabetic patients in the Algarve” (AEDMADA). This 
association, placed in Faro, was founded in 1996, and is a non-profit charity 
organization with the legacy of addressing the needs of diabetic´s patients and 
their family. The main goals of AEDMADA are to promote early diagnosis, 
possible prevention and treatment to delay or prevent complications of diabetes 
mellitus. (285)  
Subjects included in this research study were AEDMADA users that fulfilled the 
inclusion criteria described below. 
Inclusion criteria 
 Patients aged 18 years and older; 
 Using one medicine for at least 6 months. 
Exclusion criteria 
 Patient with cognitive impairment. 
Sample Calculation 
AEDMADA has a population of active users of about 400 subjects. AEDMADA 
users are mainly diabetic patients, and one of the most prevalent disease in the 
Portuguese population is hypertension with an estimated prevalence of 42% 
(15). Also in the diabetic population, hypertension presents an increased 
prevalence (80.3%), according to a national study held in the Portuguese type 2 
diabetes patients. (283) For a confidence level of 95% and a confidence interval 
of 5%, the calculated sample size was 117 subjects.  
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During the enrolment period, 126 subjects who met the inclusion criteria were 
included in the study. However, due to lack of complete and updated data on 
biomarkers for cardiovascular diseases, three (3) subjects were excluded, three 
(3) subjects did not bring the medication they were taking and two (2) subjects 
didn´t accept to participate in the study, being excluded as well. 
Data collection 
All subjects who met the inclusion criteria and accepted voluntarily to participate 
in this research study signed an informed consent prior to initiating data 
collection (Appendix C). 
Data collection was conducted through structured interviews, which was held 
during a consultation in a systematic way by completion of a questionnaire 
(Appendix D).  
Upon confirmation of the medical consultation by telephone, AEDMADA users 
were asked to bring with them all medications they were using (either 
prescribed or not by a doctor), as well as over-the-counter medicines, food 
supplements and natural health products. 
In consultation day, subjects were led to a private room, whereas the research 
project was presented and respective goals. If the subjects agreed to participate 
they would give their written consent and the interview could be initiated.  
Study Variables 
Cognitive state was verified by asking the patient to identify the current year, 
day and day of the week. 
 
3.2.2 Socio-demographic variables 
The socio-demographic variables that were considered for patient´s 
characterization are described in Table 29. 
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Table 29: Socio-demographic variables description. 
Variable Description 
Age Full years, directly asked to the patient and confirmed by the birth date in the patient´s clinical file 
Gender Masculine or feminine 
Marital status Married/ committed, single, widower, or divorced, according to information provided by patient 
Household 
Alone and autonomous; alone with support; husband/wife; 
parents; brother; son/daughter/daughter in law/son in 
law/grandchildren; partner and children; institution; partner, 
son/daughter and grandchildren; partner, children and parents, 
according to information provided by patient 
Qualifications 
1st cycle of basic education (4th grade); 2nd cycle of basic 
education (junior); 3rd cycle of basic education (9 years); 
secondary education (12th grade); professional 
course/technological (Level III); higher education; cannot read or 
write; can read and/or write without having education degree), 
according to information provided by patient 
Professional 
situation 
Retired; unemployed; self-employed; employed by others; retired 
with activity; without professional activity, according to information 
provided by patient 
Follow-up 
period 
(AEDMADA 
clinic) 
Months, data obtained from the patient file 
 
3.2.3 Variables related to patient clinical evaluation 
Clinical diagnosis: Clinical profile was described using the information 
provided by patient, completed and confirmed with the information available in 
the patient´s clinical file, and was classified according to the International 
Statistical Classification of Diseases and Related Health Problems 10th Revision 
(ICD-10) (WHO Version – 2015):  
http://apps.who.int/classifications/icd10/browse/2015/en#/V. 
Biomarkers and other risk factors for cardiovascular diseases: The 
following parameters were considered to assess cardiovascular risk: blood 
pressure value, glycemic profile (HbA1c, fasting glucose, and post-prandial 
glucose), lipid profile (total cholesterol, triglycerides, LDL-C, HDL-C), body mass 
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index (BMI), smoking habits, and physical exercise, according to the reference 
values indicated below. 
 
 Blood pressure (BP) 
During medical consultation BP was measured, at least twice, with a minimum 
interval of one to two minutes between measurements, and the lowest levels of 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
registered in the patient´s clinical file (286).  Reference values adopted for SBP 
and DBP are described in Table 30. 
Table 30: Blood pressure reference values. 
Parameters Therapeutic goal 
General (286,287) 
Systolic Blood Pressure < 140 mmHg 
Diastolic Blood Pressure < 90 mmHg 
Diabetic Patients (24) 
Systolic Blood Pressure < 140 mmHg 
Diastolic Blood Pressure < 85 mmHg 
Patients with nephropathy < 130/85 mmHg 
 
 Glycemic profile  
The parameters considered were: fasting glucose, postprandial glucose and   
glycated haemoglobin (HbA1c). The reference values adopted for these 
parameters were those from the Portuguese Society of Diabetology (SPD) and 
the Portuguese General Direction of Health (DGS) and are described in Table 
31.  
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The value of HbA1c was collected from the patient´s clinical file and was 
considered valid when obtained in a period of less than 3 months from the data 
collection. The values of the remaining parameters (fasting glucose and 
postprandial glucose) were collected in the consultation day. 
The assessment of glycemic profile control was performed considering HbA1c 
value, analysed for each patient individually, considering their individual 
characteristics in accordance with applicable guidelines (Table 31). 
Table 31: Reference values for glycemic profile.  
Fasting glucose 
Hypoglycaemia: < 70 mg/dL 
Normoglycaemia: 70 - 130 mg/dL (7.2 mmol/L)  
Hyperglycaemia: > 130 mg/dL 
Postprandial glucose  
Hypoglycaemia: < 70 mg/dL 
Normoglycaemia: 70 - 180 mg/dL (9–10 mmol/L) 
Hyperglycaemia: > 180 mg/dL 
HbA1c 
Optimal: < 6.5% 
General: < 6.5 - 7% 
Long term Diabetes mellitus (> 10 years), short life 
expectancy, comorbidities: < 7- 8% 
Target values stricter for HbA1c (e.g. 6.0-6.5%) were considered for selected 
patients: short duration of disease, increased life expectancy without significant CVD 
if values can be achieved without significant hypoglycaemia or other adverse effects 
of treatment. 
Target values less restricted (e.g. 7.5-8.0% or higher) were considered for patients 
with history of severe hypoglycaemia, limited life expectancy, complications in 
advanced stage and clinically relevant multiple morbidities and in patients where the 
target value is difficult to achieve in spite of intensive training in self-treatment, 
repeated advice and effective doses of multiple glucose lowering agents including 
insulin. 
[Adapted from (288–291)] 
 
 Lipid profile 
The reference values adopted were those from the European Society of 
Cardiology / European Atherosclerosis Society (ESC/EAS) and the Portuguese 
General Direction of Health (DGS) for the following biochemical parameters: 
total cholesterol, LDL-C, HDL-C, and triglycerides, as described in Table 32.  
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These parameters were collected from the patient´s clinical file, and were 
considered valid when obtained in a period of less than 6 months from the data 
collection. Lipid profile analysis was performed as an individual approach, 
according to the applicable guidelines (Table 32).   
 
Table 32: Lipid profile reference values.  
Total Cholesterol  < 190 mg/dL 
LDL-C 
 Low cardiovascular risk (score <1%)  
or moderate (score 1% - 5%) < 115 mg / dl 
 Asymptomatic people with high cardiovascular 
risk (score  5% to <10%)  
 Family with atherogenic dyslipidemia  
 Grade 3 hypertension (180 and / or 110 mm 
Hg) 
< 100 mg / dl 
 Very high cardiovascular risk (CV clinically 
evident disease, type 2 diabetes or type 1 with 
one or more cardiovascular risk factors and/or 
organ- target of injury, severe chronic kidney 
disease [GFR <30 ml / min / 1.73 m2] or a level 
score  10%) 
< 70 mg / dl 
HDL-C > 40 mg/dL (male) 
> 45 mg/dl (female)  
Triglycerides < 150 mg/dL 
Legend: CV: cardiovascular; GFR: glomerular filtration rate; HDL-C – High lipoprotein 
cholesterol; LDL-C – Low lipoprotein cholesterol. 
[Adapted from (292,293)] 
 
 Body mass index  
The parameter body mass index (BMI) was calculated through the formula: 
[(ratio of weight (kilograms) / height2 (squared meters)], and classified according 
the reference values of the World Health Organization (WHO), as described in 
Table 33. (294) 
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Table 33: Body Mass Index (BMI) Classification.  
BMI Classification Kg/m2 
Underweight <18.50 
     Severe thinness <16.00 
     Moderate thinness 16.00 - 16.99 
     Mild thinness 17.00 - 18.49 
Normal range 18.50 – 24.99 
Overweight 25.00 
Pre-obese 25.00 – 29.99 
     Obese 30.00 
     Obese class I 30.00 – 34.99 
          Obese class II 35.00 – 39.99 
          Obese class III 40.00 
[Adapted from (294)] 
 
 Smoking habits  
Smoking habits data were collected from information provided by the patients 
themselves during the interview, and were classified as: smoker, ex-smoker, 
non-smoker, as described in Table 34. 
. 
Table 34: Smoking habits characterization. 
Classification Habits 
Smoker Number of cigarettes or other similar products consumed per day. 
Ex-Smoker Quit smoking for at least one (1) year. 
Non-Smoker 
No smoking habits, or at least fifteen (15) years after quit 
smoking (after this period the cardiovascular risk is similar to 
someone who has never smoked, if no heart disease was 
developed).  
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 Physical exercise habits  
The physical exercise habits were classified according to: 
 Practice of physical exercise regularly (yes/no). 
 Frequency (number of times per week). 
 Duration of each session (minutes). 
 
Cardiovascular Risk: The stratification of risk for cardiovascular diseases was 
achieved using the recommendations of the Portuguese General Direction of 
Health (DGS) and European Society of Cardiology. (24,287,295)  
The cardiovascular risk of patients was classified individually in a qualitative 
way and was classified as “Very High Risk”, “High Risk”, “Moderate Risk” or 
“Low Risk”. 
 
3.2.4 Variables related to Pharmacotherapeutic Profile 
Medicines: All prescribed and consumed medicines (including over the counter 
medicines and food supplements) were considered at the time of the data 
collection and were subsequently confirmed in clinical patient process.  
During the interview, patients were asked about previous situations of 
intolerance and / or drug allergies. 
Data were collected regarding brand name medicine, drug, dosage, intakes per 
day, start date, prescriber, and any additional information can could be 
considered relevant was recorded as “observations”. 
The following parameters were considered: 
 Total number of medicines used by the patient [including over the 
counter medicines (OTCs)]; 
 Total number of food supplements; 
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Drugs were classified according ATC classification 
(http://www.whocc.no/atc_ddd_index/) for all medicines at 1st level (anatomical 
main group) and 4th level (chemical subgroup). 
The information about medicines was obtained in the Summary of Products 
Characteristic (SmPC) available at the INFARMED site 
(http://app7.infarmed.pt/infomed/inicio.php) and EMA site 
(http://www.ema.europa.eu). 
Polypharmacy was defined as patients taking 5 or more medicines.  
Potential drug-drug interactions (DDI´s): were identified using online 
available tools: http://reference.medscape.com/drug-interactionchecker, 
http://www.drugs.com/drug_interactions.html and information included in the 
SmPC. 
 
3.2.5 Results from Medication Review 
Medication Review (MR) was performed individually for each patient presenting 
for each clinical, humanistic and economic outcomes. The analysis was 
performed by health problem, considering the diagnoses identified for each 
patient and also identifying clinical situations that were not being addressed.  
 
3.2.5.1 Variables related to Humanistic Outcomes 
 
Medication Adherence: The assessment of medication adherence was 
performed using two instruments: the “Measure Treatment Adherence” scale 
adapted from Morisky & Green and validated to Portuguese language by 
Delgado & Lima (Medida de Adesão aos Tratamentos - MAT) (296), and the 
Haynes-Sackett test (297) (Table 35).  
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Table 35: Medication adherence assessment instruments. 
MAT: This scale measures levels of adherence to drug treatment, using seven (7) 
questions that use a response in a Likert scale (5 points), with a minimum value of 
one (1), which corresponds to "always", and a maximum of six (6), corresponding to 
"never". The average score of patient medication adherence was obtained by the 
ratio of the total values of each element and the total number of elements and can 
assume values between one (1) and six (6). (296) 
HS: Haynes-Sackett test is a self-reported method based on asking the patient about 
medication adherence and is divided into two parts: the first part is not a direct 
question to the patient about medication use, an environment is created to an 
appropriate conversation and the interviewer talk to the patient about the difficulty of 
taking medication ("Most patients have difficulty in take all your medicines "); in the 
second part of the question patient is asked: "Do you have any difficulties taking 
yours?". When the answer is yes, considers as a non-adherent patient. When the 
patient's answer is no, the interviewer cannot tell the truth and then insists asking 
other questions: "How do you take them?" (every day, many days, some days, a few 
days or rarely). 
Patients were classified as adherent if the percentage of adherence was between 
80-110%. (297,298) 
 
Patient Medication Knowledge: The assessment of patient medication 
knowledge (MK) was performed during patient interview considering six 
parameters: medicine´s name, drug´s strength, therapeutic indication, storage 
conditions, timing of administration and/or dosing Intervals and daily dose use, 
as described in Table 36. 
. 
Table 36: Patient´s medication knowledge assessment. 
Variable Answers Indicator 
Medicine´s 
Name 
1. Patient knows medicine´s name. 
2. Patient does not know medicine´s 
name. 
Rate (%) of medicines whose 
name was correctly identified 
Drug´s 
strength 
1. Knows drug´s strength 
2. Does not know drug´s strength 
Rate (%) of medicines whose 
drug´s strength was correctly 
identified 
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Table 36 (Continued) 
Variable Answers Indicator 
Therapeutic 
Indication 
1. Knows the correct therapeutic 
indication 
2. Does not know the correct 
therapeutic indication 
3. Does not know the therapeutic 
indication 
4. The information on the therapeutic 
indication is not complete 
Rate (%) of medicines 
whose therapeutic 
indication was correctly 
identified (1 and 4) 
Storage 
conditions 
1. Correct storage 
2. Incorrect storage 
3. Lack of information on medication 
storage 
Rate (%) of medicines 
whose storage conditions 
were correctly identified (1 
and 3) 
Timing of 
administrati
on and/or 
dosing 
Intervals 
1. Correct 
2. Incorrect 
Rate (%) of medicines 
whose timing administration 
and/or dosing intervals were 
correctly identified  
Daily dose 
use 
1. Correct 
2. Incorrect 
Rate (%) of medicines 
whose daily dose use was 
correctly identified  
 
The score of Medication knowledge (MK) per patient was calculated as the 
average (in %) of the six parameters considered in the medication knowledge 
assessment, using the formula [(MK1+MK2+MKn)/nr total medicines] x 100. 
For patients with score values below 50%, it was considered that the patient 
had “low medication knowledge”. 
 
Patient Disease Knowledge: The assessment was performed considering 
three domains, namely “target value for biochemical/physiological parameters”, 
“complications of uncontrolled disease” and “self-monitoring procedures”, as 
described in Table 37.  
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Table 37: Patient Disease knowledge assessment. 
 Parameter Answers Assessment 
Hy
pe
rt
en
si
o
n
 
 What is the target value for 
your BP? 
 Correct 
 Incorrect or  
 Do not know 
For patients 
with an issue 
identified in the 
evaluated 
parameters, a 
lack of 
knowledge will 
be considered 
 Could you please identify 
two possible complications 
for uncontrolled BP? 
 Patients are aware of the 
risks of uncontrolled BP if 
they referred correctly at least 
one negative consequence 
for uncontrolled BP 
 Did you take your BP in the 
last 12 months?  (Yes/No) 
 How often did you check 
your BP in the last 12 
months? (Nr. per month) 
 Patients who monitored 
regularly BP made a 
measurement and registration 
at least once a month or 
biweekly (299) 
Di
ab
et
es
 
 What is the target value for 
your blood sugar (fasting 
glucose and postprandial 
glucose)? 
 Fasting glucose and 
postprandial glucose 
according guidelines (288–
290) 
For patients 
with an issue 
identified in the 
evaluated 
parameters, a 
lack of 
knowledge will 
be considered 
 Could you please identify 
two possible complications 
resulting from your 
uncontrolled BG? 
 Patients are aware of the 
risks of uncontrolled BG if 
they referred correctly at 
least one negative 
consequence. 
 How often in the last 7 
days did you assess your 
BG? (number 0-7) 
 How many days a week it 
was indicated to assess 
your BG, by your doctor, 
nurse or pharmacist? 
(number 0-7) (300) 
  Mean±SD 
 
 Mean±SD 
Dy
sl
ip
id
ae
m
ia
 
 What is the target values 
for your total BC? 
 Total BC value according 
guidelines (292,293) For patients with an issue 
identified in the 
evaluated 
parameters, a 
lack of 
knowledge will 
be considered 
 Could you please identify 
two possible complications 
resulting from your 
uncontrolled BC? 
 Patients are aware of the 
risks of uncontrolled BC if 
they referred correctly at 
least one negative 
consequence for uncontrolled 
BC. 
Legend: BC - Blood cholesterol; BG - Blood glucose; BP - Blood pressure; HT - Hypertension; Nr 
– Number; SD – Standard deviation. 
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Whenever the patient had a “lack of knowledge” in one of the diseases that was 
included in the disease knowledge assessment, a “lack of knowledge” was 
considered. 
 
Health literacy: According to patient interview a score was obtained for the 
SAHL-PT, wherein a score equal or less than 14 was considered as “low health 
literacy”. 
 
Self-perceived health status: It was obtained during patient interview using 
the scale MOS SF-36 adapted to Portuguese language (301). A question was 
done to patient: “How do you consider, currently, your health?” and the patient 
was allowed to choose the answer between the following five (5) options: “Very 
poor”, “Poor”, “Fair”, “Good” or “Excellent”. 
 
3.2.5.2 Variables related to Economic Outcomes 
Medicines: All prescribed and consumed medicines (including over the counter 
medicines and food supplements) were considered at the time of the data 
collection and were subsequently confirmed in clinical patient process.  
 
Hospitalizations: Number of times that patients were hospitalized in the last 
twelve (12) months and the length of hospitalization (days). This information 
was provided by patient during the interview and confirmed with the data from 
patient´s clinical file.  
 
Physicians: During the interview, a question was held to the patient in order to 
analyse whether the patient was being followed by one or more Physicians and 
their respective medical specialty (general practice, and others specialties). 
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Rate of reimbursement of medicines: Described according to information 
provided by the patient and confirmed with the patient´s clinical file, classified 
as: general regime, special regime, or subsystem. 
 
3.2.5.3 Variables related to Clinical Outcomes 
Each health problem identified was analysed per individual patient. Their 
degree of control (effectiveness) was assessed in accordance with indicators 
defined in the respective clinical guidelines, considering information provided by 
patients, results of biochemical analysis provided by patients or available in 
patient´s clinical file. Drug´s safety was also analysed leading to the 
identification of potential adverse events reported by patients. Clinical situations 
that were untreated were also identified according the respective clinical 
guidelines, considering information provided by patients, results of biochemical 
analysis provided by patients or available in patient´s clinical file, but it was only 
considered a negative outcome when the situation was not yet identified. 
Allergies and drug intolerances were recorded according patient´s information 
and data available in patient´s clinical file. 
 
Negative Clinical Outcomes (NCO): The identification of negative clinical 
outcomes was performed with reference to various information, were classified 
as follows (Table 38). 
 
Table 38: Negative Clinical Outcomes and information´s sources. 
NCOs Type Source 
Disease Control 
Clinical guidelines, as applicable. 
Treatment recommendations within the guidelines were 
considered appropriate, deviations were considered 
inappropriate.  
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Table 38 (Continued) 
NCOs Type Source 
Suspected Adverse 
Drug Event(s) 
“Any untoward medical occurrence in a patient or clinical 
trial subject administered a medicinal product and which 
does not necessarily have a causal relationship with this 
treatment” (302) 
SmPC: 4.8 Undesirable effects 
Untreated 
Conditions 
Clinical guidelines, as applicable. 
Treatment recommendations within the guidelines were 
considered appropriate, deviations were considered 
inappropriate.  
Legend: NCO - Negative clinical outcome; SmPC – Summary of products characteristics. 
 
Drug Related Problems (DRPs): Considered as “an event or circumstance 
involving drug therapy that actually, or potentially, interferes with the desired 
health outcomes” (177), identified from the information provided by patients 
crossed with available information in reference sources on medicinal products 
(Table 39). DRPs were considered as elements of the process of use of 
medicines. All medicines were included: prescribed medicines and over-the-
counter products (OTC´s). 
 
Table 39: Medicine´s and patient´s analysis.  
M
ed
ic
in
es
 
Scope Issue Analysis Source 
Drug selection 
Therapeutic indication of 
medicine. 
Appropriateness of 
medication according to 
clinical situations, including 
contraindications. 
Potential drug-drug interaction 
or food-drug interaction. 
Duplicated drugs. 
Synergistic/preventive drug 
required.  
 Medicine´s SmPC:  
 4.1 - Therapeutic 
indications;  
 4.3 – 
Contraindications; 
 4.5 - Drug interactions 
and other forms of 
interaction. 
 Beers criteria (196) 
 
Drug form Related to drug form. 
 According to the 
difficulties reported by the 
patient. 
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Table 39 (Continued) 
M
ed
ic
in
es
 
Scope Issue Analysis Source 
Dose selection 
Recommended dose 
Maximum dose 
Number of daily doses 
Adjustments to patients with 
hepatic or renal insufficiency, 
elderly or children, as 
applicable. 
 Medicine´s SmPC: 4.2 -
Posology and method of 
administration 
Clinical Guidelines 
Treatment 
duration 
Duration of treatment and 
withdrawal period 
recommended, as 
applicable. 
 Medicine´s SmPC: 4.2 -
Posology and method of 
administration 
 Clinical Guidelines 
Pa
tie
n
t Medicine ´s use process  
Timing of administration 
and/or dosing intervals. 
Medication adherence. 
 Medicine´s SmPC: 4.2 -
Posology and method of 
administration 
 MAT scale (303) 
 Haynes-Sackett test (297) 
Patient 
knowledge  
Medication knowledge 
assessment. 
 Assessment per medicine 
used. 
 Other Other issues.  
Legend: MAT – Measure Treatment Adherence; SmPC - Summary of products 
characteristics. 
 
Drug related problems (DRPs) were classified considering seven (7) scopes, as 
described in Table 40. This classification was formulated based on the points 
analysed in the medication review activity, and from the adaptation of the 
various causes of DRP´s presented in classification of DRP´s from PCNE (v6.2)  
(177). 
 
Table 40: Drug-related Problem´s (DRPs) classification. 
DRP Scope Type 
Drug selection 
Inappropriate drug (incl. contra-indicated)  
No indication for drug 
Inappropriate combination of drugs, or drugs and food  
Synergistic/preventive drug required and not given 
Duplicate drug 
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Table 40 (Continued) 
DRP Scope Type 
Drug form Inappropriate drug form 
Dose selection 
Drug dose too low 
Drug dose too high 
Dosage regimen not frequent enough 
Dosage regimen too frequent 
Dose adjustment is required (pharmacokinetics) 
Dose adjustment is required (improvement of disease 
state) 
Treatment duration 
Duration of treatment too short 
Duration of treatment too long 
Drug use process  
Inappropriate timing of administration and/or dosing 
intervals 
Drug underused (intentional non-adherence) 
Drug not used at all 
Wrong drug used 
Patient forgets to use drug (unintentional non-
adherence) 
Patient related Low Medication knowledge  
Other Other DRPs  
Legend: DRP – Drug-related problem; Incl. – Including. 
 
Risk situations of NCOs: No negative clinical outcome (NCO) was identified, 
however problems with medication have been identified, so patient was at risk 
of suffering a NCO when at least one drug related problem (DRP) was 
identified. (142) 
 
Planned Interventions: Intention of interventions after analysis of medication 
review´s outcomes. The classification of planned interventions was performed 
from the adaptation of “outcome of intervention” presented in the classification 
of DRPs from PCNE (v6.2) (177) and only the scope of the intervention was 
identified (Table 41).  
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Table 41: Planned intervention´s classification.  
Planned Intervention Description 
No intervention No intervention has been identified 
At prescriber level Intervention such as prescriptions revaluation, 
untreated conditions identification 
At patient/carer level Intervention at patient behaviour, medicine 
adherence, educational interventions 
At drug level Intervention at drug´s use such as administration time, number of units, number of doses 
Other intervention 
Intervention non-pharmacological, referral to other 
professionals (e.g. dietitian, physical exercise 
technician) 
 
Eligibility criteria for medication review programs in Australia, Canada 
and England: The analysis of the inclusion criteria used for this service in these 
countries ascertains whether the study population meets these criteria. Other 
countries, such as the United States of America, were not included in this 
analysis because although they also have available this pharmaceutical service, 
the health system currently has significant differences from the Portuguese 
health system. 
The eligibility criteria were analysed for the programs indicated in Table 42. 
 
Table 42: Medication Review programs analysed.  
Country Program 
Australia Home Medication Review (HMR) 
Canada MedsCheck; MedsCheck for Ontarians living with Diabetes 
England Medicines Use Review (MUR) 
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3.2.6 Statistical analysis 
Data were analysed with IBM-SPSS software version 24.0 (SPSS Inc., Chicago, 
IL, USA) and presented as median, mean values and standard deviations (SD). 
Adherence to the Normal distribution was assessed using the Shapiro-Wilk test 
and also by analysing normal probability plots. (304) 
According to the variables characteristics (normal or non-normal distribution) 
parametric or non-parametric procedures were used.  
Comparison between groups of variables with non-normal distribution was 
performed using Mann-Whitney (two independent samples) or Kruskal-Wallis (k 
independent samples). 
Group differences were analysed with a one-way analysis of variance (ANOVA), 
after testing for homogeneity of variance with the Bartlett’s test. Pearson’s 
correlation coefficient was used to describe the association between variables 
with normal distribution, Spearman´s correlation coefficient was applied for 
variables with non-normal distribution. Multiple comparisons were interpreted 
with Bonferroni’s correction procedure. 
In the analysis of predictive factors for negative clinical outcomes, for the 
independent variables that do not have a normal distribution, the logarithmic 
(log10) equivalent was used, in order to achieve a variable with normal 
distribution. Further association analyses were conducted using linear multiple 
regression procedures, with forward selection of predictors.  
Statistical significance in all statistical tests was determined by two-tailed 
analysis and set at 0.05. 
 
3.2.7 Ethical aspects 
An authorization from the AEDMADA Ethics Committee was obtained for the 
study conduction at the clinic, and only the patients that accepted to participate 
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in this research and gave their written consent (Appendix C) before the start of 
the study were enrolled. 
Patient information is confidential and each patient was identified through an 
identification number (enrolment number/month/year). 
Furthermore, the project was submitted to Cranfield University Ethics approval 
(CURES), and was approved in the 22nd February 2016 (Reference: 
CURES/840/2016).  
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4 RESULTS 
4.1 Adaptation of an instrument to assess health literacy to the 
Portuguese language 
A sample of 153 subjects was used to hold the adaptation of the questionnaire 
purposed (SAHL-PT), including 58.2% female subjects, with a mean age of 
66.7±12.3 years. Their ages ranged between 35 and 93 years, and presented a 
median of 69 years. 
Approximately three quarters of the subjects were married (71.2%; n=109), 
17.6% (n=27) were widowers, 6.5% (n=10) were divorced and 4.6% (n=7) were 
single. 
In the analysed sample about 32.7% of subjects did not have the minimum level 
of education (9 years), and 20.3% (n=31) had only the 1st cycle (4 years) 
(Figure 5). 
Figure 5: Characterization of subjects’ qualifications.  
 
Most subjects were 65 years or older (56.8%; n=87), were retired (58.8%; 
n=90), and 34.0% (n=52) had a professional activity, as described in Figure 6. 
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Figure 6: Characterization of subjects´ professional situation. 
 
More than half of the individuals were living with the wife/husband (42.5%; 
n=65) or with partner and children (16.3%; n=25), and 31.4% (n=48) were living 
alone (Figure 7).    
 
Figure 7: Characterization of subjects´ household. 
 
Subjects have cardiovascular disease such as hypertension (71.2%; n=109), 
dyslipidaemia (56.2%; n=86), endocrine diseases such as diabetes mellitus 
(20.3%; n=31), nervous system disorders such anxiety (23.5%) and depression 
(22.2%) and cataracts (30.7%) (Figure 8). 
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Legend: CNS – Central nervous system; COPD – Chronic obstructive pulmonary 
disease; CVD – Cardiovascular disease; GER – Gastroesophageal reflux disease. 
Figure 8: Health problems characterization. 
 
The mean score for subjects’ health literacy was 14.48±3.03, the lowest score 
was 4, a median of 15 and 25th and 75th percentiles, respectively, 13 and 17 
points, with 37.9% (n= 58) of subjects showed having low health literacy (score 
equal or lower than 14) (Table 43).  
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Table 43: Characterization of health literacy score. 
Score N % Score N % 
4.0 1 0.7 12.0 10 6.5 
5.0 1 0.7 13.0 5 3.3 
6.0 1 0.7 14.0 17 11.1 
7.0 2 1.3 15.0 24 15.7 
8.0 4 2.6 16.0 25 16.3 
9.0 3 2.0 17.0 30 19.6 
10.0 7 4.6 18.0 16 10.5 
11.0 7 4.6 Total 153 100.0 
 
The item in which subjects presented the greater number of incorrect answers 
was item 13 “directed” (32.7%), item 18 “syphilis” (32.0%), item 7 “dose” 
(21.6%) and item 11 “nutrition” (20.3%). Subjects indicated “Don´t know” more 
often in the following items: item 18 “syphilis” (24.2%), item 5 “kidney” (18.3%) 
and item 9 “constipation” (17.0%) (Table 44).  
 
Table 44: Characterization of subject´s answers to the questionnaire. 
  
Correct 
answer 
Incorrect 
answer 
Don´t know 
Item % (N) % (N) % (N) 
Occupation 90.2 (138) 9.8 (15) 0.0 (0) 
Seizure 77.1 (118) 14.4 (22) 8.5 (13) 
Infection 87.6 (134) 8.5 (13) 3.9 (6) 
Medication 98.0 (150) 1.3 (2) 0.7 (1) 
Alcoholism 66.7 (102) 15.0 (23) 18.3 (28) 
Kidney 94.1 (144) 2.6 (4) 3.3 (5) 
Dose 72.5 (111) 21.6 (33) 5.9 (9) 
Miscarriage 89.5 (137) 8.5 (13) 2.0 (3) 
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Table 44 (Continued) 
  
Correct 
answer 
Incorrect 
answer 
Don´t know 
Item % (N) % (N) % (N) 
Constipation 73.2 (112) 9.8 (15) 17.0 (26) 
Pregnancy 94.1 (144) 5.9 (9) 0.0 (0) 
Nerves 77.8 (119) 20.3 (31) 2.0 (3) 
Nutrition 79.7 (122) 15.7 (24) 4.6 (7) 
Directed 57.5 (88) 32.7 (50) 9.8 (15) 
Hormones 76,5 (117) 16.3 (25) 7.2 (11) 
Abnormal 88,9 (136) 7.8 (12) 3.3 (5) 
Diagnosis 90.2 (138) 9.2 (14) 0.7 (1) 
Haemorrhoids 92.2 (141) 3.3 (5) 4.6 (7) 
Syphilis 43.8 (67) 32.0 (49) 24.2 (37) 
 
Only 10.5% (n= 16) of the subjects indicated all the correct answers for the 18 
items. 
Health literacy score was higher for younger subjects (p<0.001), for those using 
a lower number of daily medicines (p=0.009), or taking a decreased number of 
medicine´s units (p=0.013) and using medicines more frequently (p=0012) 
(Table 45).  
 
Table 45: Health literacy score and subject´s characteristics correlation. 
Variables r p value 
 Age -0.504 <0.001 
Marital status -0.188 0.02 
Qualifications 0.262 0.001 
Household 0.324 <0.001 
Number of daily units -0.211 0.013 
Number of daily medicines -0.220 0.009 
Frequency of use of medicines 0.203 0.012 
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The health literacy score was lower for subjects with less qualifications 
(p<0.001), being more prevalent in patients having either the 1st, or 3rd cycles 
of basic education, or without any education degree (Table 46). 
 
Table 46: Characterization of health literacy score and subject´s qualifications.   
Qualifications 
Health Literacy 
Low HL 
N (%) 
Not Low 
N (%) Mean (SD) p value 
Can read and/or write without 
having education degree 8 (6.8) 4 (3.4) 11.58 (4.1) 
p<0.001 
1st cycle of basic education  
(4th grade) 16 (13.6) 15 (12.7) 13.06 (3.05) 
2nd cycle of basic education 
(junior) 0 (0.0) 7 (5.9) 14.86 (0.7) 
3rd cycle of basic education  
(9 years) 14 (11.9) 44 (37.3) 14.53 (2.64) 
Secondary education  
(12th grade) 3 (2.5) 23 (19.5) 15.69 (2.92) 
Professional 
course/technological (Level III) 0 (0.0) 7 (5.9) 16.43 (1.4) 
Higher education 0 (0.0) 12 (10.2) 16.83 (0.94) 
Total 
  14.48 (3.03) 
Legend: HL – Health literacy; SD – Standard deviation. 
 
Older subjects (65 years) presented a lower score of health literacy (p<0.001), 
having an average score of 13.4±3.2 (median=14.0). The average score for 
younger patients (<65 years) was 15.95±1.96 (median=16.5). 
Polymedicated subjects, using 5 (five) or more medicines, showed a lower 
score of health literacy (p=0.027), presenting an average score of 13.98±3.0 
(median=14.0). Subjects using less than 5 medicines presented an average 
score of 14.94±3.0 (median=16.0). 
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The internal consistency analysis was performed using the Cronbach's alpha, 
which presented a value of 0.812, considering the 18 items. 
The reliability for the measurements was analysed using the intraclass 
correlation coefficient (ICC). The ICC was 0.802 (95%CI 0.75-0.85) which 
suggests a statistically significant (F=5.05 p<0.001) interrater reliability, 
classified as excellent. 
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4.2 ReMeD Study 
4.2.1 Sample Characterization  
There were 118 patients included in the study, 45.8% (n=54) female and 54.2% 
(n=64) male, with a mean age of 66.2±10.41 years. Their ages ranged between 
35 and 88 years, and presented a median of 67 years.  
Most patients were over 65 years (56.8%; n=67), with a similar distribution for 
both genders (Figure 9). 
 
Figure 9: Characterization of patients´ age by gender. 
 
Patients were mainly retired (71.2%; n=84), 3.4% (n=4) were retired with 
activity, and 20.4% (n=24) were employed. 
About 74.6% (n=88) of patients were married, most of them lived with her 
wife/husband (54.2%; n=64), 11.9% (n=14) lived alone and were autonomous, 
and only 1 patient (0.8%) lived alone with support. It is noteworthy that about 
12.7% (n=15) of patients lived with relatives from another family generation 
(children, grandchildren, or other). None of the patients included in this study 
was institutionalized. 
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More than one third of patients had only the four years of education (38.1%; 
n=45), and 2.5% could not read or write as described in Figure 10. 
 
Figure 10: Characterization of patients´ qualifications. 
 
The number of female patients with lower qualifications (less than 9 years of 
schooling) was higher (28.8%) than male patients (20.3%), but this difference 
was not statistically significant (p> 0.05).  
In the overall sample no statistically significant difference was observed 
between qualifications and patient´s age (years) (p>0.05). 
However, the number of older patients (65 years) having the first cycle of basic 
education (4th grade) was higher compared to younger patients (p=0.041).   
Patients were followed at the AEDMADA clinic on average about 44.18±34.28 
months (median=41.5 months). The longest time a patient was followed was 
over 8 years (103 months). 
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4.2.2 Patient´s Clinical evaluation  
Clinical Profile 
The characterization of patient´s health problems was conducted using the ICD-
10 classification (http://apps.who.int/classifications/icd10/browse/2016/en).  
Each patient had a mean of 4.78±1.94 (median=4) health problems, with a 
maximum of 11 health problems identified per patient. 
Health problems which presented a higher prevalence were those belonging to 
Chapter IV - Endocrine, nutritional and metabolic diseases, Chapter IX - 
Diseases of the circulatory system), Chapter VII - Diseases of the eye and 
adnexa and Chapter V - Mental and behavioural disorders (Table 47). 
Most prevalent diagnosis were diabetes mellitus (90.7%), hypertension (81.4%), 
disorders of lipoprotein metabolism and other lipidaemias (77.1%) (Table 47). 
 
Table 47: Characterization of health problems. 
ICD-10* Disease N % 
I B16 - Acute Hepatitis B 1 0.8 
III D50 - Iron deficiency anaemia 1 0.8 
IV 
E10 - Type 1 diabetes mellitus 6 5.1 
E11 -  Type 2 diabetes  mellitus 101 85.6 
E03 - Other hypothyroidism 2 1.7 
E78 - Disorders lipoprotein metabolism and other lipidaemias  91 77.1 
E79 - Hyperuricemia 3 2.5 
Other endocrine, nutritional and metabolic disorders 5 4.2 
V 
F32 - Depressive episode 14 11.9 
F41 - Anxiety disorders 17 14.4 
F51 - Non-organic sleep disorders 5 4.2 
Other disorders 3 2.5 
VI 
G20 - Parkinson Disease 3 2.5 
G40 - Epilepsy 2 1.7 
Other mental and behavioural disorders 8 6.8 
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Table 47 (Continued) 
ICD-10* Disease N % 
VII 
H25 – Senile cataract 9 7.6 
H52 – Disorder of refraction and accommodation 26 22 
Other diseases of the eye and adnexa 16 13.6 
VIII Other diseases of the ear and mastoid process 5 4.2 
IX 
I10-Hypertension 96 81.4 
Other diseases of the circulatory system 27 22.9 
X 
J44 -  Other chronic obstructive pulmonary disease  2 1.7 
J45 -  Asthma 1 0.8 
Other diseases of the respiratory system 11 9.3 
XI 
K21 - Gastro-oesophageal reflux disease 9 7.6 
K90-93 - Other diseases of digestive system 20 16.9 
XII L40 - Psoriasis 1 0.8 
XIII 
M6 - Coxarthrosis 4 3.4 
M17 – Gonarthrosis 14 11.8 
M19 – Other arthrosis (excl. post-traumatic) 2 1.7 
M81 - Osteoporosis 1 0.8 
Other dis. of musculoskeletal syst. and connective tissue 20 16.9 
XIV 
N39 – Other disorders of urinary system 2 1.7 
N40 - Hyperplasia of Prostate 16 0.6 
Other diseases of the genitourinary system 12 10.2 
XIX T78 - Allergy, unspecified 6 5.1 
Legend: * - Chapter; Dis – disease; Sist – system.  
 
Older patients (65 years) presented an increased number of health problems 
(5.2±1.87) compared with younger patients (4.3±1.88), which proved to be 
statistically significant (p=0.003). 
The number of health problems diagnosed per patients was higher for patients 
being followed at the AEDMADA clinic for a longer period (p=0.012; r=0.204), 
hypertense patients (p<0.001), patients with a very high cardiovascular risk 
(p=0.0228) and patients without physical activities habits (p=0.044).  
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Patients without physical activity habits presented an average of 5.18±2.16 
health problems, while patients who practiced physical activity presented a 
lower average number of health problems (4.3±1.4) (p=0.045).  
 
Characterization of biomarkers and other risk factors for cardiovascular 
diseases 
Blood Pressure 
ReMeD patients presented an average value of systolic blood pressure (SBP) 
of 151.38±20.02 mmHg and 79.93±11.48 mmHg for diastolic blood pressure 
(DBP). Over two thirds of these patients presented uncontrolled blood pressure 
values (61.0%; n=72).  
In the age range of 65-74 years patients presented a higher prevalence (28.0%) 
of uncontrolled BP compared to patients in the range of 50-74 years (19.5%) 
(p=0.003) (Table 48). 
 
Table 48: Characterization of blood pressure control and patient´s age. 
 Age (years) 
 
18-49 50-64 65-74  75 TOTAL 
BP control N % N % N % N % N % 
Controlled 5 4.2 20 17.0 10 8.5 11 9.3 46 39.0 
Uncontrolled 3 2.5 23 19.5 33 28.0 13 11.0 72 61.0 
Total 8 6.7 43 36.5 43 36.5 24 20.3 118 100.0 
Legend: BP – Blood pressure. 
 
In patients who had not been previously diagnosed with hypertension about half 
(52.2%; n=12) had uncontrolled blood pressure values, with a mean value of 
146.09±21.97 for SBP and 82.91±11.06 for DBP. 
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Patients with a diagnosis of hypertension, only about a third (36.5%; n=35) 
showed controlled blood pressure values. Patients having a controlled blood 
pressure, achieved a lower value both for SBP (p<0.001) and DBP (p<0.001), 
compared to patients with uncontrolled blood pressure (Table 49). 
 
Table 49: Characterization of blood pressure values and blood pressure profile 
control for hypertensive patients. 
BP control 
SBP DBP 
Mean ± SD Mean ± SD 
Controlled 132.5±7.18 74.43±9.3 
Uncontrolled 163.4±15.8 83.4.2±11.41 
p value <0.001 <0.001 
Legend: BP – Blood pressure; DBP – Diastolic blood pressure; SBP – 
Systolic blood pressure; SD – Standard deviation.  
 
 
More than half (59.8%; n=64) of the diabetic patients had uncontrolled blood 
pressure, with a mean value for SBP of 150.40±20.05 mmHg and 79.48±11.25 
mmHg for DBP. 
Blood pressure control showed no statistically difference for hypertense 
patient´s gender, despite the average of systolic blood pressure was higher in 
men (153.2±18.73 and 151.20.57 for female) (p>0.05). 
 
Glycemic Profile 
Near half of patients had hyperglycemia values in the parameters of fasting 
glucose (51.7%) and postprandial glucose (43.2%). All non-diabetic patients 
(n=11) presented a good control of glycemic profile, with normoglycaemia 
values for fasting and postprandial glucose. 
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The glycemic profile reached in diabetic patients enrolled in this study is 
described in Table 50.  
About half of diabetic patients presented a controlled glycemic profile (46.7%; 
n=50), and a median for HbA1c of 7.73±1.4 %. More than one third of diabetic 
patients (39.3%) presented a HbA1c value  8%. 
 
Table 50: Characterization of diabetic patients glycemic profile. 
Parameter  Mean±SD 
Fasting glucose 
Hypoglycaemia: 1.9%; n=2 
Normoglycaemia: 41.1%; n=44 
Hyperglycaemia: 57%, n=61 
148.5±51.1 
mg/dL 
Post prandrial 
glucose 
Hypoglycaemia: 0.9%; n=1 
Normoglycaemia: 51.4%; n=55 
Hyperglycaemia: 47.7%; n=51 
184.5±67.4 
mg/dL 
 
HbA1c 
  < 6.5 
  6.5 and 7 
   7 and 8 
   8 
16.8% 
18.7% 
25.2% 
39.3% 
(n=18) 
(n=20) 
(n=27) 
(n=42) 
7.73±1.4 % 
Legend: HbA1c - Glycated haemoglobin; SD – Standard deviation. 
 
The mean value for HbA1c registered in female patients (median=7.85%) was 
higher than those showed in male patients (median=7.45%), altought this 
difference was not statistically significant (p>0.05). Also a higher rate of 
glycemic profile control was achieved in male patients (26.3%) compared to 
female pateints (15.3%), but not statiscally significant. 
No statistically significant difference were found between patient´s glycemic 
profile control, blood pressure and lipid profile control (p>0.05).  
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Lipid Profile 
Only about a third (22.9%; n=27) of the patients had a controlled lipid profile 
(Table 51). 
 
Table 51: Characterization of patients´ lipid profile. 
Parameter Values Mean±SD (mg/dL) 
Total 
cholesterol 
Normal value: 72% ; n=85 
Above the reference value: 28%; n=33 174.8± 38.8 
LDL-C 
< 70 mg/dL: 10.2% (n=12) 
70 – 100 mg/dl: 35.6% (n=42)  
100 - 115 mg/dL: 22.0% (n=26) 
 115 mg/dL: 32.2% (n=38) 
104.2±34.1 
HDL-C Normal value: 69.5%; n=82 Below the reference value: 30.5%; n=36 49.4±13.3 
Tryglicerides 
Normal value: 78.8%; n=93 
Above the reference value: 
150 – 200 mg/dL: 16.1%; n=19 
>200 mg/dL: 5.1%; n=6 
126.1±64.5 
Legend: HDL-C – High density lipoprotein cholesterol; LDL-C – Low density 
lipoprotein cholesterol; SD – Standard deviation. 
 
Diabetic patients showed a high prevalence of uncontrolled lipid profile (78.5%; 
n=84), a mean value for LDL-C of 103.4±32.0 mg/dL and 171.73±36.6 mg/dL 
for total cholesterol. The majority were being treated with lipid-lowering drugs 
(62.6%; n=67). 
An uncontrolled lipid profile was observed in male patients (45.8%) more often 
than in female patients (34.4%), although this difference wasn´t statistically 
significant (p>0.05): 
Male patients with a diagnosis of dyslipidaemia presented a higher prevalence 
of previous cardiovascular events (17.6% vs 4.4% for female) (p=0.015). 
 121 
 
9.3%
17.8%
72.9%
Smoker Ex-Smoker No smoking
Smoking Habits 
Most Patients were non-smoking (72.9%; n=86), and those that smoked (9.3%; 
n=11) showed an average intake of 12.27±12.52 cigarettes per day (Figure 11). 
Figure 11: Characterization of patients’ smoking habits. 
 
Male patients and younger patients (<65 years) showed a significant higher 
prevalence in smoking habits compared to the female patients (p<0.001) (Table 
52). 
 
Table 52: Characterization of smoking habits, gender and patients´ age. 
Smoking 
habits 
Gender Age 
Feminine Masculine p 
value 
< 65 years  65 years p 
value N (%) N (%) N (%) N (%) 
 Smoker 0 (0.0%) 11 (9.3%) 
<0.001 
7 (5.9%) 4 (3.4%) 
<0.001 
 Ex-Smoker 2 (1.7%) 19 (16.1%) 16 (13.6%) 5 (4.2%) 
 No smoking 52 (44.1%) 34 (28.8%) 28 (23.7%) 58 (49.2%) 
               Total 54 (45.8%) 64 (54.2%) 51 (43.2%) 67 (56.8%) 
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Physical Exercise 
More than half of patients (57.6%; n=68) indicated not to practice regular 
physical exercise. For those who practiced, the median was 3 times per week, 
with an average duration of 66.2±36.08 minutes. 
About 13.6% of patients reported to practice physical exercise at least 5 days a 
week, and among these, male patients showed a higher prevalence (p=0.09) 
(10.2%), compared with a prevalence of only 3.4% for female patients. 
Several physical activity types were practiced by patients, although mainly 
walking (38.0%) and gymnastic aerobic (32.0%), as described in Figure 12. 
Figure 12: Characterization of patients´ physical exercise practice. 
 
Patients who indicated not to practice physical exercise showed a higher 
prevalence of dyslipidaemia (p=0.016), diabetes (p<0.001) and previous 
cardiovascular events (p<0.001).  
The number of patients practicing physical exercise and controlled blood 
pressure and controlled glycemic profile was greater those that did not exercise, 
however this difference was not statistically significant (p>0.05). 
38.0%
10.0%
32.0%
4.0%
16.0%
Walking Swiming / Water aerobics Gymnastic Dancing Other
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Body Mass Index 
Body Mass Index (BMI) 
Only about 18.6% (n=22) of patients had a BMI value considered normal, with a 
mean value of 28.64±4.7 Kg/m2; most patients were overweight or obese 
(BMI25 Kg/m2) (80.5%; n=95) ( 
Figure 13). 
 
 
Figure 13: Characterization of patients´ body mass index (BMI). 
No significant difference was identified between BMI and patient´s age 
(p>0.05), despite patients 65 years and older presented a higher prevalence of 
BMI  25 Kg/m2, no statistically significant difference were observed for age 
(Table 53) or gender. 
Table 53: Characterization of body mass index per patient´s age. 
BMI classification < 65 years  65 years p value 
N (%) N (%) 
Underweight 0 (0.0) 1 (0.85) 
0.465 
Normal 13 (11.0) 9 (7.65) 
Overweight 21 (17.8) 34 (28.8) 
Obese Class 1 14 (11.9) 19 (16.1) 
Obese Class 2 2 (1.7) 3 (2.5) 
Obese Class 3 1 (0.85) 1 (0.85) 
Obese Class 4 0 (0.0) 0 (0.0) 
Obese Class 5 0 (0.0) 0 (0.0) 
Legend: BMI – Body mass index. 
0.8%
18.6%
46.6%
28.0%
4.2% 1.7%
Underweight Normal Overweight Obese
Class 1
Obese
Class 2
Obese
Class 3
% 
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Other
Cardiovascular Event: 
Patients with a diagnosis of dyslipidaemia presented an increased prevalence 
of body mass index (BMI) 25 kg/m2 (69.5%) compared to patients having a 
BMI<25Kg/m2 (7.6%) (p<0.001).  
 
Dietary Habits 
The majority (97.5%: n=115) of patients affirmed to eat fruit every day (7 days 
per week), eating less than 3 fruit pieces per day (53.0%; n=61), 3-5 pieces 
(45.2%; n=52) or more than 5 pieces (1.8%; n=2). 
Also regarding vegetable intake patients affirmed to eat vegetables every day (7 
days per week) in 72% (n = 85) of cases, where most indicated to consume less 
than three portions daily (96.6%; n = 114). 
Olive oil was the fat most often used to prepare their own meals (94.1%; 
n=111). 
 
Previous Cardiovascular Events 
Nearly a fifth of the patients (17.8%; n=21) had already a previous 
cardiovascular event, being stroke (33.3%; n=7) and acute myocardial infarction 
(28.6%; n=6) the most prevalent among those patients (Figure 14). 
Figure 14: Characterization of previous cardiovascular events. 
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Older patients (65 years) reported a lower number of previous cardiovascular 
events (p=0.014) presenting an average of 1.9±0.27 events while younger 
patients an average of 1.74±0.44 previous cardiovascular events. 
Furthermore, male patients had suffered a higher number of cardiovascular 
events (p=0.027) (13.6% for male and 4.24% for female). Beside that, patients 
without smoking habits had a lower rate of cardiovascular events (p=0.042).  
Male hypertense patients presented an increased number of previous 
cardiovascular events (p=0.039) with a prevalence of 15.8% for male patients 
and 4.2% for female patients.  
Patients with lipidaemia disorders presented a higher prevalence of 
cardiovascular events (p=0.03).  
 
Family History 
Family history of cardiovascular events only occurred in 16.4% (n=19) of the 
patients included in this study. 
No statistically significant difference were achieved for familiy history of 
premature cardiovascular events and socio-demographic and clinical variables, 
nor to the ocorrence of cardiovascular events (p>0.05). 
 
Cardiovascular Risk Assessment 
Using a qualitative cardiovascular (CV) risk assessment methodolgy, it was 
found that most patients had a “Very high CV risk” (89.8%; n=106) ( 
Figure 15). 
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Cardiovascular Risk 

 
Figure 15: Cardiovascular Risk Assessment.
Patients with very high cardiovascular risk were mostly male (p=0.010) (51.7%), 
and were followed in the AEDMADA clinic for a longer period (p<0.001) on 
average for 50.4±31.95 months. Those with high risk had been followed on 
average for 9.4±25.7 months. Moreover, patients with very high cardiovascular 
risk had a higher prevalence of hypertension (p<0.001), diabetes (p<0.001), 
microvascular complications of diabetes (p<0.001) and uncontrolled lipid profile 
(p=0.026). 
 
Microvascular complications (Diabetic patients) 
Almost a quarter of diabetic patients already had microvascular complications 
(23.4%; n=25), being retinopathy the most frequent in the diabetic´s patients 
included in the study (Table 54). 
Table 54: Prevalence of diabetes microvascular complications. 
Microvascular 
complications Prevalence 
Diabetic retinopathy 17.8%; n=19 
Nephropathy 3.8%; n=4 
Neuropathy 9.3%; n=10 
89.8%
9.3% 0.8%
Very high High Low
% 
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Patients with diagnosis of diabetes for a longer period achieved a higher 
prevalence of microvascular complications (p<0.001).  
An increased number of health problems was depicted for patients with 
diabetes microvascular complications (p=0.026), having an average of 5.44±2.1 
health problems. Patients without microvascular complications presented an 
average of 4.7±1.9 health problems.  
No other variables (socio-demographic or clinical) showed a statistically 
difference for the existence of diabetes microvascular complications. 
 
4.2.3 Pharmacotherapeutic Profile  
In the 118 patients enrolled in this the study it was identified a total of 791 
medicines and 21 food supplements and other health products (FS). Each 
patient was using a mean of  6.70±3.03 medicines per day, presented a median 
of 6 medicines and 25th and 75th percentiles, respectively, 4 and 9 medicines. 
Per day each patient was taking a mean of 7.63±3.92 (median=7) units, taking 
at least 1 unit and a maximum of 21 units per day, corresponding to 7.93±3.99 
(median=7) doses per day per patient. 
Polypharmacy (patients taking 5 or more medicines) was found in about three-
quarters of patients (73.8%; n=89) (Table 55), and about 82.1% of older 
patients (65 years and older) were polymedicated (p=0.019).  
 
Table 55: Number of medicines per patient. 
 
Patients 
(number) < 65 years 65 years 
Medicines (number) N N (%) N (%) 
Up to 4 medicines 31 (26.3) 19 (16.1%) 12 (10.2%) 
5 to 10 medicines 75 (63.6) 27 (22.9%) 48 (40.7%) 
More 10 medicines 12 (10.1) 5 (4.2%) 7 (5.9%) 
Total 118 (100.0) 51 (43.2%) 67 (56.8%) 
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Only one in seven patients (15.2%) was using food supplements (FS), others 
only one food supplement (14.4%; n=17), obtaining an average of 0.18±0.5 FS 
per patient.  
Elderly patients ( 65 years) used a higher number of daily medicines, taking a 
daily mean of 7.16±2.8 (median=7) medicines, 0.21±0.6 food supplements, 
8.27±3.8 (median=8) units and 8.5±3.9 (median=8) doses. Globally, 82% (n=55) 
were polymedicated (5 medicines per day), and only about one-sixth of 
patients were using food supplements (16.4%; n=11). 
In 10.2% (n=12) of the patients included this study, a previous situation of 
intolerance and / or drug allergies had already occurred. 
The most prevalent medicines used by this patient´s sample were from group 
C-Cardiovascular system, A-Alimentary tract and metabolism, and N-Nervous 
system (Table 56). 
Table 56: ATC classification of medication profile. 
ATC Classification (level 1) N % 
A - Alimentary tract and metabolism 251 31.7 
B - Blood and blood forming organs 43 5.4 
C - Cardiovascular system 280 35.4 
G - Genito urinary system and sex hormones 21 2.7 
H - Systemic hormonal preparations, excl. sex h. and insulins 43 5.4 
J - Anti-infective for systemic use 4 0.5 
M - Musculo-skeletal system 29 3.7 
N - Nervous System 97 12.3 
P - Antiparasitic products, Insecticides and repellents 1 0.1 
R - Respiratory System 18 2.3 
S - Sensory Organs 4 0.5 
V - Various 1 0.13 
Total Medicines (number) 791 100.0 
Total Food Supplements and other health products 21 100.0 
Legend: ATC – Anatomical, Therapeutic and Chemical. 
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Among medicines used by patients, at least three quarters had been used for 
more than a year (75.8%; n=615), and most (66.9%) had been already used for 
at least 24 months (Table 57). 
 
Table 57: Characterization of medicines use period. 
Time 
(months) N % 
0-6 133 16.4 
7-12 64 7.8 
 12 - 24 72 8.9 
 24 543 66.9 
Total 812 100.0 
 
Antihypertensive drugs were used by 83.9% (n=99) of patients (mean of 
1.51±0.78). Most patients used one (1) antihypertensive drug (63.6%; n=63), 
24.2% (n=24) used two (2) antihypertensive drugs, 10.1% (n=10) used three (3) 
and 2.1% (n=2) used four (4) antihypertensive drugs. 
About 88.1% of older patients ( 65 years) were using antihypertensive drugs, 
using a higher number of these drugs compared to younger patients (p=0.013).  
The antihypertensive drug subgroup with highest prevalence of use in the 
sample study was “C09AA – Agents acting on the renin-angiotensin 
system;  ACE Inhibitors, Plain” (23.38%), followed by “C09DA - Agents acting 
on the renin-angiotensin system;  Angiotensin II antagonists, combinations; 
Angiotensin II antagonists and diuretics“ (18.1%) and “C08CA – Calcium 
channel blockers; Selective Calcium channel blockers with mainly vascular 
effects; Dihydropyridine derivatives” (13.64%). (Table 58).  
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Table 58:Classification of antihypertensive drugs used by patients. 
ATC Classification (level 4) N % 
C02AC - Antiadrenergic agents, centrally acting; Imidazoline receptor agonists 1 0.7 
C03BA  – Diuretics; Low-Ceiling Diuretics, excl. Thiazides; Sulfonamides, plain 7 4.4 
C03CA  – Diuretics; High-Ceiling Diuretics; Sulfonamides, plain 5 3.3 
C03DA – Diuretics; Potassium sparing agents; Aldosterone antagonists 1 0.7 
C03EA – Diuretics: Diuretics and potassium-sparing agents in combination; Low-
ceiling diuretics and potassium-sparing agents 1 0.7 
C07AB – Beta Blocking agents; Beta blocking agents, selective 16 10.4 
C07AG - Beta Blocking agents; Alpha and beta blocking agents 3 1.9 
C08CA – Calcium channel blockers; Selective Calcium channel blockers with 
mainly vascular effects; Dihydropyridine derivatives 21 13.6 
C08DA - Calcium channel blockers; Selective channel blockers; Phenyl.deriv. 1 0.7 
C08DB - Calcium channel blockers; Selective Calcium channel blockers with direct 
cardiac effects; Benzothiazepine derivatives 1 0.7 
C09AA – Agents acting on the renin-angiotensin system;  ACE Inhibitors, Plain 36 23.4 
C09BA - Agents acting on the renin-angiotensin system;  ACE Inhibitors, 
combinations; ACE Inhibitors and diuretics 10 6.5 
C09BB - Agents acting on the renin-angiotensin system;  ACE Inhibitors, 
combinations; ACE Inhibitors and calcium channel blockers  5 3.3 
C09CA - Agents acting on the renin-angiotensin system;  Angiotensin II 
antagonists, plain    14 9.1 
C09DA - Agents acting on the renin-angiotensin system;  Angiotensin II 
antagonists, combinations; Angiotensin II antagonists and diuretics   28 18.1 
C09DB - Agents acting on the renin-angiotensin system;  Angiotensin II 
antagonists, combinations; Angiotensin II antagonists and calcium channel 
blockers   
4 2.6 
Total 154 100 
Legend: ATC – Anatomical, Therapeutic and Chemical; Phenyl.deriv - Phenylalkylamine 
derivatives. 
 
About two thirds of antihypertensive drugs used were agents acting on the 
renin-angiotensin system (63.0%; n=97), being approximately half angiotensin 
converting enzyme inhibitors (33.1%; n=51) and the other half acting as 
antagonists of angiotensin II receptors (29.9%; n=46). Within this group which 
acts on the renin-angiotensin system about half (48.45%; n=47) corresponded 
to drugs associations. 
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Oral antidiabetic drugs (OADs) were used by 77.97% (n=92) of patients, and 
86% of diabetic patients, most of those using one (1) drug (43.9%; n=47) or two 
(2) drugs (30.8%; n=33). Three (3) OADs were used by 10.8% and four (4) by 
1.0% of the patients. 
The oral antidiabetic class most often prescribed was “combination of oral blood 
glucose lowering drugs” (31.6%; n=49) and biguanides (24.5%; n=38). The 
class of “dipeptidyl peptidase 4 inhibitors (DPP-4)” was used by one fifth of the 
patients (18.1%; n=28), as described in Table 59.  
 
Table 59: Characterization of oral antidiabetic drugs. 
ATC Classification (level 4) N % 
A10BA - Biguanides 38 24.5 
A10BB - Sulfonylureas 23 14.8 
A10BD - Combinations of oral blood glucose lowering drugs 49 31.6 
A10BF - Alpha glucosidase inhibitors 5 3.2 
A10BG - Thiazolidinedione 4 2.6 
A10BH - Dipeptidyl peptidase 4 (DPP-4) inhibitors 28 18.1 
A10BX -  Other blood glucose lowering drugs, excl. insulins 8 5.2 
Total 155 100.0 
Legend: ATC – Anatomical, Therapeutic and Chemical. 
 
In ATC group A10BX (Other blood glucose lowering drugs, excl. insulins) 
liraglutide is included, which is a blood glucose lowering agent for parenteral 
administration and not orally. Among diabetic patients, 6 (5.6%) were being 
treated with this drug. 
Insulin treatment was used by 38.98% (n=46) of the patients, and 43% of 
diabetic patients, using mostly (17.8%; n=19) one or two insulins (17.8%; n=19), 
and 7.5% (n=8) were using 3 types of insulins. The characterization of the 
insulins used by diabetic patients is described in Table 60. 
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Table 60: Characterization of insulins. 
ATC Classification (level 4) N % 
A10AB - Insulins and analogues for injection, fast-acting 19 23.75 
A10AC - Insulins and analogues for injection, intermediate-acting 8 10.0 
A10AD - Insulins and analogues for injection, intermediate- or long-
acting combined with fast-acting 25 31.25 
A10AE - Insulins and analogues for injection, long-acting 28 35.0 
Total 80 100.0 
Legend: ATC – Anatomical, Therapeutic and Chemical. 
 
About 12.15% (n=13) of diabetic patients were treated with insulin only, while 
30.84% (n = 33) used insulin and oral antidiabetic drugs (OADs). Nearly half of 
diabetic patients were only medicated with oral antidiabetic drugs (55.15%, 
n=59).  
For patients using a higher number of insulins, the HbA1c value was lower 
(p<0.001; r=-0.377).  
Two (2) diabetic patients were not currently being treated with any antidiabetic 
drug, since they had achieved control of glycemic profile. 
Patients with a controlled glycemic profile used significantly fewer number of 
insulins, as well as those whose presenting controlled blood pressure values 
(Table 61). 
 
Table 61: Characterization of the number of insulins and disease control (blood 
pressure, glycemic profile and lipid profile). 
 
Number of insulins 
Mean (SD) Median p value 
 Blood Pressure 
Controlled 0.44 (0.91) 0.0 0.03 Uncontrolled 0.79 (0.99) 0.0 
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Table 61 (Continued) 
 
Number of insulins 
Mean (SD) Median p value 
 Glycemic profile 
Controlled 0.29 (0.58) 0.0 
0.00 
Uncontrolled 1.16 (1.11) 1.0 
 Lipid profile 
Controlled 0.33 (0.66) 0.0 
0.08 
Uncontrolled 0.76 (1.02) 0.0 
 Legend: SD – Standard deviation. 
 
Female patients used a lower number of antidiabetic drugs (oral antidiabetic 
drugs and insulins) compared to male patients, although this difference was not 
statistically significant (p>0.05). 
Patients that experienced a previous cardiovascular event were using a higher 
number of antidiabetic drugs (p=0.005), having a prescription for 2.48±0.87 
antidiabetic drugs, compared to 1.85±1.18 for patients who had no report of 
previous cardiovascular event. 
Additionally, patients presenting microvascular complications from diabetes 
were using a higher number of antidiabetic drugs (p=0.003), taking an average 
of 2.36±1.11 antidiabetic drugs, while patients without clinical diagnosis of 
microvascular events used an average of 2.1±0.98 antidiabetic drugs. 
A longer follow-up period in the AEDMADA clinic was reported for those 
patients using a higher number of antidiabetic drugs (p<0.001; r=0.438).  
Antidyslipidemic drugs were used by 76.3% (n=90), of which most (93.33%; 
n=84) used 1 antidyslipidemic drug, and 6.67% (n=6) used 2 antidyslipidemic 
drugs. More than two thirds were using an antidyslipidemic drug from the 
subgroup of “HMG CoA reductase inhibitors” (Table 62). 
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Table 62: Characterization of antidyslipidemic drugs. 
 ATC Classification (level 4) N % 
C10AA - HMG CoA reductase inhibitors 71 73.2 
C10AB - Fibrates 17 17.53 
C10BA - HMG CoA reductase inhibitors in combination with other 
lipid modifying agents 9 9.28 
Total 97 100.0 
Legend: ATC – Anatomical, Therapeutic and Chemical; HMG coA – 
Hydroxymethylglutaryl-coenzyme A. 
 
Patients using polypharmacy (p<0.001) and having a body mass index 25 
Kg/m2 (p<0.001) had a prescription for a significant higher number of 
antidyslipidemic drugs.  
Antithrombotic agents were used by 29.7% (n=35) of patients, which using one 
(1) drug (91.4%; n=32) or two (2) drugs (8.6%; n=3) (Table 63). 
 
Table 63: Characterization of antithrombotic agents. 
 ATC Classification (level 4) N % 
B01AA - Vitamin K antagonists 2 5.1 
B01AC - Platelet aggregation inhibitors excl. heparin 35 89.8 
B01AE - Direct thrombin inhibitors 2 5.1 
Total 39 100.0 
Legend: ATC - Anatomical, Therapeutic and Chemical. 
 
Male patients used a greater number of antithrombotic agents (0.44±0.59) 
compared to female patients (0.19±0.39) (p=0.012). 
Polymedicated patients showed a statistically significant higher number of 
prescribed antithrombotic agents (p<0.001).  
 135 
 
Patients having a diagnosis of dyslipidaemia used an increased number of 
antithrombotic agents (p=0.001; r=0.309). 
Also a higher number of antithrombotic agents was used by patients taking 
more antihypertensive drugs (p=0.015; r=0.224). 
 
4.2.4 Analysis of Medication Review outcomes 
4.2.4.1 Humanistic outcomes: 
 
Medication Adherence 
According to the results obtained from the two tools used to assess medication 
adherence [Haynes-Sackett test (297) and MAT scale (296)], most patients 
were adherent to the medication, by 76.3%% and 72.0% respectively (Table 
64). 
 
Table 64: Characterization of patient´s medication adherence. 
 
Haynes-Sackett test MAT scale 
N % Mean±SD N % Mean±SD 
Adherent 90 76.3 
87.62±18.07 
85 72.0 
5.13±0.52 Non-adherent 28 23.7 33 28.0 
Total 118 100.0 118 100.0 
Legend: MAT – Measure Treatment Adherence; SD – Standard deviation. 
 
Patients reported having forgotten to take their medication “sometimes” (28.8%) 
and “often” (16.1%), and being careless with the hours of taking medication 
“sometimes” (19.5%) and “often” (8.5%).Most patients indicated to “never” 
stopped medication because they felt better (63.6%), though 16.9% did this 
“sometimes” and 3.4% “often”, while only 9.3% reported to have stopped 
medication “sometimes” for feeling worse and 2.5% stopped “often”. Regarding 
 136 
 
taking more pills on their own initiative after having felt worse, only 12.7% did 
this “sometimes” and 1.7% did often. About 10.2% of the patients declared to 
discontinue therapy for failing the end of drugs and 1.7% “often” did it. Almost 
half of patients (44.9%) have stopped medication without a doctor´s 
recommendation, and 11.9% stated to act like this “often” (Table 65). 
 
Table 65: Characterization of medication adherence according MAT scale. 
  Always Almost 
always Often 
Some 
times Rarely Never Total 
A 0 (0.0) 
0 
(0.0) 
19  
(16.1) 
34 
(28.8) 
61  
(51.7) 
4 
(3.4) 
118 
(100.0) 
B 0 (0.0) 
0 
(0.0) 
10  
(8.5) 
23 
(19.5) 
23  
(19.5) 
62 
(52.5) 
118 
(100.0) 
C 0 (0.0) 
0 
(0.0) 
4 
(3.4) 
20 
(16.9) 
19  
(16.1) 
75 
(63.6) 
118 
(100.0) 
D 0 (0.0) 
0 
(0.0) 
3 
(2.5) 
11 
(9.3) 
18  
(15.3) 
86 
(72.9) 
118 
(100.0) 
E 0 (0.0) 
0 
(0.0) 
2 
(1.7) 
15 
(12.7) 
27  
(22.9) 
74 
(62.7) 
118 
(100.0) 
F 0 (0.0) 
0 
(0.0) 
2 
(1.7) 
12 
(10.2) 
26  
(22.0) 
78 
(66.1) 
118 
(100.0) 
G 0  (0.0) 
0  
(0.0) 
14  
(11.9) 
53  
(44.9) 
43  
(36.4) 
8 
(6.8) 
118 
(100.0) 
A. Have you ever forgotten to take medication for their disease? 
B. Have you ever been careless with the hours of taking medication for their disease? 
C. Have you ever stopped taking medication for his illness, because he was better? 
D. Have you ever stopped taking medication for his illness, on its own initiative, after having felt 
worse? 
E. Have you taken a second or more pills for his illness, on its own initiative, after having felt 
worse? 
F. Ever discontinued therapy for their disease for failing to end the drugs? 
G. Have you ever stopped taking medication for their disease for some other reason than the 
statement of the doctor? 
Legend: MAT – Measure Treatment Adherence. 
 
Medication adherence was most pronounced for patients taking 5 to 10 
medicines per day, as the results obtained by using both tools to assess 
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medication adherence, showed a significant difference relative to the number of 
medicines used by patients (p<0.001) (Table 66). 
 
Table 66: Medication adherence according to number of medicines used.  
 Medication Adherence 
Up 4 
medicines 
5 to 10 
Medicines 
11 to 16 
Medicines p 
value 
% (N) % (N) % (N) 
Haynes-Sackett Test 
 Non-Adherent 11.9% (14) 11.0% (13) 0.9% (1) 
0.001*  Adherent 14.4% (17) 52.5% (62) 9.3% (11) 
                            Total  26.3% (31) 63.5% (75) 10.2% (12) 
MAT Scale 
 Non-Adherent 12.7% (15) 12.7% (15) 2.5% (3) 
0.013* 
 Adherent 13.6% (16) 50.8% (60) 7.6% (9) 
                             Total 26.3% (31) 63.5% (75) 10.1% (12) 
Legend: MAT - Measure Treatment Adherence. 
 
Polymedicated patients (5 or more medicines) presented a higher score of 
medication adherence with an average score of 90.7±13.45 and 5.2±0.46 
respectively, considering Haynes-Sackett test (p=0.036) and MAT scale 
(p=0.037). Patients using less than 5 medicines presented an average score of 
78.97±4.94 and 4.94±0.62, respectively. 
No significant difference were achieved for medication adherence (results from 
both assessment tools) relative to socio-demographic variables, neither to 
glycemic profile, blood pressure or lipid profile control (p>0.05). 
Adherent patients used an increased number of daily units, number of daily 
doses and presented a higher number of health problems per patient, 
considering the results obtained using Haynes-Sackett test, compared to non-
adherent patients (Table 67). 
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Table 67: Number of daily units, daily doses, health problems and medication 
adherence. 
 
Haynes-Sackett test MAT scale 
Medication 
Adherence 
Daily 
Units 
Daily 
Doses 
Nr Health 
Problems 
Daily 
Units 
Daily 
Doses 
Nr Health 
Problems 
Mean ± SD (Median) Mean ± SD (Median) 
 Non-   
 Adherent 
5.98±5.0 
5.0 
6.25±4.3 
5.0 
4.0±1.5 
4.0 
7.1±4.7 
6.0 
7.5±4.9 
6.0 
5.0±1.9 
5.0 
 Adherent 8.15±3.6 7.57 
8.46±3.8 
8.0 
5.06±1.97 
5.0 
7.9±3.6 
7.0 
8.1±3.6 
7.0 
4.7±1.9 
4.0 
p value 0.001 0.002 0.007 0.082 0.141 0.403 
Legend: MAT - Measure Treatment Adherence; Nr – Number; SD – Standard deviation. 
 
 
Patients using antihypertensive drugs presented a greater medication 
adherence of 89.38±15.18% according to Haynes-Sackett test (p=0.02) and 
5.18±0.46 (p=0.011) according to MAT scale. Patients not using 
antihypertensive drugs showed a medication adherence of 78.44±27.6 and 
4.4±0.72, respectively. 
Patients using 2 or more oral antidiabetic drugs (OAD) exhibited a higher 
adherence compared to patients using only one OAD (Table 68). 
 
Table 68: Medication adherence and number of oral antidiabetic drugs. 
 
Medication Adherence 
Haynes-Sackett Test MAT scale 
Mean ± SD Median Mean ± SD Median 
<2 OAD 85.97±19.1 95.24 5.07±0.55 5.14 
2OAD 90.3±16.2 94.34 5.24±0.45 5.29 
p value 0.038 0.054 
Legend: MAT - Measure Treatment Adherence; OADs: oral antidiabetic drugs;  
             SD – Standard deviation. 
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Medication adherence showed no significance difference for HbA1c values 
(p>0.05). 
 
Patient Medication Knowledge 
Patient knowledge about medication was assessed using an algorithm 
considering issues identified regarding the medicines used: name, drug´s 
strength, therapeutic indication, administration time, unit(s) number and storage 
conditions. 
In about half of the medicines, patients were unable to indicate the name of the 
medication (50.9%), and in about three-quarters (75.7%) of the medicines the 
patients were not capable to indicate drug's strength. The therapeutic indication 
was not known by the patient or was incorrect in about a quarter of medicines 
(23.6%). In about 9.0% of medicines the patients have been identified problems 
related to administration time and in 7.8% of medicines issues related to the 
number of units to use. The storage conditions were incorrect in about 57.5% of 
the medicines (Table 69). 
Table 69: Characterization of patients´ medication knowledge. 
  N % 
Name 
 Knows the name 399 49.1 
 Does not know the name 413 50.9 
Drug´s strength 
 Knows drug´s strength 197 24.3 
 Does not drug´s strength 615 75.7 
Therapeutic Indication 
 Knows the correct therapeutic indication 541 66.6 
 Does not know the correct therapeutic indication 63 7.8 
 Does not know the therapeutic indication 128 15.8 
 The information on the therapeutic indication is not 
complete 80 9.9 
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Table 69 (Continued) 
  N % 
Administration time 
 Correct administration time 739 91.0 
 Incorrect administration time  73 9.0 
Units Number 
 Correct number 749 92.2 
 Incorrect number  63 7.8 
Storage Conditions 
 Correct storage 290 35.7 
 Incorrect storage 467 57.5 
 Lack of information on medication storage 55 6.8 
 
 
About a quarter of patients (25.4%; n=30) showed a low medication knowledge 
(<50%), with an average rate of 62.77±16.01 of correct information about the 
medicines they were using.  
An increased number of health problems was observed in patients with a low 
level of medication knowledge (p=0.029), and also a lower score of health 
literacy (p=0.039) (Table 70). 
 
Table 70: Medication knowledge, number of health problems and health literacy. 
 
Nr Health Problems Health Literacy 
 
Mean±SD Median Mean±SD Median 
 Low MK 5.53±2.18 5.0 12.23±4.45 13.5 
 Not Low MK 4.57±1.77 4.0 14.6±2.48 15.0 
p value 0.029 0.039 
Legend: MK: Medication Knowledge; SD – Standard deviation.  
 
No significant differences were achieved for medication knowledge regarding 
socio-demographic variables, patient´s medication adherence, disease control 
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(hypertension, diabetes and dyslipidaemia) and number of medicines used per 
patient (p>0.05). 
The number of hospitalizations was higher in patients with low level of 
medication knowledge (mean=1.31±0.87; median=1.0), compared to patients 
who did not have this lack of knowledge (mean=1.0±0.0; median=1.0) 
(p=0.043). 
Patients getting help managing medication presented a lower score for 
medication knowledge (mean=57.7±15.4; median=55.9) over patients without 
any support (mean=64.98±15.87; median=65.91) (p=0.026). 
 
Patient Disease Knowledge  
Patients indicated to have a diagnosis of hypertension, on average, for 
10.73±7.87 years. 
The optimal values for blood pressure were correctly identified by 67.7% of 
hypertense patients, and almost all of those had measured their blood pressure 
in the last 12 months (99.0%). Only 16.7% indicated to perform occasional 
measurements and most of them performed at least a monthly measurement 
(70.8%). Nearly half of patients (48.0%) were not able to correctly indicate 
possible complications of uncontrolled blood pressure (Table 71). 
About 80.2% (n=77) of hypertensive patients indicated to have a tensiometer at 
home allowing them to measure blood pressure in the household.  
Table 71: Patients´ knowledge about hypertension. 
  N % 
Optimal value for blood pressure? 
 Correct 65 67.7 
 Incorrect 17 17.7 
 Does not Know 14 14.6 
Total 96 100.0 
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Table 71 (Continued) 
  N % 
Did you measure your blood pressure in the last 12 months? 
 Yes 95 99.0 
 No 1 1.0 
How many times? 
 At least once a day 19 19.8 
 At least once a week 32 33.3 
 At least once a month 17 17.7 
 Every six months 6 6.3 
 Every 3 months 6 6.3 
 Occasional 16 16.7 
Total 96 100.0 
The patient is able to indicate two complications of uncontrolled hypertension? 
 Yes, can identify 2 complications. 28 29.2 
 Only one complication was identified. 22 22.9 
 Patient knows that complications can be harmful 
but is not able to name it. 9 9.4 
 The patient is not able to identify complications. 30 31.3 
 Patient identified as a complication of the disease a 
side effect of medication (e.g. hypotension) or a 
symptom. 
7 7.3 
Total 96 100.0 
 
Patients who reported having diabetes mellitus, had this diagnosis for about 
13.2±9.3 years. Most of these patients (70.1%) were able to identify the correct 
range for fasting blood glucose, but could not identify the target range for post-
prandial blood glucose (94.4%). Patients indicated having measured blood 
glucose in the last 7 days on average 5.24 + 2.66 days, and 68.2% (n=73) 
indicated to have measured blood glucose every day, stating they had been 
indicated, by health professionals, to measure their blood glucose on average 
6.14 + 1.98 days (during 7 days), and in 83.2% (n=89) of cases were advised to 
daily measure blood glucose. A statistically significant difference between the 
number of measurements performed by the patients and the number of 
measurements indicated by health professionals in the last 7 days was 
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achieved, the latter being higher than the number of measurements actually 
performed by the patients (Table 72). 
It is noteworthy that 33.6% of patients diagnosed with diabetes, identified as a 
potential complication of the disease side effect(s) from medication (e.g. 
hypoglycaemia) or a disease symptom. 
In diabetic patients, 99.1% indicated to have had a glycemic control device at 
home. 
 
Table 72: Patients´ knowledge about diabetes. 
  N % 
Which is target range for fasting blood glucose? 
 Correct 75 70.1 
 Incorrect 18 16.8 
 Does not Know 14 13.1 
Total 107 100.0 
Which is target range for post-prandial blood glucose? 
 Correct 6 5.6 
 Incorrect 4 3.7 
 Does not Know 97 90.7 
Total 107 100.0 
The patient is able to indicate two potential complications of uncontrolled blood 
glucose? 
 Patient can identify 2 potential complications 16 15.0 
 Only one complication was identified 9 8.4 
 Patient knows that complications can be harmful but is not able to 
name it 12 11.2 
 The patient is not able to identify potential complications 34 31.8 
 Patient identified as a complication of the disease a side effect of 
medication (eg hypoglycaemia) or a symptom 36 33.6 
Total 107 100.0 
 
No statistically significant differences were identified in patients with low health 
literacy compared to those who did not have low literacy relative to patient´s 
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socio-demographic characteristics, medications adherence, number of 
medicines used, health literacy score and glycemic profile control (p>0.05).  
 
Patients indicated to have been diagnosed with dyslipidaemia on average for 
7.42±5.82 years. About two-thirds of these patients couldn´t identify the optimal 
value for the total cholesterol (66.0%; n = 60), and more than half (58.2%; n=53) 
of these patients were not able to identify possible complications of uncontrolled 
cholesterol (Table 73). 
 
Table 73: Patients´ knowledge about dyslipidaemia. 
  N % 
Optimal value for total cholesterol? 
 Correct 31 34.1 
 Incorrect 16 17.6 
 Does not Know 44 48.4 
Total 91 100.0 
The patient is able to indicate two potential complications of uncontrolled total cholesterol? 
 Patient can identify 2 potential complications 24 26.4 
 Only one complication was identified 14 15.4 
 Patient knows that complications can be harmful but is not able 
to name it 6 6.6 
 The patient is not able to identify potential complications 47 51.6 
Total 91 100.0 
 
A lack of knowledge regarding diseases such as hypertension, diabetes and 
dyslipidaemia was identified in many of the patients, respectively, in 61% 
(n=72), 78% (n=92) and 60.2% (n=71).  
 
Health Literacy 
Almost half of the patients (43.2%; n=51) were identified with “low health 
literacy”, with a mean of 13.97±3.24 points as the result for the application of 
SAHL-PT. 
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Patient´s health literacy score was higher for patients under 65 years (p<0.001) 
with a mean score of 14.86±2.83 (median=15.0) compared to patients  65 
years, who presented an average of 13.3±3.64 (median=14.0). For higher level 
of qualifications an increased score of health literacy was obtained, with 
patients having secondary education (12th grade) and higher education 
presenting the greater score for health literacy (p=0.003) (Table 74). 
 
Table 74: Health literacy and patients´ qualifications. 
Qualifications Mean SD Median p 
value 
 Cannot read or write 6.3 2.9 8.0 
0.001 
 Can read and/or write without having 
 education degree 10.0 4.6 9.0 
 1st cycle of basic education (4th grade) 12.8 3.26 12.0 
 2nd cycle of basic education (junior) 15.3 1.5 15.0 
 3rd cycle of basic education (9 years) 14.3 2.7 15.0 
 Secondary education (12th grade) 16.4 1.24 16.5 
 Professional course/technological  15.1 1.36 15.0 
 Higher education 16.5 0.97 16.0 
Legend: SD – Standard deviation.  
 
Patient´s health literacy presented a higher score (mean=14.57±2.5; 
median=15.0) for patients without a low level of medication knowledge 
(p=0.043) compared to patients presenting a low level of medication knowledge 
(mean=12.2±4.45; median=13.5).  
Moreover, patients without lack of knowledge about dyslipidaemia (p=0.003) 
presented a higher score for health literacy (mean=15.55±2.4, media=16.0) 
than those with lack of knowledge about dyslipidaemia (mean=13.45±3.18, 
median=14.0). 
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Patients with uncontrolled lipid profile showed a higher score for health literacy 
(mean=15.1±3.0; median=16.0) than patients with controlled lipid profile 
(mean=13.73±3.25; median=15.0) (p=0.041). 
The number of health problems reported by patients having a low health literacy 
score (mean=4.96±1.91) was greater than the number of health problems 
diagnosed for patients not having low health literacy score (mean=4.7±1.94), 
despite no statistically significant difference (p> 0.05). 
Patients presenting low health literacy score showed an increased HbA1c value 
(7.75±1.2; median=7.6) compared to those without low health literacy score 
(7.6±1.5; median=7.3). Also a lower health literacy score (mean=13.68±3.44) 
was identified for patients presenting a higher prevalence of uncontrolled blood 
pressure compared to those with controlled blood pressure (mean=14.64±2.66), 
despite no statistically significant difference (p> 0.05).  
 
Self-perceived health status 
Patients considered their health status positively in 33.1% of the cases (“good” 
or “excellent”) and 53.4% as “acceptable” (Table 75).  
 
Table 75: Characterization of self-perceived health status. 
Classification N % 
Very Bad 3 2.5 
Bad 13 11.0 
Acceptable 63 53.4 
Good 37 31.4 
Excellent 2 1.7 
Total 118 100.0 
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The number of medicines was higher for patients having a worse perspective of 
their own health status, having a statistically significant difference for patients 
considering their health as “very bad” and “bad” (p=0.025) (median=15.0 and 
8.0 medicines, respectively), as well as for those considering “very bad” and 
“acceptable” (p=0.001) (median=15.0 and 7.0, respectively) and between those 
reporting health status as “bad” and “good” (p=0.001) (median=15.0 and 6.0 
medicines, respectively). 
Patients with a positive perspective of their health status presented an 
increased score of health literacy (p=0.018; r=0.218). For those with a "bad" 
perception of health status an average of health literacy score of 12.85±2.19 
(median=13.0) was achieved, compared to those with a “good” perception of 
health status that presented a higher average score of 14.81±3.08 
(median=16.0). 
 
4.2.4.2 Economic outcomes: 
 
Number of medicines 
The number of medicines prescribed and used by patients was previously 
described in the section 4.2.3 - Pharmacotherapeutic profile, as well as the 
number of units and daily doses. 
Patients followed for a longer period in the AEDMADA clinic were treated with a 
higher number of medicines (p=0.001). Polymedicated patients were followed 
for a median of 53 months and patients taking less than five medicines were 
followed for a median of 19 months. 
The number of Physicians following patients was higher (mean2.76±1.02; 
median=3) for patients under polymedication compared to those using less than 
5 medicines (mean=2.03±0.87; median=2) (p<0.001).  
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Patients presenting greater number of health problems were using a higher 
number of medicines (mean 5.31±1.9; median=5) compared to those with a 
lower number of health problems (mean 3.42±1.15; median=3) (p<0.001). 
Patients having help with medication were using an increased number of 
medicines (mean=8.0±3.28; median=8) than those who did not indicate to 
receive help with medication (mean=6.13±2.74; median=6) (p=0.006). 
In cases of patients who had suffered a cardiovascular event, the number of 
medicines used was greater (mean=8.48±2.46; median=9) compared to those 
who did not report a previous cardiovascular event (mean=6.32±3.0; 
median=6). (p=0.001). 
In the case of patients who practiced physical exercise regularly the number of 
medicines used for these patients was lower (mean=5.76±2.55; median=5) than 
in patients who did not practice regular physical exercise (mean=7.4±3.17; 
median=7.5) (p = 0.003). 
 
Number of hospitalizations  
Only in 15% of the patients reported having experienced a hospitalization in the 
previous 12 months, with a total of 23 admissions. This event occurred mostly 
once (88.89%, n=16) in the previous year, with an average of 8.17±8.95 days of 
hospitalization, a minimum of 1 day and a maximum of 30 days. Only one 
patient indicated to be hospitalized on three (3) occasions and one in four (4) 
occasions.  
About 15.9% (n=17) of diabetic patients had been hospitalized in the last 12 
months, mostly only one time (88.2%; n=15). 
Patients who underwent inpatient the previous 12 months were treated with a 
higher number of medicines (mean=8.39±3.24; median=8.0) compared to those 
patients who were not hospitalized during this period (mean=6.4±2.9; 
median=6.0) (p = 0.024).  
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The number of hospitalizations for patients presenting microvascular 
complications of diabetes was higher (mean=0.56±1.0) compared to those who 
have not yet had these complications (mean=0.098±0.3) (p=0.004). 
Diabetic patients being treated with insulins presented a higher number of 
hospitalizations (mean=0.29±0.78) compared to those not using insulin 
(mean=0.14±0.35) (p=0.037). 
Patients with a negative perception of their health presented an increased 
length of hospitalization (p=0.03), as well as patients who had already a prior 
cardiovascular event (p=0.006) (Table 76). 
 
Table 76: Length of hospitalization, self-perceived health status and previous 
cardiovascular event. 
Self-perceived health 
status 
Length of hospitalization (days) 
Mean± SD N Median p 
 value 
 Very Bad 17.5±17.68 2 17.5 
0.03 
 Bad 11.0±7.0 3 14.0 
 Acceptable 8.43±9.74 7 5.0 
 Good 3.33±2.88 6 2.5 
 Excellent 0.0±0.0 0 0.0 
                               Total 8.17±8.95 18 5.0 
Previous 
cardiovascular event Mean N Median 
p 
 value 
 Yes 17.0±9.31 4 15.0 
0.006  No 5.64±7.83 14 4.0 
                               Total 8.17±8.95 18 5.0 
Legend: SD – Standard deviation. 
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Number of Physicians following patient 
Patients were followed mainly by two (36.4%) or three (34.7%) Physicians, 
while a small number of patients was followed by four (11.9%), five (1.7%) and 
six (1.7%) Physicians. Most patients (77.1%) was attending consultations with 
General Practitioners and specialists in the area of diabetology such as internal 
medicine (Table 77). 
 
Table 77: Characterization of Physicians´ specialities. 
Physician speciality N % 
Cardiology 22 18.6 
Endocrinology 2 1.7 
General Practice 91 77.1 
Internal Medicine  102 86.4 
Neurology 3 2.5 
Ophthalmology 35 29.7 
Other 34 28.8 
Pneumology 1 0.8 
Urology 6 5.1 
 
Polymedicated patients reported to be consulted by a higher number of 
Physicians (p<0.001).  
Patients being followed by an increased number of Physicians used a higher 
number of medicines (p<0.001; r=0.404), and also a higher number of daily 
units (p<0.001; r=0.404) and daily doses (p<0.001; r=0.448).    
Patients 65 years and older were consulted by a higher number of Physicians, 
compared to younger patients (<65 years), although the difference was not 
statistically significant (p>0.05). 
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Rate of reimbursement of medicines.  
Patients were mostly covered by the Portuguese general medicine 
reimbursement system (75.4%; n=89), while only 14.4% (n=17) were covered 
by the special system for drug reimbursement and 10.2% (n=12) by other health 
subsystems.  
Patient´s gender (p=0.001), qualifications (p=0.018), number of Physicians 
(p=0.027) and number of health problems (p=0.043) presented a significant 
difference relative to patient´s rate reimbursement of medicines. Many of the 
patients covered by the general medicine reimbursement system were male 
(57.3%; n=51) and most patients covered by the special system for drug 
reimbursement were female (82.35%; n=14).  
Patients that couldn´t write or read were all covered by the special system for 
drug reimbursement (n=3).  
A total of 3 Physicians were the most frequent number of these professionals 
following study patients covered by the special system for drug reimbursement 
(47.1%; n=8), whereas patients covered by the general medicine 
reimbursement system were more frequently followed by 2 Physicians (41.6%; 
n=37). 
No significant difference was found between medicines reimbursement and 
patient´s medication adherence (p>0.05). 
 
4.2.4.3 Clinical outcomes: 
 
Negative Clinical Outcomes  
A total amount of 360 negative clinical outcomes (NCOs) were identified, being 
those present in 99.2% (n=117) of the patients included in this study. An 
average of 3.05±1.13 NCOs per patient, a median of 3 NCOs, 25th and 75th 
percentiles, respectively, 2 and 4 NCOs, for patients presenting NCOs a 
minimum of 1 (one) NCO and a maximum of 7 NCOs was detected.  
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The most frequent NCOs were related to “Disease control” (52.8%) and 
“Untreated conditions” (38.1%), being less frequent those related to “Safety” 
(9.2%) (Table 78). 
 
Table 78: Characterization of Negative Clinical Outcomes (NCOs). 
NCO N % Mean±SD Median 
Disease Control 190 52.8 1.64±0.82 2.0 
Safety 33 9.2 0.23±0.5 0.0 
Untreated Conditions 137 38.1 1.2±0.7 1.0 
Total 360 100.0 3.05±1.13 3.0 
Legend: NCO – Negative clinical outcomes; SD – Standard deviation. 
 
The prevalence of negative clinical outcomes (NCOs) was higher for diseases 
from Chapter IV - Endocrine, nutritional and metabolic diseases (67.5%) and 
Chapter IX - Diseases of the circulatory system (22.3%) (Table 79), coinciding 
with the diseases with greater prevalence in the study sample (Table 47). 
Negative clinical outcomes of “disease control” were found more frequently in 
disorders of lipoprotein metabolism and other lipidaemias (18.1%), hypertension 
(16.4%) and diabetes mellitus (15.8%). Outcomes relative to “untreated 
conditions” presented a higher prevalence in others disorders of endocrine, 
nutritional and metabolic diseases (30.8%) and hypertension (2.5%) while 
NCOs relative to “safety” were most frequent in others disorders of the digestive 
system (3.2%) and other disorders of endocrine, nutritional and metabolic 
diseases (2.5%).  
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Table 79: Characterization of negative clinical outcomes and diseases. 
Ch
ap
te
r
*
 Disease 
Disease 
Control Safety 
Untreated 
Conditions Total 
N     (%) N    (%) N    (%) N     (%) 
III Anaemia 1 0.3 0 0.0 1 0.3 2 0.6 
IV 
Diabetes  57 15.8 0 0.0 0 0.0 57 15.8 
Dyslipidaemias 65 18.1 0 0.0 22 6.1 87 24.2 
Other 1 0.3 9 2.5 89 24.7 99 27.5 
V 
Depressive dis. 2 0.6 0 0.0 1 0.3 3 0.8 
Insomnia 1 0.3 0 0.0 0 0.0 1 0.3 
Other 0 0.0 2 0.6 2 0.6 4 1.1 
VI NS - Other 0 0.0 2 0.6 0 0.0 2 0.6 
IX Hypertension 59 16.4 1 0.3 9 2.5 69 19.2 
Other 2 0.6 2 0.6 7 1.9 11 3.1 
XI Other 1 0.3 11 3.1 2 0.6 14 3.9 
XIII Other 0 0.0 2 0.6 1 0.3 3 0.8 
XIV BPH 1 0.3 0 0.0 0 0.0 1 0.3 
Other 0 0.0 1 0.3 2 0.6 3 0.8 
XIX Allergy, Unsp. 0 0.0 3 0.8 1 0.3 4 1.1 
Total 190 52.8 33 9.2 137 38.1 360 100 
Legend: * ICD-10 Chapter; BPH – Benign prostatic hyperplasia; Dis. – Disorders; Unsp. – 
Unspecified; NS – Nervous system. 
 
About a fifth (21.5%) of the medicines and supplements used by patients, for 
those who had negative clinical outcomes, the most frequent NCOs were 
relative to the “control of disease” (80.5%) and the remaining outcomes related 
to “security” (19.5%). 
Considering socio-demographic variables, no statistically significant difference 
was identified regarding the number of NCOs identified in patient´s medication 
review.  
The average number of NCOs found in patients aged 65 years or older was 
higher (mean=3.06±1.04; median=3.0) than the number of NCOs achieved in 
younger patients (mean=3.04±1.25), although this difference was not 
statistically significant (p>0.05). 
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For the various specific types of negative clinical outcomes, in “disease control” 
a statistically significant difference was achieved for the follow-up period in 
AEDMADA clinic (p=0.037; r=0.193). Moreover, in NCOs of “safety” a higher 
number of negative outcomes (p=0.030) was observed for female patients 
(mean=0.34±0.59; n=53) compared to male patients (mean=0.14±0.39; n=64). 
For NCOs related to “untreated conditions” no association were identified within 
the socio-demographic variables.   
In cases where there was an uncontrolled blood pressure (p<0.001; r=0.347), 
uncontrolled glycemic profile (p<0.001; r=0.476), increased HbA1c values 
(p<0.001; r=0.349) and previous cardiovascular events (p=0.028; r=0.202), 
patients presented higher prevalence of NCOs. 
Those patients with hypertension (p=0.007; r=0.245), diabetes mellitus 
(p=0.017, r = 0.219) and previous cardiovascular event (p=0.002; r=0.284) had 
a significantly higher number of NCOs relative to "disease control".  
Patients with a disorder of lipid metabolism showed an increased number of 
NCOs relative to “untreated conditions” (p=0.017; r=0.219). 
Patients with polypharmacy presented an increased number of NCOs, with a 
statistically significant difference achieved for both “disease control” and 
“untreated conditions” negative outcomes (Table 80).  
Table 80: Characterization of negative clinical outcomes and polypharmacy. 
 
NCOs (number) 
Mean±SD Median p value 
NCOs 
(total number) 
<5 medicines 2.9±1.14 3 
0.307 
5 medicines 3.1±1.13 3 
“Disease 
control” 
<5 medicines 1.29±0.69 1 
0.003 
5 medicines 1.76±0.83 2 
“Safety” 
<5 medicines 0.13±0.34 0 
0.254 
5 medicines 0.26±0.54 0 
“Untreated 
conditions” 
<5 medicines 1.48±0.93 1 
0.016 
5 medicines 1.09±0.56 1 
Legend: NCOs – Negative clinical outcomes; SD – Standard deviation. 
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The number of daily units (p=0.023; r=0.210) and the number of daily doses 
(p=0.033; r=0.196) were in higher number for patients with increased number of 
NCOs.  
Moreover, a greater number of antidiabetic drugs (oral antidiabetic drugs and 
insulins) (p=0.001; r=0.305) were being taken patients manifesting an increased 
number of NCOs. 
For NCOs relative to “disease control” significant differences were identified for 
the number of medicines (p = 0.001; r=0.297), daily units (p = 0.00; r=0.316), 
daily doses (p = 0.00; r=0.328). 
For polymedicated patients (5 medicines) a higher number of NCOs 
(mean=3.1±1.13; median=2) relative to “disease control” (p=0.003) was 
identified, when compared to those patients using a lower number of medicines 
(mean=1.76±1.14; median=1).  
A lower number of NCOs (mean=1.09±0.56; median=1) relative to “untreated 
situations” were identified for patients using polypharmacy, compared to those 
using a lower number of medicines (mean=1.48±0.93; median=1) (p=0.012).   
The number of NCOs identified was higher for patients having uncontrolled 
blood pressure, uncontrolled glycemic profile, increased values of HbA1c and 
for those who had a previous cardiovascular event (Table 81). 
 
Table 81: Characterization of negative clinical outcomes and clinical variables 
correlation. 
 Clinical variables 
NCOs (total) 
NCOs 
“disease 
control” 
NCOs 
“untreated 
conditions” 
r 
p  
value r 
p  
value r 
p 
value 
Number of health problems 0.077 0.406 0.100 0.280 -0.086 0.353 
Hypertension 0.103 0.266 0.245 0.007 0.168 0.070 
Diabetes mellitus 0.116 0.210 0.219 0.017 0.070 0.450 
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Table 81 (Continued) 
 Clinical variables 
NCOs (total) 
NCOs 
“disease 
control” 
NCOs 
“untreated 
conditions” 
r 
p  
value r 
p  
value r 
p 
value 
Blood pressure control 0.347 <0.001 0.358 <0.001 0.156 0.092 
Glycemic profile control 0.476 <0.001 0.532 <0.001 0.238 0.013 
Lipid profile control 0.115 0.216 0.231 0.012 0.032 0.734 
HbA1c values 0.349 <0.001 0.375 <0.001 0.211 0.024 
Previous CV event 0.202 0.028 0.284 0.002 0.006 0.945 
Legend: CV – Cardiovascular; NCO – Negative clinical outcome. 
 
Patients presenting a larger number of NCOs of “disease control” had a 
diagnosis of hypertension (p=0.007), diabetes mellitus (p=0.017), and a lower 
control on blood pressure (p<0.001), lipid profile (p=0.012), and glycemic profile 
(p<0.001), as well as higher values of HbA1c (p<0.001). 
The number of NCOs relative to “safety” showed no statistically significant 
differences in the clinical variables. 
When patients presented a diagnosis of dyslipidaemia a higher number of 
NCOs of “untreated conditions” were observed (p=0.017), as well as patients 
with uncontrolled glycemic profile (p=0.013) and higher HbA1c values (p=0.024) 
also showed a higher number of such NCOs. 
Regarding the analysis of parameters included in the humanistic outcomes from 
medication review, no statistically significant differences were found concerning 
the number of NCOs other than the knowledge of the disease relative to 
dyslipidaemia (p=0.015) (Table 82). Patients who presented a lack of 
knowledge for this disease (dyslipidaemia) presented an average of 3.07±1.03 
(median=3) NCOs and patients without this characteristic presented an average 
of 2.55±1.06 (median=2.5) NCOs (p=0.015). 
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Table 82: Negative clinical outcomes and humanistic outcomes correlation. 
 Humanistic Outcomes r 
Medication Adherence (MAT scale) -0.078 0.403 
Medication Adherence (Haynes-Sackett test) -0.028 0.762 
Medication Knowledge -0.040 0.669 
Lack of knowledge (Hypertension) 0.018 0.860 
Lack of knowledge (Diabetes mellitus) 0.006 0.952 
Lack of knowledge (Dyslipidaemia) 0.252 0.015 
Disease Knowledge (Total) -0.127 0.171 
Health Literacy -0.082 0.377 
Help with your medications -0.051 0.585 
Self-perceived health status -0.054 0.560 
Legend: MAT - Measure Treatment Adherence. 
 
Regardless of no statistically significant differences obtained for patients with 
low health literacy score, low medication knowledge, non-adherent patients to 
medication, patients having help with medication and negative perceptions for 
health status, for those patients an increase in the number of NCOs was 
achieved (p>0.05). 
Considering economic outcomes (Table 83), a statistically significant difference 
was identified for the number of Physicians consulted by patients (p=0.018; 
r=0.208) and patient´s medication reimbursement rate (p=0.045; r=0.185), 
relative to the number of NCOs. 
Table 83: Negative clinical outcomes and economic outcomes correlation. 
 Economic Outcomes r 
Medication reimbursement 0.185 0.045 
Number of total of medicines 0.151 0.104 
Number of hospitalizations   0.037 0.692 
Number total of Physicians 0.218 0.018 
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For NCOs relative to “disease control”, patients with longer hospitalizations 
presented a higher number of these negative outcomes (p=0.033; r=0.503). 
Considering the NCOs relative to “safety” only the “number of Physicians 
consulted by patients” presented a significant difference (p=0.001; r=0.302), 
with patients being followed by a higher number of Physicians presenting a 
higher number of this type of NCO.  
For the NCOs relative to “untreated conditions” no significant differences were 
identified within the parameters included in the scope of economic outcomes. 
 
Drug-Related Problems  
A total of 552 drug-related problems (DRPs) were identified among patient´s 
medication, whereas DRPs were pointed out by 95.8% (n=113) of patients, with 
an average of 4.7±2.9 (median=4) DRPs per patient.  
The most prevalent DRPs were related to “Drug selection” (38.2%), followed by 
“Medicine´s use process” (27.9%) and “Dose selection” (20.7%), as described 
in Table 84. 
 
Table 84: Characterization of drug-related problems (DRPs). 
DRP 
Scope N (%) Type N % 
Drug 
selection 
211 
(38.2) 
Inappropriate drug (incl. contra-indicated)  101 18.3 
No indication for drug 66 12.0 
Inappropriate combination of drugs, or 
drugs and food  27 4.9 
Synergistic/preventive drug required and 
not given 17 3.1 
Duplicate drug 0 0.0 
Dose 
selection 
114 
(20.7) 
Drug dose too low 66 12.0 
Drug dose too high 9 1.6 
Dosage regimen not frequent enough 32 5.8 
Dosage regimen too frequent 2 0.4 
Dose adjustment is required 
(pharmacokinetics) 1 0.2 
Dose adjustment is required (improvement 
of disease state) 4 0.7 
 159 
 
Table 84 (Continued) 
DRP 
Scope N (%) Type N % 
Drug form 1 (0.2) Inappropriate drug form 1 0.2 
Treatment 
duration 34 (6.2) 
Duration of treatment too short 2 0.4 
Duration of treatment too long 32 5.8 
Medicine´s 
use 
process  
154 
(27.9) 
Inappropriate timing of administration 
and/or dosing intervals 73 13.2 
Drug underused (intentional) 34 6.2 
Patient forgets to use drug (unintentional) 15 2.7 
Drug not used at all 31 5.6 
Wrong drug used 1 0.2 
Patient 
Medication 
knowledge  
30 (5.4) Low medication knowledge rate 30 5.4 
Other 8 (1.4) Other  8 1.4 
Total 552 (100.0)  552 100.0 
 
Analysing the type of DRPs identified, “Inappropriate drug” (18.3%), 
“Inappropriate timing of administration and/or dosing intervals” (13.2%), “No 
indication for drug” (12.0%) and “Drug dose too low” (12.0%) were the most 
frequent types identified in patient´s medication.  
The analysis of drug related problems (DRPs) per medicine (drug´s ATC and 
food supplements) did not include DRPs relative to “Medicines knowledge” 
whereas the evaluation of the patient's knowledge about medicines was 
calculated for the total number of medicines used by the patient.  
The total number of NCOs did not presented a statistically significant difference 
relative to the number of DRPs (p=0.151). However, a significant difference was 
achieved between the number of DRPs relative to “Drug selection” (p=0.026; 
r=0.315) and the total number of NCOs, as well for NCOs related to "disease 
control" (p=0.010; r=0.237). 
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The number of DRPs presented a significant difference (p<0.001) with the 
number of health problems (p<0.001; r=0.496).   
Also for the number of antihypertensive drugs (p=0.005; r=0.259), oral 
antidiabetic drugs (p=0.028; r=0.202) and antiplatelet drugs (p=0.043; r=0.186), 
statistically significant differences were achieved relative to the number of 
DRPs. 
A greater number of drug-related problems of “drug selection” was achieved for 
patients using an increased number of antidiabetic drugs (oral and insulins) 
(p=0.029; r=0.201) and antiplatelet drugs (p=0.002; r=0.286), as well as for 
patients with uncontrolled blood pressure (p=0.019) with an average number of 
this type of DRPs of 2.06±1.91 and 1.17±1.0 for patients with controlled blood 
pressure. 
Furthermore, an increased number of DRPs of “dose selection” was achieved 
for patients using a higher number of antidyslipidemic drugs (p=0.013; r=0.228) 
and a lower number of insulins (p=0.010; r=-0.237).  
Patients who had a prior cardiovascular event presented a greater number of 
DRPs of "dose selection" (p=0.020), as well as those who had a diagnosis of 
dyslipidaemia (p=0.007) with an average of 1.07±1.0 DRPs of this type and 
0.63±1.11 for those who had no diagnosis of this health problem.  
An increased number of DRPs of “medicine´s use process” was detected for 
patients using a higher number of oral antidiabetic drugs (p=0.043; r=0.287), 
and for patients using a higher number of antiplatelet drugs a greater number of 
DRPs of “medicine´s use process” (p=0.045; r=0.285) was found. 
Considering the type of DRP, the highest prevalence of DRPs (37.2%) was 
identified in medicines belonging to the C group (Cardiovascular System), A 
group (Alimentary Tract and Metabolism) (27.0%) and N group (Nervous 
System) (17.2%) (Table 85).  
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Table 85: DRP prevalence for ATC group A, C and N. 
DRP Type 
ATC (Level 1) 
A Group 
N (%) 
C Group 
N (%) 
N Group 
N (%) 
Inappropriate drug (incl. contra-indicated)  22 4.2 44 8.4 15 2.9 
No indication for drug 19 3.6 8 1.5 15 2.9 
Inappropriate combination of drugs, or drugs 
and food  9 1.7 12 2.3 3 0.6 
Synergistic/preventive drug required and not 
given 2 0.4 13 2.5 1 0.2 
Duplicate drug 0 0,0 0 0,0 0 0.0 
Inappropriate drug form 0 0.0 0 0,0 1 0.2 
Drug dose too low 12 2.3 28 5.4 12 2.3 
Drug dose too high 1 0.2 4 0.8 1 0.2 
Dosage regimen not frequent enough 3 0.6 16 3.1 6 1.1 
Dosage regimen too frequent 2 0.4 0 0.0 0 0.0 
Dose adjustment is required  0 0.0 0 0.0 1 0.2 
Dose adjustment is required (improvement of 
disease state) 2 0.4 2 0.4 0 0.0 
Duration of treatment too short 0 0.0 0 0.0 1 0.2 
Duration of treatment too long 7 1.3 0 0.0 21 4.0 
Inappropriate timing of administration and/or 
dosing intervals 28 5.4 29 5.6 6 1.1 
Drug underused (intentional) 15 2.9 12 2.3 4 0.8 
Patient forgets to use drug (unintentional) 3 0.6 8 1.5 1 0.2 
Drug not used at all 10 1.9 15 2.9 2 0.4 
Wrong drug used 0 0.0 1 0.2 0 0.0 
Other 6 1.1 2 0.4 0 0.0 
Total 141 27.0 194 37.2 90 17.2 
Legend: ATC – Anatomical, Therapeutic and Chemical; DRP – Drug-related problem. 
 
The problem “Inappropriate drug” presented a higher prevalence in medicines 
such as A10BH (Dipeptidyl peptidase 4 (DPP-4) inhibitors) (1.34%); C07AB 
(selective Beta blocking agents) (1.72%), C10AB (Lipid modifying agents – 
Fibrates) (1.34%), N05BA (Anxiolytics, Benzodiazepine derivate) (1%). 
A higher prevalence was achieved for DRP “No indication for drug” with 
increased prevalence in A02BC (Proton pump inhibitors) (2.9%), and 
B01AC (antithrombotic agents, Platelet aggregation inhibitors excl. heparin) 
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(2.3%). Additionally to this type of problem under the "Drug selection" the 
problem "No indication for drug" was the second most frequent.  
The pharmacotherapeutic groups with the highest prevalence were the N 
(Nervous system) group (2.9%), A (Alimentary tract and metabolism) group (3.6 
%) and B (Blood and blood forming organs) group (2.3%). In A group, the 
subgroups with the outstanding number of problems were A02BC (Proton pump 
inhibitors) (2.9%) and B01AC (Antithrombotic agents, Platelet aggregation 
inhibitors excl. Heparin) (2.3%). 
Considering DRPs relative to “Dose selection”, most prevalent problems were 
“Drug dose too low” (12.6%) and “Dosage regimen not frequent enough” (6.1%) 
For the problem “Dosage regimen not frequent enough” the drug´s group with 
more problems were C group (Cardiovascular system) (3.1%) and N group 
(Nervous system) (15.1%). 
In the scope of “Medicine´s use”, the “Inappropriate timing of administration 
and/or dosing intervals” was the DRP with higher prevalence (13.2%), followed 
by “Drug underused (intentional)” (6.2%) and “Drug not used at all” (5.6%). For 
the first type of problem, the subgroup C08CA (Selective calcium channel 
blockers with mainly vascular effects, Dihydropyridine derivatives) (1.7%) and 
A02BC (Proton pump inhibitors) (2.9%) were the drug subgroups with highest 
number of DRPs.  
Problems of “intentional non-adherence” were more frequent in the drug 
subgroups A10BA (Blood glucose lowering drugs, biguanides) and C10AA 
(Lipid modifying agents, HMG CoA reductase inhibitors), both with 1.15%. The 
subgroups C09AA (angiotensin-converting-enzyme inhibitors) and C10AA (Lipid 
modifying agents, HMG CoA reductase inhibitors) verified an increased number 
of DRPs relative to “Drug not taken at all” (1.3% for both).  
DRPs relative to medication adherence were higher in the intentional (6.5%) 
character than in the unintentional (2.9%). 
 “Drug dose too low” was the more evident DRP in the subgroups C10AA (Lipid 
modifying agents, HMG CoA reductase inhibitors) (2.7%) and N05BA 
(Anxiolytics, Benzodiazepine derivate) (1.15%). 
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Older patients (65 years) presented a higher number of DRPs (5.52±2.89; 
median 5) compared to younger patients (mean=3.57±2.48; median=3) 
(p<0.001). In this group of patients, the most prevalent DRPs were relative to 
“Drug selection” (40.4%), “Medicine´s use process” (29.5%) and “Dose 
selection” (21.8%). 
The type of DRPs most observed in older patients, were “Inappropriate drug” 
(19.3%), “Inappropriate timing of administration and/or dosing intervals” 
(14.0%), “No indication for drug” (12.6%) and “Drug dose too low” (12.6%). 
Taking into account the humanistic outcomes from medication review, only the 
patient´s medication knowledge showed a statistically significant difference 
(p=0.012; r=-0.229) with the number of DRPs, with an average of 5.87±2.69 
problems for the patient who had low medication knowledge and 4.27±2.85 
problems for patients without low medication knowledge (p=0.003) (Table 86). 
 
Table 86: Characterization of drug-related problems and humanistic outcomes 
correlation. 
 Humanistic Outcomes r p value 
Medication Adherence (MAT scale) 0.046 0.620 
Medication Adherence (HS test) -0.137 0.140 
Medication Knowledge -0.229 0.012 
Lack of knowledge (Hypertension) -0.053 0.608 
Lack of knowledge (Diabetes) -0.061 0.529 
Lack of knowledge (Dyslipidaemia) -0.133 0.203 
Disease Knowledge (Total) -0.005 0.960 
Health Literacy -0.068 0.466 
Help with your medications 0.008 0.932 
Self-perceived health status 0.027 0.768 
Legend: MAT – Measure Treatment Adherence.  
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Patients that were non-adherent to medication, patients who achieved a low 
health literacy score and those having a lack of disease knowledge presented a 
higher number of DRPs, although no statistically significant differences were 
observed (p>0.05). 
Moreover, patients manifesting a more negative perception of their health status 
had a higher number of detected DRPs, although without statistically significant 
differences (p>0.05). 
Analysing economic outcomes resulting from medication review (Table 87), a 
statistically significant difference was found for the number of DRPs with 
patient´s medication reimbursement (p=0.02; r=0.284 and with the number of 
Physicians following the patient (p=0.007; r=0.246). Also a higher number of 
DRPs were identified for patients taking an increased number of medicines 
(p<0.001; r=0632) 
 
Table 87: Drug-related problems and economic outcomes correlation. 
 Economic Outcomes r p value 
Medication reimbursement rate 0.284 0.02 
Number of total of medicines 0.632 <0.001 
Number of hospitalizations  0.137 0.138 
Number total of Physicians 0.246 0.007 
 
Patients who had attributed the general system of reimbursement of medicines 
had a statistically significant lower number of DRPs (p=0.006) and patients 
having the special system of medicine´s reimbursement showed a higher 
number of DRPs (median=6.0). 
The number of DRPs detected increased with the number of medications used 
by the patient, and displayed a higher average value for patients using 11 or 
more medicines (Table 88). 
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Table 88: Characterization of drug-related problems and number of medicines. 
Medicines (number) Mean±SD Median N p value 
 Up 4 medicines 2.61±1.94 2.0 31 
0.006 
 5 to 10 Medicines 5.05±2.77 5.0 75 
 11 to 16 Medicines 7.67±1.87 8.0 12 
                               Total 4.68±2.88 4.0 118 
Legend: SD – Standard deviation. 
 
For patients with a greater number of hospitalizations a higher number of DRPs 
was achieved, although this difference was not statistically significant (p>0.05). 
About 19.4% of older patients ( 65 years old) were using potentially 
inappropriate medication (PIMs), 17 drugs (3.5%) were identified as 
inappropriate according Beers criteria adapted to Portuguese language (196).  
Those older patients using PIMs were using mostly one (1) PIM (69.2%).  
Potentially inappropriate medication (PIM) more often identified was “long term 
benzodiazepine” (29.4%) and “long term NSAID” (17.6%), although the more 
commonly identified PIMs were independent of diagnosis, with only 2 PIMs 
identified as inappropriate for a specific diagnosis (Table 89).  
 
Table 89: Characterization of potentially inappropriate medication (PIM) 
according Beers criteria. 
PIM N % 
In
de
pe
n
de
n
t o
f 
di
a
gn
o
sis
 
Long term benzodiazepine 5 29.4 
Stimulant laxatives 2 11.8 
Long term NSAID, COX-2 nonselective 3 17.6 
Amiodarone 2 11.8 
Muscle relaxants and antispasmodics 2 11.8 
Indomethacin 1 5.9 
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Table 89 (Continued) 
PIM N % 
Co
n
sid
e
rin
g 
Di
a
gn
o
sis
 
Coagulation disorders (acetylsalicylic acid) 1 5.9 
Arrhythmias (amitriptyline) 1 5.9 
Total 17 100.0 
Legend: COX-2 – Cicloxigenase- 2; NSAID – Non-steroidal anti-inflammatory 
drug. 
 
 
Polymedicated patients (5 or more medicines) were treated with at least one 
PIM in 21.8% (n=12) of the cases, however no statistically significant difference 
was achieved (p>0.05). 
The use of inappropriate drugs increased significantly with the number of 
medicines used by patients (p=0.047), and also with the number of drug related 
problems (p=0.049). No significant statistically differences were found for the 
number of negative clinical outcomes, or humanistic outcomes (p>0.05). 
 
Risk situations for negative clinical outcomes 
Risk conditions for NCOs were identified in 74.6% (n=88) of patients, a total of 
293 risk situations and a mean of 2.48±2.31 (median=2.0) per patient. Most 
patients had up to four (4) risk situations (60.2%) (Figure 16). 
 
Figure 16: Number of risk situations for negative clinical outcomes. 
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The number of risk situations for NCOs presented a statistically significant 
difference for patient´s age (p<0.001) (Table 90), showing an increase with 
patient´s age, while no other significant differences were identified for socio-
demographic parameters.  
 
Table 90: Risk situations of negative clinical outcomes (NCO) and patient´s age. 
Age class 
(years) 
Risk situations of NCOs (number) 
Mean SD N Median p value 
18-49 years 0.75 1.75 8 0.0 
0.0004 
50-64 years 1.95 2.1 43 2.0 
65-74 years 2.70 2.1 43 2.0 
 75 years 3.63 2.8 24 3.0 
               Total 2.48 2.3 118 2.0 
Legend: NCO - Negative clinical outcomes; SD - Standard deviation. 
 
Patients 65 years presented a higher number of risk situations (3.03±2.37) 
than younger patients (1.76±2.05) (p=0.001). 
Most frequent risk situations were relative to the occurrence of the following 
DRPs: “no indication for drug” (17.4%), “inappropriate drug” (16.1%), 
“inappropriate timing of administration and/or dosing interval” (15.1%), “drug 
dose too low” (12.5%) and “duration of treatment too long” (9.9%). 
For the first type of DRP referred above, the drug subgroups most prevalent 
were B01AC - platelet aggregation inhibitors excluding heparin (26.4 %) and 
A02BC – proton pump inhibitors (22.6%). Also the problem “inappropriate timing 
of administration and/or dosing interval” was more prevalent for drugs from the 
subgroup A02BC – proton pump inhibitors (50.0%).  
The drug subgroup N05BA – anxiolytics: benzodiazepine derivate, showed a 
higher number of problems relative to “duration of treatment too long” (58.1%). 
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Risk situations relative to “drug selection” showed a statistically significant 
difference for patient´s age (p<0.001; r=0.355) and patient´s professional 
situation (p=0.026; r=0.199). Patients 65 years presented an average of 
2.28±1.9 risk situations compared to younger patients (<65 years) with an 
average of 1.14±1.2 risk situations. 
In older patients, a higher number of risk situations of “drug selection” was 
detected (p=0.029; r=0.201), patients 65 years presented an average of 
1.16±1.23 and 0.71±0.86 risk situations for patients under 65 years. 
An increased number of risk situations relative to “treatment duration” (p=0.027; 
r=0.203) was detected for female patients, with an average of 0.39±0.6 and 
0.2±0.54 for male patients. 
Risk situations relative to "medicine's use process" stands out a statistically 
significant increase on the "inappropriate timing of administration and / or 
dosing intervals" for patients followed for longer in clinical AEDMADA (p=0.010, 
r=0.236).  
A statistically significant difference was found for risk situations of "drug 
underused (intentional)" and patient´s qualifications (p=0.005; r=-0.258), with a 
lower number of this type of risk situation for patients having the 1st cycle (mean 
0.47±0.66) compared to patients with 12th grade (mean 0.83±0.29) (p=0.048). 
The number of risk situations achieved no statistically significant difference for 
the humanistic outcomes from the medication review (Table 91). 
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Table 91: Risk situations for NCOs and humanistic outcomes correlation. 
 Humanistic Outcomes r 
Medication Adherence (MAT scale) 0.105 0.290 
Medication Adherence (Haynes-Sackett test) 0.040 0.668 
Medication Knowledge 0.055 0.555 
Lack of knowledge (Hypertension) 0.045 0.668 
Lack of knowledge (Diabetes) 0.110 0.258 
Lack of knowledge (Dyslipidaemia) 0.170 0.102 
Disease Knowledge (Total) 0.090 0.335 
Health Literacy 0.076 0.413 
Help with your medications 0.033 0.721 
Self-perceived health status 0.090 0.334 
Legend: MAT – Measure Treatment Adherence. 
 
Patients taking a higher number of medicines, those who had a greater number 
of hospitalizations in the previous year, and consulting a large number of 
Physicians achieved an increase number of risk situations for negative clinical 
outcomes (Table 92).  
 
Table 92: Risk situations for NCOs and economic outcomes correlation. 
 Economic Outcomes r p value 
Number of total of medicines 0.645 <0.001 
Number of hospitalizations  in the last year 0.255 0.005 
Number total of Physicians 0.193 0.037 
Medication reimbursement 0.107 0.249 
 
The number of risk situations was higher for polymedicated patients (5 
medicines) (p<0.001), presenting an average of 3.1±2.35 and patients using a 
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lower number of medicines presented an average of 0.87±1.15 risk situations. 
Also patients taking an increased number of daily units (p<0.001) and daily 
doses (p<0.001) presented a higher number of risk situations. 
Furthermore, an increased number of oral antidiabetic drugs (p=0.037), 
antihypertensive drugs (p=0.003), antidyslipidemic drugs (p=0.025) and number 
of antithrombotic drugs (p=0.001) were used by the patients that presented a 
higher number of risk situations. However, no statistically significant difference 
was found for the number of insulins (p>0.05). 
Patients with a higher number of hospitalizations (p=0.006), with more 
Physicians consulted (p=0.037), increased number of health problems 
(p<0.001), as well as uncontrolled glycemic profile (p=0.002) and increased 
HbA1c values (p=0.004) showed an increased statistically significant number of 
risk situations for NCOs. 
 
4.2.4.4 Potential Interventions 
 
A total of 507 potential interventions were identified, an average of 4.3±1.74 per 
patient (median=4.0), with 25th and 75th percentile of 3.0 and 5.0 respectively, 
with a maximum of 12 interventions per patient. 
Four (28.8%) or three (19.5%) potential interventions were more often identified 
per patient. In about two thirds of patients three, four or five potential 
interventions (66.1%) were the most common numbers of potential 
interventions, and only one patient had any potential intervention identified. 
The potentials interventions with highest prevalence were “other intervention” 
(52.6%) and “at prescriber level” intervention (27.9%), with a median of two (2) 
and one (1) interventions per patient, respectively (Figure 17).  
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Figure 17: Characterization of potential interventions.  
 
A median of 1 intervention per health problem/situation was identified. The 
majority of potential interventions was identified for situations presenting 
negative clinical outcomes (76.3%). Approximately 44% of the interventions 
were marked for NCOs of “disease control” (p<0.001), 26.8% of “untreated 
situations” (p<0.001) and 5.5% of “safety” (p=0.004). The remaining identified 
interventions (23.7%) were identified for health problems that did not have 
negative clinical outcomes at the time of completion of the medication review. 
The number of potential interventions increased with the number of diagnosed 
health problems (p=0.007; r=0.248). Patients using 5 or more medicines 
showed a higher number of potential interventions at drug level (p=0.037; 
r=0.226), with an average of 0.54±0.8 interventions and 0.26±0.63 for patients 
using less than 5 medicines. 
A statistically significant difference was observed for the number of potential 
interventions and the number of marked drug-related problems (DRPs) 
(p<0.001), presenting an increased number of DRPs relative to “drug selection” 
(p=0.041), “dose selection” (p=0.032), “treatment duration” (p=0.001) and 
“medicine´s use process” (p=0.017). 
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Health problems/clinical situations with more identified potential interventions 
were dyslipidaemias (27.0%), obesity and other hyperalimentation (18.7%), 
hypertension (17.4%) and type 2 diabetes mellitus (15.0%) (Table 93). 
No significant differences were achieved for the number of potential 
interventions relative to socio-demographic variables (gender, age, marital 
status, household, qualifications, professional situation and follow-up period in 
AEDMADA clinic) (p>0.05). 
 
Table 93: Characterization of potential interventions and health problems/clinical 
situations. 
  
Health Problems/ Clinical situations 
E78 E65-E68 I10 E11 F41 
K90-
K93 
Ty
pe
 
o
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n
te
rv
en
tio
n
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r 
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l i
n
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e
n
tio
n
s 
(%
)] 
At prescriber 
level 30(21.9) 1(1.1) 53(60.2) 23(30.3) 14(82.4) 4(26.7) 
At patient / 
carer level 24(17.5) 0(0.0) 8(9.1) 20(26.3) 2(11.8) 4(26.7) 
At drug level 6(4.4) 1(1.1) 9(10.2) 16(21.1) 1(5.9) 4(26.7) 
Other 
intervention 77(56.2) 93(97.9) 18(20.5) 17(22.4) 0(0.0) 3(20.0) 
Total (N) 137(100) 95(100) 88(100) 76(100) 17(100) 15(100) 
Total (%) 27.0 18.7 17.4 15.0 3.4 3.0 
Legend: E11 – Type 2 diabetes mellitus; E65-E68 – Obesity and other hyperalimentation;  
E78 – Disorders of lipoprotein metabolism and other lipidaemias; F41 - Anxiety disorders; 
I10 – Hypertension; K90-K93 - Other diseases of digestive system. 
 
The number of potential interventions increased with the number of medicines 
used by patients (p=0.022; r=0.210) and the number of daily units (p=0.032; 
r=0.197), as well as with their HbA1c value (p=0.023; r=0.213). 
Patients with controlled glycemic profile presented a lower number of potential 
of identified interventions (mean=3.88±2.04; median=4) compared to patients 
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with uncontrolled glycemic profile (mean=4.47±1.48; median=4) (p=0.038; 
r=0.201).  
Also for patients who had a normal BMI (mean=3.36±1.56; median=3.5) a lower 
number of potential interventions (p=0.048; r=0.183) were identified. 
Patients with a higher number of identified potential interventions at the 
prescriber level showed an increased number of drug-related problems of the 
types “duration of treatment too long” (p=0.001; r=0.304), “inappropriate drug” 
(p=0.015; r=0.223) and “drug dose too high” (p=0.040; r=0.190). 
 
4.2.5 Predictive factors for clinical outcomes 
In order to analyse the association between the variables in this study, a list of 
variables was used as independent variables to construct multiple linear 
regression models for clinical outcomes (Table 94). 
 
Table 94: List of independent variables used in multiple linear regression. 
Patient´s age 
Older patients (65 
years) 
Polypharmacy 
Professional situation 
Dyslipidaemia diagnosis 
Previous CV event 
Glycemic profile control 
Blood pressure control 
 
HT diagnosis and using 4 
drugs  
Using 3 medicines regularly  
Medication knowledge 
Medication reimbursement 
Nr of antidiabetic drugs 
Nr of antidyslipidemic drugs 
Nr of antihypertensive drugs 
Nr of antiplatelet drugs 
Nr of daily doses 
Nr of daily units 
Nr of hospitalizations in 
the last 12 months 
Nr of insulins 
Nr of medicines 
Nr of oral antidiabetic 
drugs 
Nr of Physicians  
High risk medication* 
Legend:*Nonsteroidal anti-inflammatory drugs, antiplatelet drugs or diuretics; CV – 
Cardiovascular; HT – Hypertension; Nr – Number. 
 
For the independent variables that do not have a normal distribution its 
logarithmic (log10) equivalent was used, in order to achieve a variable with 
normal distribution. 
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Establishing the number of negative clinical outcomes as the dependent 
variable, the number of Physicians consulted by patients, the glycemic profile 
control and blood pressure control were included as independent variables. The 
number of daily units and number of daily doses were excluded from the list of 
independent variables to be considered, due to their interrelation and their 
association with the number of Physicians. In addition, the number of insulins 
and previous cardiovascular events were excluded from the list of independent 
variables to be considered, due to their interrelation and association with the 
glycemic profile control. 
Table 95 shows the results of the multiple regression analysis for the model 
created considering NCOs as dependent variable. 
 
Table 95: Predictive model for negative clinical outcomes. 
Regression 
model b 
Standard 
error 
 p r2 
Negative clinical outcomes as the dependent variable, F=18.6 p<0.001 
Constant -0.307 0.48  0.525 
0.351 
Number of 
Physicians 0.24 0.09 0.21 0.010 
Blood pressure 
control 0.70 0.20 0.28 0.001 
Glycemic 
profile control 1.03 0.18 0.45 <0.001 
 
This model shows that number of Physicians consulted by patients, blood 
pressure control, and glycemic profile control predicted some of the variation in 
negative clinical outcomes (NCOs). According to the r2 values, these factors 
predicted 35.1% of the variation in the negative clinical outcomes. 
The glycemic profile control variable had a greater effect on the dependent 
variable (NCOs), although the variable blood pressure control also presented a 
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considerable weight, whereas the number of Physicians showed a significant 
but lower effect. 
All independent variables established presented a statistically significant effect 
(p<0.05) on the dependent variable in the purposed model. 
On the overall, this model shows that most of the variation in negative clinical 
outcomes can be due to other variables not assessed or to the interaction 
between variables. 
Considering drug-related problems (DRPs) the dependent variable, older 
patients (65 years), the number of antidiabetic drugs and the number of 
antihypertensive drugs were used as independent variables to construct 
multiple linear regression models for drug-related problems (DRPs). The 
number of daily units, number of daily doses, number of antiplatelet drugs, 
number of Physicians consulted by the patient and the rate medicines 
reimbursement rate were excluded from the list of independent variables to be 
considered, due to their interrelation and their association with the number of 
medicines. The number of oral antidiabetic drugs was also excluded from the 
list of independent variables to be considered due to their interrelation and 
association with the number of antidiabetic drugs. Table 96 shows the results of 
the multiple regression analysis for the model created considering DRPs as 
dependent variable. 
 
Table 96: Predictive model for drug-related problems. 
Regression model b Standard 
error 
 p r2 
Drug-related problems as the dependent variable, F=25.98 p<0.001 
Constant 0.865 0.538  0.111 
0.479 
Number of medicines 0.713 0.084 0.75 <0.001 
Age  65 years 1.33 0.411 0.23 0.002 
Antidiabetic drugs -0.527 0.194 -0.21 0.008 
Antihypertensive drugs -0.546 0.259 -1.69 0.037 
 176 
 
This model shows that the number of medicines, age 65 years, number of 
antidiabetic´s drugs and number of antihypertensive drugs significantly 
predicted some of the variation in drug-related problems. According to the r2 
values, these factors predicted 47.9% of the variation in the drug-related 
problems results. 
The number of antihypertensive medicines and number of medicines used by 
patients had a greater effect on the dependent variable (DRPs), although the 
variable number of antidiabetic´s drugs and older patients also had a 
considerable weight. 
All independent variables established presented a statistically significant effect 
(p <0.05) on the dependent variable in the purposed model. 
On the overall, this model show that almost half of the variation in the results of 
the drug-related problems could be due to other variables not assessed. 
 
4.2.6 Analysis of eligibility criteria to conduct medication review in 
Australia, Canada and England  
Applying to the sample of patients included in the study ReMeD the inclusion 
criteria for conducting current medication review in Australia, held by the 
Pharmaceutical Society of Australia, a statistically significant difference was 
achieved for negative clinical outcomes with patients taking more than 12 doses 
of medicine per day and for those attending a number of different Physicians 
(Table 97).  
Although results from medication review performed to ReMeD study patients 
didn´t achieved a statistically significant difference in the number of negative 
clinical outcomes (NCOs) for patients using 5 medicines, this difference was 
statistically significant in the number of identified drug-related problems and the 
number of risk situations for NCOs.  
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Drug related problems presented a statistically significant difference for patients 
taking five or more regular medicines, taking more than 12 doses of medicine 
per day, experiencing symptoms suggestive of an adverse medicine reaction 
and attending a number of different doctors, i.e. for all criteria except for 
“experiencing significant changes to their medicine regiment (in the last three 
months)”, “recently discharged from hospital” and “having difficulty managing 
their own medicines because of low level of health literacy and language 
skills or impaired sight” (p>0.05). 
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Table 97: Comparison of eligibility criteria for medication review programs in Australia.  
A
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Pro 
gram Criteria Clinical Outcomes 
p 
value 
H
o
m
e
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w
 
Currently taking five or more 
regular medicines 
< 5 medicines  5 medicines  
 
0.307 
<0.001 
<0.001 
 
NCOs Mean 2.9± 1.15 (median 3) 
DRPs Mean 2.61±1.94 (median 2) 
Risk Mean: 0.87±1.15 (median 0) 
NCOs Mean 3.1±1.13 (median 3) 
DRPs Mean 5.41±2.81 (median 5) 
Risk Mean: 3.06±2.35 (median 3) 
Taking more than 12 doses of 
medicine per day 
< 12 doses / day  12 doses / day  
0.008 
<0.001 
<0.001 
 
NCOs Mean 2.93±1.12 (median 3) 
DRPs Mean 4.09±2.49 (median 4) 
Risk Mean: 2.01±2.01 (median 2) 
NCOs Mean 3.62±2.93 (median 3) 
DRPs Mean 7.38±3.07 (median 7) 
Risk Mean: 4.67±2.39 (median 4) 
Experiencing significant 
changes to their medicine 
regimen (in the last three 
months) #1 
Yes No 
0.599 
0.828 
0.986 
NCOs Mean 3.0±1.0 (median 3) 
DRPs Mean 3.67±2.5 (median 4) 
Risk Mean: 2.0±2.0 (median 2) 
NCOs Mean 3.05±1.14 (median 3) 
DRPs Mean 4.7±2.9 (median 4) 
Risk Mean: 2.5±2.33 (median 2) 
Recently discharged from 
hospital#2 
Yes No 
 
0.686 
0.140 
0.007 
NCOs  Mean: 3.0±1.14 (median 3) 
DRPs Mean: 5.89±3.6 (median 5) 
Risk Mean:5.33±1.64 (median 5) 
NCOs Mean: 3.06±1.14 (median 3) 
DRPs Mean:4.46±2.69 (median 5) 
Risk Mean: 2.19±2.07 (median 2) 
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Table 97 (continued) 
A
u
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Pro 
gram Criteria Clinical Outcomes 
p 
value 
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Taking medicine with a narrow 
therapeutic index or that 
requires therapeutic 
monitoring#3 
NCOs Mean 3.17 ± 0.75 (median 3) 
DRPs Mean 6.36±2.88 (median 6) 
Risk Mean 4.0±2.68 (median 4.5) 
NCOs Mean 3.0 ± 1.97 (median 3) 
DRPs Mean 6.0±1.75 (median 6) 
Risk Mean 4.0±2.68 (median 4) 
0.780 
0.783 
1.000 
Experiencing symptoms 
suggestive of an adverse 
medicine reaction 
Yes No 
 
0.891 
0.021 
0.271 
NCOs Mean 3.26±1.23 (median 3) 
DRPs  Mean 5.52±3.08 (median 5) 
Risk Mean: 2.5±2.38 (median 2) 
NCOs Mean 2.93±1.06 (median 3) 
DRPs Mean 4.21±2.67 (median 4) 
Risk Mean: 2.46±2.29 (median 2) 
Having difficulty managing 
their own medicines because 
of low level literacy and 
language skills or impaired 
sight #4 
Yes No  
 
0.745 
0.212 
0.330 
NCOs Mean 3.08±1.04 (median 3) 
DRPs Mean 4.98±2.76 (median 5) 
Risk Mean: 2.65±2.22 (median 2) 
NCOs Mean 3.03±1.2 (median 3) 
DRPs Mean 4.45±2.9 (median 4) 
Risk Mean: 2.35±2.38 (median 2) 
Attending a number of 
different doctors, both General 
Practitioners and specialists 
#5 
Yes No 
 
0.018 
0.020 
0.126 
NCOs Mean 3.34±1.24 (median 3) 
DRPs Mean 5.29±3.01 (median 5) 
Risk Mean: 2.81±2.42 (median 3) 
NCOs Mean 2.76±0.93 (median 3) 
DRPs Mean 4.07±2.63 (median 4) 
Risk Mean: 2.15±3.16 (median 2) 
Legend: DRPs – Drug-related problems; NCOs – Negative clinical outcomes; Risk – Risk situation for negative clinical outcomes.  
#1 – Patients using medicines for a period less than 6 months were considered; #2Patients that have been hospitalized in the last 12 months were 
considered; #3 – According to INFARMED: cyclosporine, Levothyroxine sodium, Tacrolimus), in this analysis only levothyroxine was used by patient´s 
study; #4 – Analysis was performed considering patient´s health literacy; #5 – Patients attending more than 2 different doctors were considered. 
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In the case of "experiencing significant changes in medicine regimen" it was 
considered in the ReMeD study the patients that were using medicines for a 
period less than 6 months, while for patients "recently discharged" were only 
considered patients who had undergone hospitalization in the last 12 months. 
The number of ReMeD study patients that used "medicines with narrow 
therapeutic index" was greatly reduced. 
A statistically significant difference was achieved in the group of patients who 
fulfilled at least one of the eligibility criteria for holding medication review 
concerning NCOs (p = 0.024), number of DRPs (p = 0.001) and number of risk 
for NCOs (p = 0.001). 
Considering the current eligibility criteria for medication review in Canada, a 
statistically significant difference was observed for the number of NCOs relative 
to the inclusion criteria for the program MedsCheck and MedsCheck living with 
diabetes, with an increased number of NCOs and DRPs for patients using 3 or 
more medications for a chronic condition (Table 98). 
Also a significant higher number of NCOs was identified for patients diagnosed 
with type 1 or type 2 diabetes and taking one or more medication for treating 
diabetes. 
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Table 98: Analysis of eligibility criteria for medication review programs in Canada. 
C
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a
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Program Criteria Clinical Outcomes p 
value 
M
e
d
s
C
h
e
c
k
 
Minimum of 3 
prescription 
medications for a 
chronic condition #1 
< 3 medications  3 medications 
 
 
0.018 
0.020 
0.128 
NCOs Mean: 2.9±1.06 (median 2) 
DRPs Mean: 3.23±2.71 (median 2) 
Risk Mean: 1.32±1.91 (median 0) 
NCOs Mean: 3.08±1.15 (median 3) 
DRPs Mean: 5.01±2.83 (median 5) 
Risk Mean: 2.75±2.32 (median 2) 
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D
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s
 Individuals diagnosed 
with type 1 or type 2 
diabetes and taking 1 
or more medications 
for treating diabetes. 
Yes No 
 
 
0.045 
0.454 
0.422 
NCOs Mean: 3.1±1.14 (median 3) 
DRPs Mean: 4.74±2.9 (median 5) 
Risk Mean: 2.54±2.33 (median 2) 
NCOs Mean: 2.46±0.88 (median 3) 
DRPs Mean: 4.15±2.82 (median 3) 
Risk Mean: 2.54±2.33 (median 2) 
Legend: DRPs – drug-related problems; NCOs – negative clinical outcomes; Risk – risk situation of negative clinical outcomes. 
#1 – Patients with 3 or more medicines, including antihypertensive, antidiabetics, antidyslipidemic and antiplatelets drugs, were considered. 
For the eligibility criteria applied to medication review service in England (Medicines Use Review), no statistically significant 
difference were reached with the number of NCOs and the established criteria. However, a statistically significant higher 
number of DRPs was achieved for “patients taking high risk medicine” and “patients at risk of or diagnosed with cardiovascular 
disease and regularly being prescribed at least four medicines” (Table 99). 
Furthermore, an increased number of risk situations for NCOs were identified for patients who met all the eligibility criteria, 
except for “patients who are prescribed two or more medicines for respiratory disease” (p>0.05).  
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Table 99: Analysis of eligibility criteria for medication review programs in England. 
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Prg Criteria Clinical Outcomes p 
value 
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 Patients taking “High risk 
medicine”: NSAIDs, 
anticoagulants (including low 
molecular weight heparin), 
antiplatelets or diuretics #1 
Yes No 
 
0.924 
0.002 
<0.001 
NCOs Mean: 3.1±1.24 (median 3) 
DRPs Mean: 5.4±2.76 (median 5) 
Risk Mean: 3.3±2.3 (median 3) 
NCOs Mean: 3.0±1.02 (median 3) 
DRPs Mean: 3.98±2.9 (median 3) 
Risk Mean: 1.78±2.1 (median 1) 
 Patients who are prescribed two 
or more medicines for 
respiratory disease 
(adrenoreceptor agonists, 
antimuscarinic bronchodilators, 
theophylline, compound 
bronchodilator preparations, 
corticosteroids, cromoglicate 
and related therapy, leukotriene 
receptor antagonists and 
phosphodiesterase type-44 
inhibitors) #2 
yes No 
 
 
0.747 
0.576 
0.376 
NCOs Mean: 2.67±1.5 (median 3) 
DRPs Mean: 5.05±1.7 (median 6) 
Risk Mean: 3.0±0.0 (median 3) 
NCOs Mean: 3.06±1.1 (median 3) 
DRPs Mean: 4.67±2.9 (median 4) 
Risk Mean: 2.47±2.34 (median 2) 
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Table 99 (Continued) 
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Prg Criteria Clinical Outcomes p 
value 
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 Patients recently been 
discharged from hospital who 
had changes made to their 
medicines while they were in 
hospital. #3 
Yes No 
 
0.686 
0.140 
0.007 
NCOs  Mean: 3.0±1.1 (median 3) 
DRPs Mean: 5.9±3.6 (median 5) 
Risk Mean:5.3±1.6 (median 5) 
NCOs Mean: 3.1±1.14 (median 3) 
DRPs Mean:4.46±2.7 (median 4) 
Risk Mean: 2.19±2.07 (median 2) 
 Patients at risk of or diagnosed 
with cardiovascular disease 
and regularly being prescribed 
at least four medicines 
Yes No 
 
0.182 
<0.001 
<0.001 
NCOs Mean: 3.12±1.4(median 3) 
DRPs Mean: 5.35±2.9(median 5) 
Risk Mean:3.0±2.42 (median 2) 
NCOs Mean: 2.9±1.09 (median 2) 
DRPs Mean: 3.03±2.1 (median 2) 
Risk Mean:1.2±1.37 (median 1) 
Legend: DM-med: number of medicines used to treat Diabetes (oral antidiabetic drugs and insulins); DRPs – drug-related problems; NCOs – negative 
clinical outcomes; NHS – National Health Service; Nr - number; NSAIDs – Non-steroidal anti-inflammatory drugs; Prg – Program; Risk – risk situation 
of negative clinical outcomes. 
#1 – According to patient´s drug profile the following ATC groups were considered for AINEs: M01AB, M01AC, M01AE, M01AH, M01AX; 
anticoagulants: B01AA, B01AC, B01AE, B03AA, B03AB, B03AD, B03BB; diuretics: C03BA, C03CA, C03DA, C03EA; 
#2 – According to patient´s drug profile the following ATC groups were considered: R03AC, R03AK, R03BB, R03DC; 
#3 - Patients that have been hospitalized in the last 12 months were considered. 
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Despite no statistically significant differences were identified for all the eligibility 
criteria considered relative to the number of NCOs, DRPs and risk situations for 
NCOs, for patients who fulfilled at least one of eligibility criteria for holding 
medication review a statistically significant difference in the number of NCO (p = 
0.049), number of DRPs (p = 0.001) and number of risk situations for NCOs (p 
= 0.001) was identified. 
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5 DISCUSSION  
5.1 Adaptation of an instrument to assess health literacy to the 
Portuguese language 
The main goal of the adaptation to Portuguese language of the “Short 
Assessment of Health Literacy - Spanish and English (SAHL-S&E)” was to 
obtain a tool that could be useful to identify patients with low health literacy, 
since it is a relevant factor that can affect subject´s health outcomes. (305–308) 
The internal consistency of the instrument (0.812) was considered as “good”, 
indicating that reliability of the test scores was similar among sample. 
(284,309,310) 
Moreover, a positive correlation was achieved for the score test and subject´s 
qualifications, as also found in the validation of the Short Assessment of Health 
Literacy - Spanish and English (SAHL-S&E), for Spanish-speaking and English-
speaking populations. These results could mean the test is suitable for use in 
the Portuguese speaking population with low qualifications. (273) 
In the analysed sample, a low health literacy level was identified in 37.9% of 
subjects. This was consistent with the expected outcome, taking into account 
the qualifications of the subjects included in the study, where about 32.7% of 
the subjects did not have the minimum level of education (9 years) defined as 
the minimum education in Portugal. (311) 
Low health literacy is often correlated to negative health outcomes, such as 
identified by Souza et al. (2014) in a Brazilian older population with type 2 
diabetes, where an association between low health literacy and patients 
showing an increased HbA1c values was found. (272)     
The SAHL-PT test uses the literary ability and readability for terms associated 
with health, and can be considered a good instrument for screening of low 
health literacy subjects. As a result, this test is a very useful resource to identify 
situations of low health literacy.    
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Since there are no instruments available, with the same purpose of this test, 
validated for the Portuguese population, it was not possible to determine any 
correlation with other measuring instruments available for health literacy. 
Moreover, in the questionnaire adaptation procedures, a second application of 
questionnaires (retest) was not performed, which is a limitation of the applied 
methodology. However, since the patients included in this project were recruited 
from community pharmacies, it was not practicable the return of all subjects for 
a new application of the questionnaire. 
 
5.2 ReMeD Study 
5.2.1  Sample characterization and clinical evaluation 
The AEDMADA clinic, which was where our study was performed, aims to 
support diabetic patients and their families on providing differentiated 
healthcare. Currently the clinic does not provide services to institutionalized 
patients, so there were no patients with this feature included in the study. Since 
only outpatients were included, and were mainly diabetic patients, the study 
sample should not be considered representative of the general Portuguese 
population.  
Nevertheless, even if it was not our main goal, the comparison of our sample to 
the Portuguese population was performed in order to compare patient´s 
characteristics and health outcomes. 
As expected, regarding the socio-demographic characteristics, while in the 
Portuguese population only about 19% are 65 years and older, most of our 
sample (56.8%) was above that age. Regarding gender, the results obtained 
were more similar to the general population, as in our study about 45.8% of the 
sample was female. Similar differences were found when comparing the 
Portuguese population and the Algarve resident population: 19.5% of the 
residents belong to the age group of 65 years and older, and 51.93% of the 
Algarve population was female and 48.07% male. (312)  
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According to the reported data from Census 2011, in the Algarve region, about 
57.5% of the population was professionally active, compared to the 23.8% in 
the ReMeD, as expected due to the increased age of the AEDMADA users. 
(312) Patient´s qualifications showed some differences in their levels of 
qualification comparing the ReMeD patients to the resident population of this 
region, with an increased number of subjects with 1st cycle of basic education 
(38.1% in the sample vs 26% in the Algarve region population) and a lower 
number of illiterate subjects (5% in the sample vs 11% in the Algarve region 
population). (313) 
Considering the specific characteristics of our study setting, and comparing the 
results of the Portuguese TEDDI CP study, which aimed to characterize type 2 
diabetic patients followed in primary care units in Portugal, regarding gender 
distribution and marital status (74.6% of TEDDI CP patients being married or 
cohabitating) they were relatively similar to those obtained in the ReMeD study. 
(283)  Also regarding qualification level, a similar distribution was achieved in 
the ReMeD patients, as would be expected since the ReMeD population is 
mostly diabetic.   
Also as expected, considering the type of patients followed in the AEDMADA 
clinic, we detected a very high prevalence of diabetic patients in the study 
sample (90.7%). In the Portuguese general population diabetes mellitus 
presents a prevalence of 13.1% (patients between 20 and 79 years old). (23) 
The prevalence of diabetic patients is not 100%, as would be expected, since 
the AEDMADA clinic also follows relatives of diabetic patients who do not have 
diabetes.  
Hypertension presented a prevalence of 81.4% in the study sample, and around 
42% for the general Portuguese population. (15,18) Similar to the observed in 
the ReMeD population, also in the TEDDI CP study, a similar prevalence for 
hypertension (80.3%) was found. (283) 
Accordingly, an increased prevalence of lipid disorders (77.1%) was achieved in 
the ReMeD study, compared to the results obtained from the general 
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Portuguese population identified in the VALSIM study (47%), that enrolled 
patients from primary health care. (282)  
As expected, considering ReMeD patient´s profile, an increased rate of chronic 
diseases or prolonged health problems was found in the ReMeD patients, as in 
the Portuguese population aged between 65 to 74 years (65%; 66% in women 
and 62% men). (9) 
The high number of morbidities, mainly chronic diseases, identified in the study 
population along with the advanced age allows to signal a population that may 
require intervention and may potentially benefit from a medication review 
service. 
 
Biomarkers and other Risk Factors for Cardiovascular Diseases 
Blood Pressure 
Considering the results from the last Portuguese prevalence study on 
hypertension, held in 2011/2012, a similar rate to those found in the ReMeD 
study was achieved for BP control (42.5%). (18)   Probably the patient centered 
services provided by the clinic could contribute to this degree of control, as well 
as an increased use of antihypertensive drugs and wider information provided 
to the Portuguese population.   
Regarding exclusively the Portuguese diabetic population, a prevalence of 
37.7% of patients presents a blood pressure value <130/80 mmHg, very similar 
to the one obtained in the ReMeD study for patients with a controlled blood 
pressure (40.2%). (23) However, in our study, the reference values considered 
were 140/85 mmHg for diabetic patients and 130/85 mmHg for those with 
nephropathy. (24) 
Accordingly, although the rate of control of hypertension has been increasing in 
the last decade in Portugal, this pathology still presents a high prevalence, 
being one of the main factors that contribute to the high rate of morbidity and 
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mortality due to cardiovascular events. (10,18) An intervention strategy, with the 
participation of the Pharmacist, aiming the control of blood pressure values 
would be an asset for this population.  
Glycemic Profile 
Diabetic patients included in the study sample presented a longer mean of 
diagnosis duration (13.2±9.3 years), compared to the median of 7 years 
observed in the Portuguese TEDDI-CP study, probably due to the specificity of 
the service provided to diabetic patients. (283) 
When comparing diabetic patients enrolled in the ReMeD study to those 
referred in the Portuguese report from 2014, the former showed a higher mean 
value of HbA1c (7.7%). Also, a higher prevalence of patients with a HbA1c  
8% was found in the ReMeD patients (39.3% ReMeD vs. 20% Portuguese 
report). (23) These results  suggest that probably most clinic diabetic patient´s 
are those who have more difficulty in achieving control of the glycemic profile, 
therefore needing more intervention to improve the degree of control. However, 
it is important to note that this national report only contains the values of HbA1c 
of diabetic patients who had records for this parameter and according to the 
information contained in the report, only 81.9% of diabetic had consultation 
records and only 85.3% of these patients had registration of this biochemical 
parameter. (23)  
Lipid Profile 
Patient´s lipid profile was analysed individually, considering patient´s global 
cardiovascular risk. In the ReMeD study sample a very low degree of control of 
the lipid profile was found (14.4%), while in the Portuguese VALSIM study the 
prevalence of controlled levels of LDL-C was 61.6%. Nevertheless, 
hypercholesterolemia (increased thotal cholesterol) was observed in 47% of the 
Portuguese patients included in VALSIM study, and in only 28% of ReMeD 
patients. (282) Although the national study VALSIM used as a reference 
parameter the value of total cholesterol and not the value of c-LDL as used in 
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the ReMeD study, the results from our study are indicative of an imminent need 
for intervention to improve patient´s lipid profile. 
Similarly, the degree of control of lipid profile found both in the national report 
for diabetes (2014) and in the Portuguese TEDDI-CP study, was higher than 
those found in the diabetic patients enrolled in the ReMeD study. (23,283)  
This lower degree in the lipid profile control might be attributed to the high 
number of diabetic patients included in the ReMeD study (90.7%) that present 
other cardiovascular risk factors, classifying them with a very high global 
cardiovascular risk (89.8%), which according to current guidelines advise a 
LDL-C below than 70 mg/dL to reduce the risk of cardiovascular events. (295) 
In order to achieve improved results regarding the lipid profile, intervention is 
absolutely necessary and could be initiated through a medication review, in 
order to identify the issues associated with medication used by each patient. 
 
Other Risk Factors for Cardiovascular Diseases 
Besides the risk factors mentioned above, other were analysed. 
Patients enrolled in the ReMeD study were mainly non-smokers (72.9%). 
Interestingly, this was also found in other Portuguese studies such as VALSIM 
study (hypertension prevalence in primary care) and TEDDI-CP study (type 2 
diabetes patients in primary care). (283,314)  
Despite the low prevalence of smokers in our sample, this is still undoubtedly a 
group where a pharmaceutical intervention in the field of smoking cessation 
could be performed, in order to contribute to the reduction of the overall 
cardiovascular risk of patients. 
Regarding another modifiable risk factor, in the ReMeD study, only about half of 
patients reported to practice regular physical exercise. A Portuguese report 
about physical activity published in 2011 described a positive correlation in the 
amount of minutes per day of sedentary activity with individual´s age, where 
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36% of the subjects reported not to practice any kind of physical exercise. (33) 
The elderly Portuguese population has already been recognized as one of the 
most sedentary (76%) among several European countries. (315)    
The results presented regarding the practice of physical exercise by the ReMeD 
patients also suggest a need for intervention in the implementation of this habit 
on a regular basis, and adapted to the patients' age and physical condition. 
Obesity has been widely identified as a major risk factor for cardiovascular 
diseases. (316) 
About 35% of our sample aged 18-64 years was overweight (BMI 20-24.9 
Kg/m2), while 25.5% were obese (BMI  25 Kg/m2). A similar prevalence of 
39.4% for overweight and 14.2% for obesity was observed in a survey (2003-
2005) in the Portuguese population between 18-64 years. (317)   
Also overweight (49.2%) and obesity (39.6%) has been pointed in the 
Portuguese  report about diabetes (2014), but higher than those observed in the 
ReMeD patients. (23)  
Towards these results, the decrease in patients' BMI is also a marked need, 
requiring an adequate intervention to patient´s characteristics and physical 
condition.  
Surprisingly, most ReMeD patients reported the consumption of fruit and 
vegetables on a daily basis, and to use olive oil to prepare their meals. 
Considering that the majority of patients included in this study were 65 years or 
older, it was expected that many reported a daily and regular consumption of 
soup and fruit at least in one of the meals, since many patients come from rural 
areas and have their own fruit and vegetables production. Accordingly, the 
consumption of vegetables and fruits has been already pointed out as high in 
the populations of the west Mediterranean, compared to other European areas.  
(318) 
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In addition, the consumption of olive oil is also a very ingrained habit in the 
Portuguese population, as it is purchased from national production essentially. 
(318,319) 
The adoption of Mediterranean diet, which includes the consumption of extra 
virgin olive oil has been associated to an increased effectiveness in the 
reduction of cardiovascular diseases (primary and secondary prevention). (320) 
Due to their potential relevance in clinical results, the analysis of specific dietary 
habits adopted by the patients would be an interesting area for future research, 
in a potential partnership with other health professionals in the area of nutrition.. 
The causes of hospitalizations suffered by diabetic patients were similar to 
those found in the national report about diabetes (2014), being 28.8% of 
hospitalizations caused by stroke and 32.7% by myocardial infarction. (23) 
Also the prevalence of cardiovascular events found in the ReMeD sample was 
similar to those described in a Portuguese exploratory descriptive cross-
sectional study, using data from the fourth national health survey (2005-2006), 
which identified a prevalence of 2.31% for stroke, 2.13% for ischemic heart 
disease and 6.23% for cardiovascular disease. (321)  
The family history of premature cardiovascular events was shown to be 
associated to a higher risk of early cardiovascular disease. (26) This risk factor 
was verified in 16.4% of the ReMeD patients, although the association was not 
verified in our study sample. The existence of this unmodifiable risk factor may 
be a useful point to identify target patients for intervention, in order to prevent 
the development of cardiovascular disease or minimize its negative impact on 
patient health. 
 
Cardiovascular Risk Assessment 
Regarding the cardiovascular risk assessment, about 90.7% of patients had a 
diagnosis of diabetes in our study, and of these 83.2% were hypertensive and 
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73.8% presented dyslipidaemia, which makes the majority of patients having a 
very high cardiovascular risk. (295) 
Being circulatory diseases the main cause of death in Portugal (10), intervention 
aimed to reduce cardiovascular risk, with intervention directed to the 
achievement of control on the various risk factors should be a priority in the 
ReMeD study population. 
 
Microvascular complications (Diabetic patients) 
Almost a quarter of diabetic patients included in the ReMeD study already had 
detectable microvascular complications (23.4%; n=25), 76% of which had a 
previous diagnosis of diabetic retinopathy. The national report about diabetes 
(2014) did not quantify the prevalence of these complications in diabetic 
patients, and only included data on the number of visits performed under the 
“diabetic retinopathy screening program” and the prevalence of diabetes in 
patients with chronic renal failure. (23)  
The monitoring of the degree of control of the glycemic profile of diabetic 
patients is of extreme importance for the non-occurrence of these microvascular 
complications. Thus, the identification of situations of non-control and adequate 
intervention is a contribution to minimize the appearance of these possible 
complications. 
 
5.2.2 Pharmacotherapeutic Profile  
Each patient included in the ReMeD study was using an average of 
approximately 7 medicines, 8 units and 8 doses per day, with polypharmacy (5 
or more medicines) being observed in 73.8% of the patients.  
Polypharmacy can be associated to an increase in negative clinical outcomes in 
patients, such as can cognitive impairment, decline of functional status, 
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mortality and morbidity associated to falls, alteration of the patient's nutritional 
status, among others. (322) 
Particularly in patients 65 years and older, who are expected to spend more 
than half of their life expectancy with polypharmacy (323), managing their 
medication should be considered as an important contribution. 
Similarly, a Portuguese cross-sectional study conducted in nursing homes 
including institutionalized patients aged 65 years or above, and taking at least 
one daily medication, identified a rate of polymedication in about 76.6% of 
patients, with more than half (51.8%) of patients taking 6-10 medicines per day. 
(146) This suggests that the ReMeD sample has characteristics of a 
polymedicated population. 
Most drugs used by ReMeD patients were from group C-Cardiovascular 
system, A-Alimentary tract and metabolism, and N-Nervous system, with 
antihypertensive drugs being used by 83.9% of the patients. Other studies have 
shown similar results, either in populations of elderly patients followed in units of 
primary health care in Portugal, or in patients who participated in medication 
review programs. (197,324)  
In our study, hypertense patients used mainly one antihypertensive drug 
(63.6%), whereas 24.2% used two antihypertensive drugs, which were mainly 
agents acting on the renin-angiotensin system. These patients are at risk of 
suffering drugs side effects and potential drug-drug interactions (325), being the 
methodology used in the ReMeD study useful for the identification and 
monitoring of these events. 
The high prevalence of hypertense patients treated with associations of drugs 
acting on the renin-angiotensin system (48.45%; n=47) can be justified by the 
high prevalence of patients with very high cardiovascular risk (89.8%), showing 
they are being treated according to the guidelines applicable in Portugal for the 
treatment of hypertension. (287,326) 
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As expected, in our study, diabetic patients were treated with oral antidiabetic 
(78.0), and most of those were using either one (51.1%) or 2 OADs (35.9%). 
Most were using an association of oral blood glucose lowering drugs (31.6%) 
and biguanides (24.5%), while 39.0% were using insulin (mainly only one type, 
41.3%). Every drug treatment has possible side effects, which in some cases 
can be avoided if identified promptly. 
In an observational multicenter study, aimed to explore the routine of clinical 
practice in Spain and Portugal, diabetic patients, particularly those receiving 
OADs, identified the unwanted loss of body weight and hypoglycaemia as the 
most valued parameters regarding their medication, which patients were willing 
to pay to avoid. (327) The identification, prevention and monitoring of side 
effects of OADs such as hypoglycaemia may be an outcome of the medication 
review service, which have already been recognized as a relevant issue by 
diabetic patients. 
Regarding antidyslipidemic agents, about three quarters of the ReMeD patients 
were prescribed with this type of drugs (76.3%), a higher prevalence compared 
to the 47% of patients who used statins in the Portuguese VALSIM study 
conducted in primary health care users in Portugal (2013), but similar to those 
in the TEDDI-CP study, in which about 72% of the enrolled patients used lipid-
lowering drugs. (282,283) This shows that a medication review service would 
probably benefit a hight proportion of our study sample and the aged population 
in general, which usually presents an increased use of this group of drugs. 
(197) 
Almost one third (29.7%) of the ReMeD study sample had a prescribed 
anticoagulant/antiplatelet drug, similar to Eiras et al. (2016) findings, wherein  
30% of older patients ( 65 years) from a Portuguese primary care center were 
using antithrombotic drugs. (197)   
The patient´s medication analysis performed during ReMeD study allowed to 
identify situations such as polymedication that can contribute to health negative 
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outcomes. Likewise, this analysis enabled the identification of drugs that 
present an increased risk for the occurrence of negative outcomes. 
 
5.2.3 Analysis of Medication Review outcomes 
The methodology adopted to perform medication review (MR) and the 
nomenclature used is not universally systematized, being different in different 
countries and even between different research groups in this field. Although 
some MR programs include follow-up interventions as an activity, most of them 
are focused in the clinical outcomes. (94,142,151,159,324) 
Since the applied methodology was developed specifically for this pilot project 
in the context of clinical practice, the results will be discussed individually for 
each type of outcomes: humanistic, economic and clinical. 
 
5.2.3.1 Humanistic outcomes 
 
Medication Adherence 
ReMeD patients presented a high medication adherence rate and were using a 
higher number of medicines, similar to what was described in a review about 
therapies adherence in patients with a diagnosis of type 2 diabetes. (328)  
In this study, a high adherence rate was observed in patients using medication 
for chronic diseases such as oral antidiabetic drugs and antihypertensive drugs. 
Others have found a similar pattern, when evaluating a group of older patients 
(65 years), using 3 (three) or more concomitant medicines, in a retrospective 
cohort study held in type 2 diabetes patients having at least one prescribed oral 
antidiabetic agent, in which the medication adherence to antidiabetic drugs was 
evaluated using the proportion of days covered (80%) over 12 months. (329) 
This high rate of medication adherence can be considered as a positive point to 
decrease the number of MACE (major adverse cardiovascular events). Patients 
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seem to be more sensitive about taking their chronic medication, however, 
should not devalue the importance of medication adherence to the remaining 
treatments.  
 Since several methodologies can be used to assess medication adherence, the 
use of two or more tools simultaneously has been pointed as the most accurate 
way to perform this assessment. (226) 
For that reason, in the ReMeD study, the assessment of medication adherence 
included MAT scale, that allowed to identify, despite the high rate found for the  
overall adherence to medication (~74%), patients' attitudes regarding 
medication use such as those taken when they felt worse, better, and when 
they had no medication available. Interestingly, Campbell et al. found 30% of 
clinic outpatient aged 65 years and older showing low adherence rate and 
28.5% that stopped taking medication when feeling worse, a similar value 
obtained in the ReMeD study considering patients that reported to act like this 
“often”, “sometimes” and “rarely” representing a total prevalence of 27.1%. 
(330)  
In addition, the use of the tool “Haynes Sackett test” was also used, allowing to 
identify the medicines in which the medication adherence rate was lower, thus 
allowing to point out which drugs / therapeutic areas in which patients are more 
or less compliant with the prescription. 
 
Medication adherence rate has not been consistently included as an outcome of 
the medication review, as verified by Renaudin et al. (2016). (331) 
Nevertheless, this parameter seems to be an outcome to consider when 
conducting a medication review, since non-adherence can be associated to a 
higher number of negative outcomes such as hospitalization, emergency 
department visit or even death. (332) Moreover, an improvement in medication 
adherence can be achieved after the completion of a medication review. 
(331,333) 
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 All the facts formerly presented indicate that it is definitively an advantage to 
include medication adherence assessment in the outcomes of the medication 
review, as done in the ReMeD study.  
 
 
Patient Medication Knowledge 
About a quarter of the ReMeD patients (25.4%) showed a low medication 
knowledge (MK).  
Regarding the Portuguese population, a cross-sectional study conducted in 
community pharmacies in the Lisbon Metropolitan area (Portugal), using the 
transcultural adaptation to European Portuguese of the questionnaire PKM-PT-
PT, showed that 65.9% of patients didn´t know the medication they were using. 
Compared to the ReMeD patients, the latter had higher rates of MK, such as 
“therapeutic goal” (70.9%) and “process of use” (36.7%), while “safety” (1.9%) 
and “conservation” (5.8%) were those with the lowest rate. (334) 
Also similar results to those obtained in the ReMeD study were achieved by 
Romero-Sanchez et al. (2016) in subjects requesting medicines at community 
Spanish pharmacies, in which they identified an inadequate medication 
knowledge in 71.9% of the patients, with 65.7% having no medication 
knowledge and 6.2% insufficient medication knowledge. (233)  
Patients knowledge about medication has been associated to poor blood 
glucose control in type 2 diabetes patients, with patients over 65 years and 
increased HbA1c level being associated to lower rate of MK. (237) 
When analysing the ReMeD study results considering MK, a deficiency in the 
identification of drugs (name and drug strength) was clearly identified. It is then 
important, as a result of the medication review, to draw up a list of medicines 
and give it to each patient so they can carry it with them whenever they access 
health services or whenever they need to show a health professional the 
medicines they are taking. 
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Moreover, the identification of patients with low MK score may serve to signal 
patients to be included in therapeutic education programs. A significant 
improvement in MK can be reached after a medication review and being 
provided with a counselling session by Pharmacists, as shown by Goh et al. 
(2014), in patients from policlinics in Singapore using 5 or more chronic 
medicines and referred to MR by the prescribers due to adherence or 
knowledge issues. (333)  
Farsaei et al. (2011) also showed that an improvement was achieved in 
diabetes management, in type 2 diabetic patients, including a significant 
decrease in HbA1c through the implementation of an educational program 
which included several subjects, such as OADs, adherence, diabetes dairy log 
and pill box usage, conducted by Pharmacists after a period of three months of 
intervention. (335) 
Over time, some methodologies have emerged for the evaluation of medication 
knowledge, although not all of them including the same evaluation parameters 
and approaches. In some studies the tools used to assess MK are only applied 
to one drug per patient (240,336). In the ReMeD study this assessment was 
applied to all medicines used by patients. Although this methodology becomes 
exhaustive, it allows to better identify the items in which the patients presented 
more weaknesses regarding the knowledge of each medicine, compromising 
their full benefits. This approach enables to draw up a plan according to the 
patients' difficulties regarding MK. However, the methodology used to assess 
MK in the ReMeD study was not previously validated, which should be done in 
the future. 
 
Patient Disease knowledge   
A lack of knowledge regarding diseases such as hypertension, diabetes and 
dyslipidaemia, was identified in most patients, respectively, in 61%, 78% and 
60.2% of the cases. The medication review program applied to the patients of 
the ReMeD study allowed the identification of patients who needed additional 
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knowledge about the management of their disease, namely in the monitoring of 
biochemical and/or physiological parameters and potential complications of the 
disease.  
Providing self-management education on diabetes (DSME), depending on the 
way provided, either promoted by one person or by a team, was shown to 
contribute to an improvement of HbA1c levels in diabetic´s patients. (337)  
Importantly, the Portuguese National Plan until 2020 (Portugal 2020) includes 
the development and implementation of education programs for health and self-
management of the disease (338), which could be an opportunity to launch the 
implementation of a MR service.  
As a result of the medication review, the identification of patients that can be 
included in education programs for health and self-management of the disease 
can be achieved. 
 
Health Literacy 
Almost half of ReMeD patients (43.2%) were identified to have “low health 
literacy”, and a low score was associated to older patients (65 years). An 
association between patient´s health literacy and patient´s age, with older 
patients presenting less qualifications (less than high school), being 2.4 times 
as likely to report fair or poor health literacy, was also identified. (339)  
Moreover, patients having one or more chronic diseases were found to present 
a lower health literacy, especially among older patients, such as found in our 
study. (8,340) 
A worse control of diseases has already been associated with low level of 
health literacy, as achieved in the control of blood pressure in hypertensive 
patients by Willens et al. (2013). (341) Also a lower control of glycemic profile 
has been achieved in diabetic patients with lower score of health literacy. 
(342,343) 
Patients presenting a low health literacy have been associated with an increase 
difficulty in the interpretation of labels (prescription medications and nutrition) 
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and health messages, referred as a key factor for disease knowledge, self-
efficacy, contributing to improvements in health outcomes in diabetic´s patients. 
(8,272,344) 
The identification of patients with low health literacy score, as included in the 
ReMeD study, enables the identification of patients that could present an 
increased risk of uncontrolled diseases, such as those with higher prevalence in 
this study and in the Portuguese population. In addition, it also allows identifying 
groups of patients that may benefit from therapeutic education programs. 
It has been recently identified that an improvement on the outcomes of patients 
regarding medication adherence and medication knowledge could result from 
the interventions in low health literate populations that include an additional aid 
for written information on a personalized approach. (279) 
Since patients with limited health literacy increase health care costs, the 
identification of these patients could potentially contribute to a reduction in 
health costs. (345) 
Although the tool used in the ReMeD study aims to identify patients with low 
health literacy, this may be useful to adjust the patient-pharmacist 
communication, since it could be a barrier to understanding medicines 
instructions and consequently medication adherence. 
 
Self-perceived health status 
Patients included in our study rated their health status positively, mainly (53.4%) 
as “acceptable”, a similar result of the obtained in the Portuguese “Study of 
Satisfaction of Users of the Portuguese Health System” (2015), in which the  
population considered their health status positively (65.2%), considering it 
"good" in 36.0% of the cases and 31.5% as “acceptable”. (346)   
Importantly, a more negative health status has been associated to a lower 
health literacy level leading to an increased number of negative health 
outcomes. (8) 
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Patients being followed for a longer period in AEDMADA clinic presented a 
significant difference regarding patient´s self-perceived health status (p=0.024) 
compared to those being followed for a shorter period, which may indicate that 
the fact that the patients are followed for a longer time provides them with a 
more positive opinion of their health status. 
The self-perceived health status can provide some information about the 
patient's image of their health status and the way that the patients approach the 
disease. 
Globally, the humanistic outcomes, although they may not have explicit clinical 
significance, seem to contribute to identify factors that may improve the health 
outcomes of the patients, hence the importance of their inclusion in the 
medication review process. 
 
5.2.3.2 Economic outcomes 
 
Number of medicines 
With respect to the number of medicines, the ReMeD patients were using a 
mean of 7 medicines per day. Several  studies,  although  exclusively  enrolling  
patients  over  65  years using polypharmacy,  have found    a    relatively    
similar number,    including a Spanish    project    of pharmacotherapy   with 
follow-up   conducted   in   nursing   homes   (mean   of   6.4 medicines),  and  
the  conSIGUE  project,  a  program  of  medication  review  with follow-up held 
in Spanish community pharmacies (mean of 8.32±3.1 chronic medicines). 
(158,347,348) 
The consumption of more drugs commonly represents an increase in costs both 
for the patients and the health system, as it has been observed in the 
consumption of medicines in Portugal. (47)  Furthermore, the increase in the 
number of medicines used by patients contribute to a higher complexity of 
medication regimen, which can lead to a poor management in patient´s 
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medication and the emergence of clinical negative outcomes, so it is important 
to consider this parameter as an economic outcome. (146) 
An outcome provided from the medication review can include the identification 
of patients with high therapeutic complexity, enabling the definition of the 
appropriate measures that lead to a reduction of the complexity, as well as the 
improvement of health outcomes. 
In the ReMeD study the therapeutic complexity was not considered as an 
outcome. However, the methodology used to collect medication data allows to 
identify the main issues related to the medicines use. 
 
Number of hospitalizations  
Diabetic patients enrolled in the ReMeD study showed a prevalence of 
hospitalizations (15.9%) similar to the general population of Portuguese diabetic 
patients, which had a rate of 15.4% (more than 24 h hospitalization) in 2014. 
Moreover, considering hospitalization days, the numbers are at a similar range. 
In 2014, the average number of hospitalization days recorded for diabetic 
patients was 4.5 days for hospitalizations > 24h and 11.3 days for all the 
hospitalizations length, while the mean number of hospitalization in the ReMeD 
sample for diabetic patients was 8.4 days (considering only hospitalizations > 
24h). (23) 
The number of visits to the emergency department, although not included in the 
ReMeD outcomes, should be included as an economic outcome, since such 
visits may represent an increase of the costs for the health system, which are 
not included in the regular care process and that can be associated to the use 
of medication.  
The analysis of the impact on hospital admissions performed in the conSIGUE 
project achieved a significant decrease in medication-related hospitalizations in 
patients receiving medication review with follow-up (MRF) relative to the control 
group, as well as lower probability of being hospitalized (3.7 times higher in the 
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control group) and lower costs in hospitalizations, justifying  the potential of 
this MR service,   which   would   benefit  both patients   and government by 
decreasing costs for the NHS. (349) 
Hospitalizations suffered by the patients can drive towards the increased of 
poor disease control which may be associated with medicine´s use, whether 
due to adverse reactions or drug´s ineffectiveness. 
This economic outcome has to be considered in the calculation of the costs 
associated with health negative outcomes and disease burden, and 
subsequently as one potential indicator on the economic impact of the 
medication review service, as used previously by other authors. (141,349,350) 
 
Number of Physicians following patient 
In the ReMeD study, patients were followed mainly by 2 or 3 Physicians, 
attending consultations mostly with General Practitioners and specialists in the 
area of diabetology, which suggests that most patients were followed by several 
professionals, and possibly at various levels of care. The management of the 
disease by a group of health professionals can be beneficial if this approach is 
done in an integrated way. However, if this does not happen, it may possibly 
become a limitation and contribute to an increase in negative clinical outcomes. 
The activity of medication reconciliation in the hospital setting, held by 
Pharmacists at hospital transition, has been already associated to a lower 
number of hospital revisits related to adverse drug events and also lower 
emergency department visits. (351) 
Moreover, it  was  shown  that  a  lower  number  of  Physicians following a 
certain patient  is positively correlated  with  their increased independence in  
daily activities,  less comorbidities, and less hospitalization episodes. (352) 
 
The identification of patients who are being followed by different Physicians and 
at different levels of health care (public and private, for example) could be 
useful allowing their signalling during the medication review, so that 
discrepancies could be respectively analysed.  
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Rate of reimbursement of medicines 
In our study, patients were covered mostly by the Portuguese general medicine 
reimbursement system (75.4%), whereas only 14.4% were covered by the 
special system for drug reimbursement (lower co-payment on the purchase of 
medicines). (46) This last group has less financial capacity to support health 
costs, including medicines, but it will have access to reimbursed medicines at 
lower prices than most of the other groups. 
Interestingly, the co-payment level has been previously identified as a predictor 
of medication adherence for antihypertensive medications, in a retrospective 
observational study conducted in members of an American care organization, 
showing a significant increased compliance among patients with pharmacy 
claims for drugs that required lower co-payments. (353) 
This economic outcome, while not having a direct impact on patients' health, 
may allow the identification of patients with limitations in the acquisition of 
medicines and health services, particularly those that are not reimbursed, which 
can lead to health negative outcomes. 
 
5.2.3.3 Clinical outcomes 
The clinical outcomes obtained from the review of the medication can assume 
diverse designations, depending on the methodology used for this service, as 
well as according to the concepts of outcomes considered by each research 
group. In the ReMeD study we considered three types of clinical outcomes: 
NCOs, DRPs and Risk situation of NCOs. 
 
Negative Clinical Outcomes (NCOs) 
The number of NCOS identified per patient in the ReMeD study (3.05±1.13) 
were similar to those found in a Spanish study where a medication review with 
follow-up was performed, conducted in a community pharmacy of the province 
of Gipuzkoa, during a period of 18 months. In the referred Spanish study, an 
average of 3.1±2.5 NOMs (Negative Outcomes related to Medicines) were 
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identified per patient, mostly regarding effectiveness (47.3%), followed by safety 
(36.5%) and necessity (16.2%). (142) The concept of NOM considered by these 
authors included "uncontrolled health problems that appear due to the use or 
nonuse of medicines". (142) 
In a controlled trial including type 2 diabetic patients from Brazilian community 
pharmacies, most frequent negative clinical outcomes (mean: 2.3±1.6) were 
ineffectiveness of the drug therapy (68.1%), and the need for additional 
pharmacotherapy or the use of unnecessary drugs, being identified in  15.1% of 
the outcomes. (354) In the ReMeD study, the diabetic patients also presented a 
larger number of NCOs, particularly those with uncontrolled glycemic profile. 
A Medication Review Management (MRM) program conducted through home 
visits in Jordan, used a different approach which considered the identification of 
treatment-related problems (TRP), described by AbuRuz et al. (2006) as “an 
event or circumstance involving patient treatment that actually or potentially 
interferes with an optimum outcome for a specific patient”(132). (355) The TRPs 
identified included: unnecessary drug therapy, untreated conditions, 
ineffective/incomplete drug therapy, inappropriate dosage regimen, adverse 
drug effects, actual or potential drug interactions, non-adherence to non-
pharmacological and pharmacological therapy and suboptimal monitoring. (355) 
An interesting point of this classification system of TRPs is the inclusion of 
untreated conditions that require pharmacological or non-pharmacological 
therapy.  Sometimes the necessary approach for the treatment of some clinical 
situations may include the adoption of non-pharmacological measures, such as 
for the treatment of dyslipidaemia or obesity. (356) Non-pharmacological 
interventions should have priority in the intervention plans drawn up by the 
Pharmacist, in order to achieve improvement in patient´s health outcomes.  
In the ReMeD study, the highest prevalence of NCOs were related to “disease 
control”, and in these the most observed were related to disorders of lipoprotein 
metabolism and other lipidaemias (18.1%), hypertension (16.4%) and diabetes 
(15.8%). These findings are in agreement with results obtained in the analysis 
of the degree of control of the biochemical and physiological parameters 
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described in the previous chapter “Results 4.2.2 Patient´s clinical evaluation”. 
Patients included in ReMeD study showed a low rate of lipid profile control 
(14.4%), the blood pressure values were controlled in only a third of patients 
(30.5%), and the control rate of glycemic profile in diabetic patients was 
reached in about half of patients (41.5%).  Therefore, a high number of NCOs 
were expected regarding “disease control”. 
Moreover, in the ReMeD study a high prevalence of NCOs related to “Untreated 
conditions” was identified (38.1%), which may suggest a very positive point of 
this methodology. This situation has already been mentioned by Hurkens et al. 
(2016), noting that situations of “indication without medication” were frequently 
missed, even when the professionals had access to information regarding 
laboratory results, reason for admission and medical history conducted. (357) 
Most of the methodologies applied in the MR focus on the analysis by 
medicines, hence the designation often used in the clinical outcomes presented 
as results, such as “medication related problems” and “drug-related problems”, 
(135,159,358).  
In the ReMeD study, the approach adopted was based on clinical situation, 
since the clinical evaluation of the patient is usually based on the data related to 
their clinical history, including the pathologies already diagnosed and the 
symptoms / signs presented by each patient. Furthermore, the selection of the 
treatment is made according to their clinical state and diagnoses. Thus, we did 
not, like other research groups, use an approach per medicine, using the 
explicit concept of effectiveness of prescribed / used therapy, which should not 
be done per drug, but by clinical situation, since for example in clinical situations 
that several drugs are prescribed simultaneously, it becomes difficult to identify 
the relative effectiveness of each medicine. 
However, through the approach used in the ReMeD study, the analysis of the 
medication is also performed, thus fulfilling one of the points described as 
purpose of the medication review identified by the PCNE: "a structured 
evaluation of a patient's medicines with the aim of optimizing medicines use and 
improving health outcomes ". (96) 
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Drug-Related Problems (DRPs) 
In the ReMeD study an average of 4.7±2.9 drug-related problems (DRPs) was 
identified per patient, with DRPs being appointed in 95.8% of the patients 
included in the ReMeD study. 
Likewise, a “brown bag medication review”, which included patients 60 years or 
older taking at least 5 medicines, found an average of 4.3±2.8 DRPs, a value 
similar to those obtained in the study ReMeD. (359) However, it is important to 
note that the methodology used for the classification of DRPs was PCNE 6.2 
classification system, where the ADEs (adverse drug events), for example, are 
considered a DRP and not a negative clinical outcome. In the referred study, 
the most frequent causes identified for DRPs were relative to “drug selection” 
(40%), “dose selection” (28%),  “participant problems” (14%) and “drug use or 
administration process” (11%), which in the ReMeD study were also the scopes 
with higher prevalence. (359) 
For issues identified as DRPs in the ReMeD study, another study conducted in 
a University Hospital in Sweden at admission time, between January 2007 and 
March 2008, patients presented similar results relative to “inappropriate drug”, 
and “inappropriate treatment duration”, using MAI criteria. (134) The authors 
used the “Lund Integrated Medicines Management model” (LIMM), including 
medication reconciliation upon admission and discharge, and medication review 
and monitoring, by a multi-professional team, including a clinical Pharmacist, 
while the ReMeD study was conducted exclusively at outpatients. (134) In 
addition, the criteria used to identify the suitability of the medication were also 
different. The suitability of the therapy in the ReMeD study was mainly 
performed according to the guidelines produced and adopted in Portugal, 
therefore it is difficult to standardize the criteria for different countries. 
A group of Portuguese Pharmacists conducted a descriptive observational 
cross-sectional study carried out in six Portuguese nursing homes. In this study, 
a median of 14.5 DRP per patient was achieved, being the most prevalent 
“Adverse Drug Event, non-allergic” (49.51 %), “Drug treatment more costly than 
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necessary” (19.11 %), “Effect of drug treatment not optimal” (14.82 %) and 
“Unnecessary drug treatment” (6.16 %). (145) The system adopted for the drug-
related problems classification was the II Granada Consensus. (172) The 
number of DRPs identified in this sample was superior to those in the ReMeD 
study, however the referred study included only institutionalized patients 65 
years and using 5 or more medicines. The average number of drugs used in 
these patients was 10 medicines, and a median of 11 dosages per day. 
Furthermore, from the identified DRPs only 2.1% were manifested, whereas the 
remaining were merely potential DRPs.  (145) In the former study, the identified 
DRPs were mainly potential DRPs while in the REMED study those identified 
were explicit rather than potential. Moreover, in referred study issues related to 
medication adherence and patient medication knowledge were not identified by 
the researchers, probably due to patients being instutionalized.  
In a Spanish program including medication review with follow-up in a community 
pharmacy, Ocampo et al. identified an average of 4.5 DRPs per patient, during 
the follow-up period. The most frequent DRPs identified were “adverse effects 
probability” (21.2%), followed by “non-adherence” (15.6%) and “inappropriate 
dose, frequency and/or duration of treatment” (15.5%). (142) Similar results 
were found in the ReMeD study considering issues identified relative to 
medicine´s use process (adherence) and dose selection (inappropriate dose).  
Norwegian Pharmacists who participated in the project developed by Granas et 
al. (2010) identified a lower number of DRPs in a medication review conducted 
in type 2 diabetes patients (in a community pharmacy setting). (182) DRPs were 
categorized using a modified PCNE classification system, considering 5 main 
areas: adverse reactions, drug use problems, other drug-related problems, drug 
choice problem, dosing problem, and drug interactions. Furthermore, this study 
included an evaluation group to review retrospectively all DRPs identified by the 
Pharmacists, which identified 76 additional DRPs even in patients who had no 
previous identified DRPs. (182)  This approach held by an evaluation group of 
reviewing the DRPs identified by the Pharmacists may be interesting and allow 
a uniformity in the clinical approach. 
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Different results were reported from other studies, such as those identified in 
patients from five hospitals of all sectors of health services (public, private, and 
military), where a high average of 11.2±6.2 DRPs per patient was found. Those 
patients enrolled presented at least one chronic medical condition and received 
at least two medications. (360) The most prevalent DRPs reported were “a need 
for additional or more frequent monitoring”, “inappropriate adherence to self-
care activities or nonpharmacological therapy”, and “the patient was not given 
instruction in or did not understand nonpharmacological therapy or self-care 
advice”, showing a different profile than those obtained in the ReMeD study 
regarding the identification of issues with medicines (DRPs). (360)  
In the ReMeD study a high prevalence in the problem of “Inappropriate drug” 
was identified in the use of DPP-4 inhibitors. The Portuguese guideline, from 
the General Health Direction, for the treatment of type 2 diabetes mellitus 
patients, indicates that insulin secretagogues (sulphonylureas, glinides, and 
DDP-4 inhibitors) should be suspended as soon as complex insulin regimens in 
addition to basal insulin (or insulin premix) are prescribed and maintaining 
treatment with metformin. (291) Nevertheless, recent systematic review and 
meta-analysis, identified DPP-4 inhibitors to be an advantage in addition to any 
type of insulin therapy in type 2 diabetes, by reducing both fasting and post-
prandial glucose levels through increasing insulin secretion and decreasing 
glucagon secretion while not contributing to the increase bodyweight and risk of 
hypoglycaemia, used alone or in combination with metformin. (361) Additionally, 
other reviews indicate the combination of DPP-4 inhibitors with insulin as a safe 
procedure, obtaining a smooth decrease on the HbA1c levels (0.6%), whereas 
the risk of hypoglycaemia was not increased, and presenting a neutral effect on 
the weight gain. (362,363) Since the latest update of the Portuguese guideline 
for the pharmacological approach in type 2 diabetes mellitus was produced in 
2013, an updated review according to international guidelines should be 
achieved. 
In addition, in the analysis of ReMeD patient´s medication, drugs from the 
B01AC subgroup (antithrombotic agents, platelet aggregation inhibitors excl. 
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heparin) showed a high rate of DRPs relative to “No indication for drug”. 
According to the literature, the risk of vascular mortality is not significantly 
changed with the treatment with aspirin for primary prevention of cardiovascular 
events, as well as in individuals with multiple risk factors, the use of clopidogrel 
in combination with aspirin vs. aspirin didn´t show a significant improvement in 
cardiovascular outcomes. (26) Antithrombotic therapy in individuals without 
cardiovascular disease is not a recommendation from the European Society of 
Cardiology, neither from the Portuguese General Direction of Health. (26,364) 
This suggests that in some ReMeD patients, prescribers should review the use 
of this medication. 
ReMeD patient´s medicines containing drugs from the subgroup C08CA 
(calcium channel blockers, d, such as lercanidipine), presented some DRPs 
(1.7%; n=9) relative to “Inappropriate timing of administration and/or dosing 
intervals”. It is important to note that these drugs present a high first-pass 
metabolism, and the absolute bioavailability of lercanidipine administered orally 
to patients in the post-prandial conditions, is about 10%, although the 
bioavailability is about 30% when administered in the fasted state, so it is 
recommended the administration before meals. (365) Pharmaceutical 
counselling on the timing of administration of these drugs should be considered 
as a consequence of the medication review. 
Likewise, drugs from the subgroup A02BC (proton pump inhibitors) presented a 
pronounced prevalence (2.9%) of DRPs relative to “Inappropriate timing of 
administration and/or dosing intervals” in the ReMeD patients. Importantly, 
proton pump inhibitors, such as pantoprazol, may have the absorption affected 
by the concomitant food intake, leading to an increased variability of latency 
period. (366) In some other cases, as with the esomeprazole, food intake 
delays absorption, although these effects have no significant influence on the 
effect of esomeprazole in intragastric acidity. (367) 
Recently, a national campaign was launched by INFARMED to alert against the 
risk of a prolonged use of proton pump inhibitors. (368) The study and analysis 
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of proton pump inhibitors use may constitute an area of future research and 
intervention by the Pharmacist. 
Drug subgroup C10AA (Lipid modifying agents, HMG CoA reductase inhibitors) 
presented, in our study, an increased prevalence of problem relative to 
“intentional non-adherence” (1.15%). These results go in agreement with 
previous studies that have already shown that elderly patients are normally 
more prone to non-adherence in the use of lipid lowering agents than younger 
or middle-age patients. (320) Moreover, Ferrajolo et al. (2014), in an Italian 
population-based study, identified the use of statins for primary prevention as a 
predictive factor for nonadherence, and that those patients had higher 
probability (64%) to be more non-adherent than those who started statins on 
secondary prevention (210) 
For drugs from the former subgroup C10AA, issues entitled “drug dose too low” 
presented a high prevalence (2.7%). In the decision of the pharmacological 
treatment of dyslipidaemias the choice of statin and respective dose should first 
be made on the basis of global cardiovascular risk presented by the patient and 
then depending on the individual objectives to be achieved for the individual 
LDL cholesterol levels, according to the guidelines of the European Society of 
Cardiology (ESC) and the European Atherosclerosis Society (EAS), and 
adopted by the General Direction of Health (DGS) in Portugal. (292,369,370) 
The data obtained from the ReMeD patients, suggests that in the patients 
where this issue was identified, they should be referred to their Physician for 
reassessment of dyslipidaemias treatment, including the drug selected, dose 
and the existence of adverse reactions. 
Similarly, the drug subgroup N05BA (Anxiolytics, Benzodiazepine derivates) 
also presented a high prevalence of problems relative to “drug dose too low” in 
ReMeD patients. Benzodiazepine and similar drugs are indicated for the 
treatment of anxiety and insomnia and should not be routinely used in the 
symptomatic treatment of mild to moderate anxiety or insomnia. (371) The 
benzodiazepine dose should always be individualized based on the severity of 
symptoms and the individual patient response, proceeding to a reassessment 
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within a period not exceeding 4 weeks. (371,372) Considering alprazolam as an 
example, the recommended dosage for an anxiety state is 0.25 mg to 0.5 mg 
three times daily increasing, if necessary, for a total of 3 mg per day. (373) 
Some patients from the ReMeD study were using a lower dose than 
recommended in the SmPC of the respective medicine. In addition, and very 
importantly, patients presenting this issue should be referred to their Physician 
for reassessment of the insomnia treatment. 
Considering the high consumption of benzodiazepines in the Portuguese 
population (374), it would be useful to implement a joint strategy with 
prescribers in order to reduce the use and the misuse of these drugs. 
The identification of inappropriate medication can be performed using several 
tools, developed and validated by various authors. According to Beers criteria 
(196), about a fifth of ReMeD patients were using potentially inappropriate 
medication (PIM), a lower prevalence than the one achieved in another 
Portuguese observational cross-sectional survey conducted in elderly subjects 
in community pharmacies in Lisbon district (38.5%). (375) Nevertheless, as 
found in the ReMeD study, the most prevalent PIMs were long acting 
benzodiazepines, and also the number of PIMs used was significantly higher in 
patients using an increased number of medicines. (375) 
Another Portuguese observational and cross-sectional study, held in November 
2012, including older subjects ( 65 years) consulted in a Family Unit Care in 
the area of Oporto, identified an increased number of PIM (37.0%). (376) In the 
referred study, the 2012 Beers criteria was used as a reference, which covers 
other PIMs such as sliding-scale insulin, which was not part of PIMs 2002 list, 
although they have not yet been adapted for Portugal. (194) 
A more recent Portuguese study, held by Alves da Costa et al. (2016), analysed 
a sample of polymedicated ( 5 medicines), older patients ( 65 years) resident 
in Portuguese nursing homes to assess the prevalence of PIMs, and used 
Beers criteria [Portuguese version (2008) and American version (2012)], and 
STOPP/START criteria (Screening Tool of Older Person’s Prescriptions / 
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Screening Tool to Alert doctors to Right Treatment). Using the first tool, this 
study found that 60.3% of patients were using PIMs, and using the second tool 
85% of the patients were using PIMS, a substantially higher prevalence than 
found in the ReMeD study (19.4%). (205) Patients included in the ReMeD study 
over 65 years were using polypharmacy in 82% (n=55) of cases. The most 
prevalent PIMs independent of diagnosis found in the home resident sample, 
using Portuguese version of Beers criteria (2008), were short-acting 
benzodiazepines, laxatives, and muscle relaxants, very similar to what was 
found in the ReMeD study. (205) 
The Beers criteria are one of several tools to detect PIM in elderly patients, 
however their operationalization for Portugal has not yet been performed for the 
most recent versions of this tool. As verified by da Costa et al., the tool selection 
for the detection of PIM has influence on the results obtained, and the 
Portuguese version of Beers criteria allows to detect a lower number of PIM 
compared to the last American version or the START/STOPP criteria. (205) 
Moreover, the Beers criteria does not include missing medication, which can be 
identified in situations such as the prevention of cardiovascular events using the 
START / STOPP criteria. It would be useful to operationalize these tools, in their 
latest version, for the Portuguese reality, thus allowing an additional way to 
identify issues related to the medication use in the elderly, which is a growing 
age group in the Portuguese population. These tools seem to be a very relevant 
contribution to include in computer applications embedded in the IT resources 
that are already used by the Portuguese health institutions. 
Globally, the identification of DRPs, although there is no consensus in this 
concept, seem to be a fundamental point in the medication review process. 
Regardless of the nomenclature used, the identification of issues in the 
medicines used by patients is of extreme importance in order to enable 
Pharmacists to identify patient centered interventions. 
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Risk situations for negative clinical outcomes  
The risk situations (rNOMs) were noted whenever the patient did not present 
NCOs, although an issue was identified with some of the drugs used (DRPs). In 
the ReMeD sample these risk situations were identified in about three-quarters 
of the patients.  
The number of risk situations identified in the ReMeD study were associated 
with an increase in the age of the patients, polypharmacy, use of antithrombotic 
agents, polymorbidity, and use of oral antidiabetic drugs, factors that had 
already been identified as a risk factor for the occurrence of DRPs by Kaufmann 
et al. (2015). (377) Other risk factors, classified as “important”, were also 
identified by these authors, such as dementia, cognitive situation, low IQ, 
confused patient, antiepileptics, combinations of NSAID and oral 
anticoagulants, insulin, missing information, half-knowledge of the patient, the 
patient does not understand the goal of the therapy, medication with a narrow 
therapeutic window, and non-adherence. (377) 
This clinical outcome, although it does not translate to an explicit negative 
outcome, allows to signal the patients that present a higher risk for the 
occurrence of these NCOs. Petrovic et al. (2016) already recognized that the 
assessment of appropriateness in geriatric pharmacotherapy should include a 
screening to identify patients at risk of DRPs and adverse drug reactions 
(ADRs) and should include, in addition to the clinical outcomes of patients, 
capacities obtained from a health care team, that would allow avoiding potential 
negative outcomes that could be harmful to patient´s quality of life. (378) 
Therefore, the identification of the existing issues in the use of the medication 
(DRPs), may enable a corrective intervention and prevent the occurrence of 
future NCOs, and should consequently be an outcome of the medication review.  
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5.2.3.4 Potential Interventions 
In the ReMeD study, the potential interventions identified with the highest 
prevalence were “other interventions” and interventions “at prescriber level”, a 
scenario with some similarity to the one found in a project including a 
medication review with follow-up held in a community pharmacy (Gipuzkoa, 
Spain) in 2015, where the main interventions were implemented at prescriber 
level (63.7%) and at patients level of educational interventions (36.3 %). (142) 
Also in the Spanish study conSIGUE, about 50% of the interventions in all study 
periods were intended to prescribers, a greater amount of potential 
interventions in this scope than those identified in the ReMeD study (27.9%). 
(379) However, the conSIGUE study was conducted in the field of community 
pharmacy, including only patients aged 65 years and older and using 
polypharmacy (5 or more medicines). (379) 
Based on these results, it is clear the importance of this activity in a 
multidisciplinary team, with better accessibility and direct contact with other 
health professionals, enabling faster intervention to achieve improved health 
outcomes. The Pharmacist´s intervention has been referred by Riordan et al.as 
a path to improve medication appropriateness in older adults, with greater 
impact on the results when there is Pharmacist collaboration with the 
Physicians acting in primary care. (380) 
In the ReMeD study, disorders of “lipoprotein metabolism and other lipidaemias” 
and “obesity and other hyperalimentation” presented the highest rate of 
potential “other interventions”, regarding actions such as non-pharmacological 
interventions and referral to other professionals. These results show patient´s 
need for non-pharmacological interventions in diseases such as dyslipidaemias 
and obesity, which present a high prevalence in the Portuguese population. 
An intensive lifestyle intervention is highly relevant in patients with type 2 
diabetes, especially when associated with medication management, as 
identified in the Look AHEAD trial, which was developed with the aim of 
assessing the effects of weight loss through behavioural means on 
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cardiovascular morbidity and mortality (intensive multi-component lifestyle 
intervention versus diabetes support and education). (381) 
The predictive variables identified for the weight loss in overweight type 2 
diabetes adults were the following: baseline variables fasting glucose, anxiety, 
numb feeling in extremities, insulin dose and waist-to-hip ratio. (382) A large 
part of the ReMeD population study may be a good target for a weight loss 
program prepared by a nutritionist in conjunction with other health 
professionals, since about one-sixth of the population was diagnosed with 
anxiety and about 40% was using insulin. 
It should be also highlighted the number of potential interventions proposed for 
the ReMeD patients under the anxiety disorders treatment scope, which are 
essentially at the prescriber level. In the case of the treatment of this medical 
disorder, clinical guidelines indicate that treatment with benzodiazepines calls 
up a maximum duration of 8 to 12 weeks, including a discontinuance period 
being subsequently reviewed in a specialized consultation, and should not rely 
on the use of more than one benzodiazepine anxiolytic. (371) Some patients 
included in the ReMeD did not meet these recommendations, which is reflected 
by the increased number of potential interventions at the level of prescriber with 
the number of drug-related problems such as "too long duration of treatment" 
and "inappropriate drug".  A reassessment of the anxiety treatment should be 
performed by prescribers, also considering the inclusion of non-pharmacological 
measures in the treatment. 
The ReMeD patients presenting a diagnosis of type 2 diabetes mellitus showed 
the highest rate of no intervention purposed, which can be intuitive since the 
patients included in this study were recruited in a clinic focused on the study, 
treatment and monitoring of patients with diabetes, which may justify a reduced 
need for interventions under this health problem. Nevertheless, the proposed 
interventions at various levels presented themselves in a similar order of 
magnitude, with potential interventions proposed within the prescriber and the 
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patient being the most prevalent, which may point to an important multifactorial 
approach for these patients. 
 
5.2.4 Predictive factors for clinical outcomes associated to 
medication review 
For the model considering negative clinical outcomes as dependent variable, 
blood pressure control and glycemic control were the parameters with a heavier 
effect in the number of negative clinical outcomes.  
Clinical outcomes associated with uncontrolled diseases or ineffectiveness of 
treatment have been reported by several authors as the main clinical outcomes 
of medication review in a community pharmacy setting  as well as in clinical or 
residential context. (142,144,355) 
Also in the Spanish conSIGUE project, about 28.5% of health problems 
identified in the intervention group were uncontrolled, and about 45.7% of 
negative results associated with medication were related to ineffectiveness at 
the first period of the study. (379) 
Future research should include target groups of patients to carry out medication 
review, hypertense and diabetic patients, since these groups are probably at 
greatest risk of negative clinical outcomes. 
According to the results, the model considering drug-related problems as a 
dependent variable, the number of medicines, older patients (65 years) and 
number of antidiabetic drugs could predict about 47.9% of the variable results. 
Several of the studies in which a MR was conducted, included as target 
populations people aged 65 years and over, although with specific 
methodologies, having been recognized improvement in the outcomes of 
patients. (141,158,383) 
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A correlation between the number of pharmaceutical care issues and the 
number of medicines was also described by Krska et al. (2001), in a 
randomized controlled trial conducted in older patients. (383) 
in addition, the reduction of medicines number has been reported as one of the 
main outcomes from medication review. (141,158) 
The number of medicines used by patients and the discrepancies between 
prescribed and taken medications were identified as predictive factors for an 
advantage to patients undertaking medication review by Rose et al. (2016). For 
this analysis it was considered the acceptability of the Physician to implement 
pharmaceutical recommendations and factors influencing Physicians' 
acceptance. Also older patients with multimorbidity, polymedication and a 
cardiovascular disease experience, were identified as subjects that can benefit 
from medication review. (384) 
Considering predictive factors for clinical outcomes identified in the ReMeD 
study, target groups to undertake medication review should include, in future 
research, older patients (65 years), polymedicated patients and patients using 
antidiabetic drugs.  
 
5.2.5 Comparison of eligibility criteria for medication review 
programs in Australia, Canada and England 
The eligibility criteria established for the various medication review programs 
showed to have some points in common, namely the number of medicines used 
by patients and the number / type of pathologies. 
In Australia, several groups of researchers have tried to improve the medication 
review process over recent years. A systematic review regarding the outcomes 
from clinical medication review (CMR) service held in community setting in 
Australia, identified that most of the studies included in the analysis were 
conducted in patients at risk for negative outcomes from medication use (n=40). 
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Moreover, others studies were carried out in groups of elderly patients (n=10), 
and further studies were conducted in patients with specific clinical conditions 
(eg, chronic heart failure, chronic obstructive pulmonary disease, diabetes and 
others) or with specific humanistic characteristics as problems in medication 
adherence, culturally and linguistically diverse. (159)  
The eligibility criteria for conducting a medication review in Canada under the 
MedsCheck program, only include a criteria based on the number of 
medications used by patients for chronic conditions. If these criteria were 
applied to the sample of patients included in ReMeD study, about 85% of 
patients would meet these criteria. 
An analysis of MedsCheck annual (MCA) provided in Canada from 2007-2013, 
identified an increased number of MCA provided among this 6-year period in 
patients aged over 66 years compared to younger subjects (42% vs 31%), with 
a higher prevalence of hypertension, heart failure and cancer in the older 
patients (66 years) cohort and most of those having at least one dispensing of 
an antihypertensive or antidyslipidemic drug during the previous year before 
MCA. (324)  
Canadian researchers developed and validated a tool called “Medication Risk 
Assessment Questionnaire” (MRAQ) to identify patients at risk for DTPs, in a 
community pharmacy environment, consisting of five questions to be self-
answered by the patient, with a good value of reliability (k = 0.91, p<0.01). (385) 
Pammett et al. (2016) reported a higher number of moderate-severity drug-
therapy problems (DTPs) in eligible patients for medication review according to 
provincial criteria compared to those who did not accomplish the eligibility 
criteria for all provincial programs available in Canada. (386)  
Despite the eligibility criteria for the MCA service in Canada being less 
restrictive than those applied in other countries, the profile of individuals who 
benefited from this service seems to be similar to that found in the groups that 
benefit from similar programs in other countries. 
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The Medicines Use Review service, available in the United Kingdom (UK), has 
more specific eligibility conditions than the existing programs in the two previous 
countries (Australia and Canada), including patients using "High risk medicines" 
"Medicines for respiratory disease" and patients "At risk or diagnosed with 
cardiovascular disease and using regularly at least 4 medicines", and also as 
defined for the two other countries under analysis, patients recently discharged 
from hospital with changes in medicines (during hospitalization). 
The criteria for this specific service available in community pharmacies in 
England, which comply with the conditions for their provision, are closely related 
to the results obtained previously, resulting in potentially advantageous for 
improving health outcomes, which allowed the funding authorized by the 
National Health Service (NHS) to pharmacies for providing this service with 
these features focused in practical use of medicines. (119) 
In 2001, a randomized controlled trial conducted in Scotland that enrolled 
patients 65 years and older using at least 4 (four) medicines and having at least 
2 (two) chronic health problems, already identified "pharmaceutical care issues" 
(PCI), having identified diuretics and other medications used in the 
cardiovascular system related to possible PCI, and also referred the need of 
access to patients records to enable identification of some PCI. (383) 
The main goal common to all countries and services is an attempt to identify 
groups that may benefit from this medication review activity, whether the 
medication used, patient´s clinical outcomes or their personal characteristics 
that may influence the treatment and thus lead to negative results in the health 
status of the individual. 
The methodology and the team involved in the conduction of a medication 
review are key points, since it may influence the data obtained and 
consequently the outcomes of this activity. 
Willeboordse et al. (2016) compared information about patient´s medication use 
and drug-related problems using a questionnaire and a face-to-face interview, 
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with results showing an agreement on results obtained by both methods, but a 
higher number of reported drug-related problems obtained in the interview than 
the questionnaire. Although the results were similar for younger patients with 
proper health literacy, for older patients with more diseases and lower health 
literacy the interview was the methodology that allowed more accurate results. 
(387) This suggests that, in the case of the ReMeD study, and considering the 
age characteristics of the population, the approach through interview that was 
used was the most appropriate. 
The eligibility criteria adopted to date in these three countries do not invalidate 
that there are other target groups that may benefit from the medication review. 
Each country / community identifies the eligibility criteria according to the needs 
of its population, the purpose of which is to identify individuals who may be at 
greater risk of negative health outcomes. Not always these criteria allow the 
identification of all individuals who can benefit from this service. It is therefore 
important to establish the appropriate criteria for each population and to monitor 
the results obtained and to update these criteria according to the health 
outcomes of the individuals.  
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6 CONCLUSION 
In order to contribute to the improvement of patient´s health outcomes, 
particularly associated to the medication use, this study aimed to develop a 
methodology to analyse the outcomes of the process of medication use through 
medication review (ReMeD study). 
The adaptation to Portuguese language of the “Short Assessment of health 
literacy – Spanish and English” (SAHL-S & E) was one of the objectives for this 
investigation. A good value of internal consistency (Cronbach's alpha) and 
intraclass correlation coefficient was reached, in addition to an excellent and 
statistically significant interrater reliability, in the Portuguese version. Therefore, 
the tool achieved (SAHL-PT) seems easy to apply and appropriate to screen 
subjects who have low health literacy. 
The ReMeD study was conducted in a sample of 118 patients, where around 
half of the patients were male (54.2%) and older than 64 years (56.7%), and 
most were married (74.6%) and lived with family members (87.3%). About half 
of the sample had qualifications below the 9th grade, and patients were followed 
in the AEDMADA clinic on average for 3.5 years. 
Clinically, we can conclude that patients within the sample presented could 
benefit from an intervention plan, due to the high number of morbidities 
identified and low rate of control for risk factors of cardiovascular diseases. This 
screening for patients with negative health outcomes, including low degree of 
control of chronic diseases and those to minimize the development of diabetes 
complications, can be an asset of medication review service.  
The analysis of the pharmacotherapeutic profile identified a population mainly 
using polymedication (73.8%), and therefore at risk of suffering negative 
outcomes associated with medication. 
The outcomes of medication review (MR), for the ReMeD population, were 
presented in the humanistic, economic and clinical scope.  
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Considering the humanistic outcomes, an increased rate of medication 
adherence was observed. However, the assessment of medication adherence 
during medication review allows to identify medicines with lowest rate of 
adherence and identify patients who reported not taking medications under 
certain circumstances, such as when they felt better or worse or to identify 
specific medicines in which there is a lack of adherence. A low medication 
knowledge score was identified in a quarter of the patients, this assessment 
enable to signal patients that should be included in therapeutic educational 
programs and those who may need help identifying their medications.  
The identification of a lack of knowledge for disease such as hypertension, 
diabetes and dyslipidaemia, allows the identification of patients' specific needs 
in terms of disease management.  
Patients identified as having low health literacy could be useful to identify 
patients at risk of uncontrolled disease, patients that could benefit from 
therapeutic education programs and for which an adjustment is required in the 
patient / health professional communication. 
Economic outcomes are parameters that may contribute to identify actions that 
could improve patient´s savings on their medication as well as to recognize the 
economic impact of negative clinical outcomes. Considering these outcomes, 
we can conclude that patients used a median of six (6) medicines, seven (7) 
units and seven (7) doses per day, with polypharmacy being present in most of 
the patients, which may indicate an increased therapeutic complexity, and 
intervention can be identified as necessary. Almost three quarters of the 
patients (71.1%) were followed by more than 1 Physicians, which could lead to 
an increase discrepancies in patient´s medication and contribute to health 
negative outcomes, and these should be analysed during medication review. 
The previous hospitalizations identified contributes to the burden of disease and 
to the increase in health costs. Pointing patients with a special rate of medicines 
reimbursement could help identify patients with financial difficulties in acquiring 
medicines.  
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The clinical outcomes obtained with the approach applied, performed by clinical 
situation, enables the identification of the treatment´s outcomes with clinical 
significance, and later to define actions that allow to achieve the intended 
clinical objectives. Although this is not an approach used globally in the review 
of medication process, this methodology allows the direct analysis of the impact 
of therapeutic on patient´s health outcomes.  
The identification of the issues (DRPs) associated with the medication used, 
enables the Pharmacist to achieve patient´s necessities regarding medication 
management and also to collect information that will be useful to share with 
other team care professionals and to define a patient´s centered intervention. 
The methodology used enabled signalling patients at risk of suffering a NCO, 
which could contribute to a preventive Pharmacist´s intervention, correcting the 
issue identified and preventing the occurrence of patient harmful. 
The identification of the potential intervention adopted in this methodology 
allows a purpose of an individualized work plan to be established on a patient´s 
centered approach, and may serve as a basis for future patient 
monitoring/intervention activities performed by the Pharmacist or the referral to 
other health professionals. 
The number of Physicians, blood pressure control and glycemic profile control 
were identified as predictive factors for negative clinical outcomes, enabling to 
predict 35.1% of the variation in NCOs. Still, the number of medicines, patient´s 
age 65 years, the number of antidiabetic drugs and the number of 
antihypertensive drugs allowed to predict 47.9% of variation in DRPs. 
In future research, older patients (65 years), polymedicated patients, diabetic 
and hypertense patients should be included as target groups to undertake 
medication review. 
Some of the eligibility criteria established for the medication review programs 
available in Australia, Canada and England could probably be applied in the 
ReMeD population. However, each service, according to its target population, 
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should establish its criteria based on the identified specific needs and health 
outcomes, for which the knowledge of the population-specific health outcomes 
is fundamental. 
The ReMeD study was conducted in a clinical context, having direct contact 
with patients, access to their medical record and in communication with other 
health professionals, which was the key to successfully implement this study. 
The methodology used, including a patient´s clinical centered  approach allows 
to identify clinical situations with negative results and to target points of 
intervention, either by the Pharmacist or other health professionals involved. 
The analysis of medicine´s use included in the ReMeD study, allowed to detect 
issues related to the medicines used by patients, and also enables to signal the 
needs and difficulties of these patients with medication. Furthermore, the 
identification of risk situations for the occurrence of NCOs may allow a better 
performance of the Pharmacist acting to prevent the manifestation of negative 
outcomes and worsen health outcomes. 
This approach can definitively be useful to the development of new strategies 
aimed to improve patient's medication use and the empowerment for disease 
management. An opportunity to a Pharmacist´s intervention arises in the scope 
of therapeutic education and health promotion, disease prevention and control 
of disease progression. 
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7 FUTURE RESEARCH 
In the future, a validation of this methodology, applied by other Pharmacists in 
collaboration with other health professionals, should be done, as well as an 
evaluation of the inter-reliability of the method. 
Furthermore, an economic evaluation of the costs of the service provided is 
needed, including the assessment of the time spent in the medication review 
process, in order to allow the calculation of the relative cost of the professional 
responsible (Pharmacist) for this service. Also the quality of life assessment 
could be included, in order to allow a future cost analysis and to estimate the 
costs and potential price of providing and implementing the service of 
medication review. Moreover, the evaluation of the patients’ satisfaction with the 
service should be also included as an outcome, allowing to understand patient´s 
perspective and capital gains, being identified by the users of the service. 
In the near future, the implementation of this medication review service is 
planned in a primary health care unit belonging to the public health system. It 
could aim the medication review in patients diagnosed with hypertension or type 
2 diabetes, to identify and analyse the clinical, humanistic and economic 
outcomes associated with the use of medication. From this analysis, an 
individual report would be prepared per patient, would be sent to the patient's 
attending Physician, indicating the issues identified and respective intervention 
proposals. Subsequently, the acceptance rate of the proposed intervention 
would be analysed. One year later, a new medication review would be 
performed and the respective results would be analysed, comparing to those 
obtained in the first analysis. 
Another planned project is the implementation of medication review in 
residential care units, which includes subjects aged 65 or over. It would be 
applied, as a pilot project, to 30 residents in a residential care unit in Olhão 
(Faro district). This pilot project would allow the adequacy of the methodology of 
medication review to the resident´s characteristics and specify needs, as well as 
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the available clinical data and the integration of the Pharmacist role in this 
setting. 
Still as a consequence of the ReMeD study outcomes a need for a "medication 
list" tool was identified, allowing patients to always carry the information about 
the medication used. A pilot study would be carried out where this tool would be 
used, initially assessing the patient's medication knowledge prior to the delivery 
of the list and 3 months after the intervention. 
The medication review activity will be a relevant area to explore in the future of 
the activity of the Pharmacist in Portugal, and the research in this area should 
continue. 
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8 LIMITATIONS 
The ReMeD study was conducted in a clinical setting primarily intended for the 
treatment, monitoring and care of diabetic patients. This population has, for this 
reason, particular characteristics and outcomes targeted in the area of diabetes 
and other frequent chronic health problems often associated with it. 
The methodology used to assess medication knowledge in the ReMeD study 
did not include items within the dimension of security, as included in some other 
tools available for this purpose. In fact, these items were originally included in 
the questionnaire, but the answers given by the patients couldn’t be considered 
valid for inclusion in the tool used. Most patients failed to respond when placed 
on the question about adverse effects of the drug, or on the drug´s therapeutic 
goals. Due to its relevance to the outcomes, medication knowledge assessment 
was performed for all medicines used by the patient, although most studies 
published only included the evaluation of medical knowledge for one medicine 
per patient. Unfortunately, this became a most lengthy and difficult process to 
the patient, where hence he probably failed to properly identify the specific side 
effects and potential interactions to each drug. In a future approach, this 
assessment should be made not so exhaustively for all drugs, but individually to 
each specific group of drugs. 
The number of visits to the emergency department should has been included as 
an economic outcome, since these visits could be identified as an additional 
increase in the costs for the health system, which are normally not included in 
the regular care process and can be associated to the use of medication. 
The existing state of organization of the patients' clinical file is not properly 
systematized. Although the records are mainly integrated on a digital file they 
are also made on paper in some cases. In addition, patients are mostly followed 
by several Physicians, which makes it more difficulty to integrate all clinical 
information. It would be useful to reorganize the collection of patients' clinical 
data and, if possible, to create a mechanism for sharing information among all 
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health professionals who follow these patients at the various levels of 
healthcare. 
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10 APPENDICES 
 : Questionnaire for SAHL-PT adaptation 
1. AGE: ________years  
2. GENDER:      Male       Female  
3. WEIGHT: ________kg   HEIGHT: ________cm     
4. MARITAL STATUS:     
5. QUALIFICATIONS:  
7. PROFESSIONAL SITUATION: 
8. HOUSEHOLD: 
9. HEALTH PROBLEMS: 
 
 
 
 
 
 
10. MEDICATION: 
Number of medicines used daily:   
Number of daily units (cps, cáps, other):  
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 : SAHL-PT Test (Portuguese) 
 
 Chave ou Distração 
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 : Informed consent form 
 
Informed Consent 
Title of the Research Project:  
Evaluation of health outcomes associated with medication in Southern Portugal using a 
novel approach for medication review: ReMeD study. 
The main objectives of this research project are: Assessment of cardiovascular risk in 
the population of users of AEDMADA; Characterization of pharmacotherapeutic profile; 
Analysis of the degree of control of risk factors for cardiovascular diseases 
(hypertension, diabetes, dyslipidemia); Identification of negative clinical outcomes; 
Identification of drug related problems; Identification of risk situations for negative 
clinical outcomes in the use of medication. 
Data will be collected regarding socio-demographic parameters and the following 
parameter values: weight, height, blood pressure, pulse, blood glucose, HbA1c, total 
cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, smoking, medication use 
and others as applicable.  
Questionnaires will be used to assess medication adherence, degree of health literacy 
and medication use.  
The collection of these data will be performed during an interview. 
I, ___________________________________________, declare that I consent my 
participation in this research project. 
By giving my consent I declare that:  
I agree with the goals of the research project and my involvement in it; All doubts about 
the project have been fully clarified; I understand that at any time I can give up to 
participate in the project without affecting my relationship with the researchers or 
AEDMADA; I understand that my participation is confidential and information about me 
will not be used so that my identity is revealed; Participate in this project is completely 
voluntarily; I know I can at any time stop the interview and, if I wish, my participation 
will not be included in the study. 
Faro, _______________ 20___  
(Patient Signature)     (Investigator Signature) 
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 : ReMeD Questionnaire 
QUESTIONNAIRE 
Socio-demographic Data 
Name  
Age(years)  
Gender  
Marital Status  
Household 
Qualifications   
Professional 
Situation 
 
Biochemical and physiological parameters; Lifestyle. 
Weight  
Height  
BP SBP:                    DBP: 
Pulse  
Lipid Profile 
Total Colesterol:                           Date: 
c-LDL:                                           Date: 
C-HDL:                                         Date: 
Triglycerides:                                Date: 
Glycemic 
profile 
Fasting glycemia:                         Date:  
Postprandial glycemia :                Date:                     HbA1c:                         Date: 
Smoking 
Habits Smoker ___ Nr cigarettes/day: ___         Ex-Smoker ___             No-smoking ___ 
Physical 
Exercise 
Habits 
Do you practice physical exercise regularly?    Yes    No 
How many times a week?                              How long each session?  
Food Habits 
 
In a typical week how many days ate fruit? 
How many pieces of fruit eaten one of these days? 
In a typical week how many days ate vegetables? 
How many portions of vegetables eaten in those days? 
What kind of fat do you use most often to prepare your own meals? 
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Clinical Profile 
Health Problems 
Diseases of the circulatory system:  
1- Hypertension     2 - Other: 
Digestive Diseases:  
1- GER Disease  2 – Peptic ulcer  3 - Other:  
Diseases of the Respiratory System:  
1- Asthma    2 - DPOC      3 - Other:  
Diseases of the Musculoskeletal System and connective tissues:  
1 - Osteoarthrosis   2 - Osteoporosis     3 - Other:  
Endocrine, nutritional and metabolic Diseases: 
1 - Diabetes mellitus  2 – Hypothyroidism   3 – Hyperthyroidism   4 – Dyslipidaemia        
5 – Hyperuricaemia    6 - Other:    
Mental and Behavioural Disorders: 
1- Depression 2 – Anxiety  3 – Alzheimer Disease  4 - Other(s):  
Diseases of Nervous System:  
1 – Parkinson Disease  2 – Epilepsy  3 – Alzheimer Disease   4 - Other(s):  
Diseases of the Genitourinary System: 
1 – Urinary incontinence  2 – Benign prostate hyperplasia   3 – Other: 
Diseases of the Eye and Adnexa:  
1 – Cataracts    2 – Visual impairment    3 – Other:  
Others: 
Diabetes Microvascular 
Complications 
Retinopathy    Yes   No;  Nephropathy Yes   No;  Neurophaty    Yes    No 
CV events 
Any cardiovascular event?  
(stroke, myocardial infarction, transitory ischemic attack, other)?   Yes    No 
Do you have any family (1st degree) with premature cardiovascular event/disease 
(men <55 years, women <65 years)?      Yes     No  
Hospitalizations Have you been hospitalized in the last year?    Yes   No        How many times? _____How long?_____Cause? _______________  
Falls Have you fallen in the last 12 months?    Yes   No;  Where?     Do you had any broken bones from the fall?   Yes  No; Where?  
Complaints 
 
 
Other 
 
- Who renews the prescriptions? 
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Pharmacotherapeutic Profile 
 #01 #02 #03 #04 #05 
Medicine      
Drug´s Strenght K    NK  K    NK  K    NK  K    NK  K    NK  
Medicine´s  Name K    NK Can   Cannot K    NK Can   Cannot K    NK Can   Cannot K    NK Can   Cannot K    NK Can   Cannot 
Regimen 
     
When do you take? 
     
Howmany units/time? ____ units ____ units ____ units ____ units ____ units 
Why are you taking? 
     
How long?      
Medicines´ effects (+)                      (-) (+)                      (-) (+)                      (-) (+)                      (-) (+)                      (-) 
Nr days taken (7d)?  ____ days ____ days ____ days ____ days ____ days 
Nr days missed (7d)? 
     
Where do you keep? 
     
Medicine bother you? Yes / No  How ? 
 
Yes / No  How ? 
 
Yes / No  How ? 
 
Yes / No   How ? 
 
Yes / No   How ? 
 
Who prescribed? 
     
Comments      
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Medication Adherence 
 
Haynes-Sackett (Haynes et. al, 1980)  
 Most people have difficulty taking medication. Do you have difficulty taking your medication? 
yes   No 
Yes (tablets missed last 7 days / number indicated tablets) × 100; Non-adherent: <80% 
 
MAT – Medida de Adesão aos Tratamento (Delgado & Lima, 2001) 
a) Alguma vez se esqueceu de tomar os medicamentos para a sua doença?  
Sempre  Quase sempre  Com frequência  Por vezes  Raramente  Nunca  
b) Alguma vez foi descuidado(a) com as horas da toma dos medicamentos para a sua doença?  
Sempre  Quase sempre  Com frequência  Por vezes  Raramente  Nunca  
c) Alguma vez deixou de tomar os medicamentos para a sua doença por se ter sentido melhor?  
Sempre  Quase sempre  Com frequência  Por vezes  Raramente  Nunca  
d) Alguma vez deixou de tomar os medicamentos para a sua doença, por iniciativa, após se ter sentido 
pior?  
Sempre  Quase sempre  Com frequência  Por vezes  Raramente  Nunca  
e) Alguma vez tomou mais um ou vários comprimidos para a sua doença, por sua iniciativa, após se ter 
sentido pior?  
Sempre  Quase sempre  Com frequência  Por vezes  Raramente  Nunca  
f) Alguma vez interrompeu a terapêutica para a sua doença por ter deixado acabar os medicamentos?  
Sempre  Quase sempre  Com frequência  Por vezes  Raramente  Nunca  
g) Alguma vez deixou de tomar os medicamentos para a sua doença por alguma razão que não seja a 
indicação do médico?  
Sempre  Quase sempre  Com frequência  Por vezes  Raramente  Nunca  

Medication 
Management 
Do you have someone to help with your medications?    Yes       No 
                   If yes, how? 
Self-perceived 
health status(PT) 
How do you consider, currently, your health? 
         Very poor      Poor       Fair     Good      Excellent 
Health Services Access 
Medication reimbursement system  NHS ____   NHS – R ____   Other: ____ 
Who is the doctor (s) that makes your follow-up? General Practice______ Specialist______   Which? _____ 
Patient knowledge about disease 
 Hypertension 
 How many years have hypertension? ______________________ years 
 What is the optimal value for your blood pressure?___________ mmHg 
 Could you point two possible complications of hypertension?     
______________________________ 
 Have you measured your blood pressure in the last 12 months?     Yes    No 
 If yes, how many times?  _______________________ 
 
 Do you have tensiometer at home?      Yes       No 
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Patient knowledge about disease (continued) 
Diabetes 
 How many years do you have diabetes? ______________________ years 
  
 Do you know the optimal values for your Glycemia?   Yes    No 
                      Fasting ______________  Postprandial _______________ 
 Do you have glucometer at home?    Yes    No 
 How many days you measured your glycemia in the last 7 days?      0  1  2  3  4  5  6  7 
 
 How many times a week was appointed to measure glycemia by your doctor, nurse or 
pharmacist?   0  1  2  3  4  5  6  7 
 Could you point two possible complications of uncontrolled glycemia? 
__________________________________________________________________ 
Dyslipidaemia 
 How many years do you have dyslipidaemia? ______________________ years 
 
 Do you know the optimal value for total cholesterol?    Yes    No     
 Optimal value ?  _________________ 
 Could you point two possible complications of uncontrolled cholesterol values? 
_________________ 
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 : Publications 
E.1.1 Portuguese National Congress of Pharmacists  
(Lisbon, October 2015) 
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E.1.2 National Congress of Diabetes  
 
(Vilamoura, March 2016); http://unidospeladiabetes.pt/ 
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E.1.3 Manuscripts in progress to submit [potential journal]  
 “Adaptation to Portuguese language (Portugal) of the Short Assessment 
of Health Literacy - Spanish and English (SAHL-PT)” [Public Health 
Journal (Revista de Saúde Pública); IF:1.283] 
 “Assessment of medication knowledge in a diabetic population” 
[Research in Social and Administrative Pharmacy; IF: 1.936] 
 Analysis of medication review outcomes in clinical setting” [International 
Journal Clinical Pharmacy; IF: 1.339] 
 
 
